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Abstract 
An inherited disorder, ADA deficiency is a form of severe combined immunodeficiency, 
which is ultimately caused by an absence of adenosine deaminase (ADA), a key enzyme of 
the purine salvage pathway. The absence of ADA-activity in sufferers eventually results in a 
dysfunctional immune system due to the build-up of toxic metabolites. To date, this has been 
treated with mixed success, using PEG-ADA, made from purified bovine ADA coupled to 
polyethylene glycol. It is likely however, that an enzyme replacement therapy protocol based 
on recombinant human ADA would be a more effective treatment for this disease. Therefore, 
as a preliminary step to produce biologically active human ADA in transgenic tobacco plants 
and tobacco BY-2 cell suspensions a human ADA cDNA has been inserted into a plant 
expression vector under the control of the CaMV 35S promoter and terminator. In an attempt 
to maximise the yield various recombined gene constructs containing apoplast targeting 
sequences were tested along with different translational regulatory sequences such as TMV 
omega and RUBISCO untranslated regions.  
 
Tobacco plants and BY-2 cells transformed with cytosolic constructs showed levels of 
recombinant ADA of up to 80 ng mg
-1
 TSP. By comparison, transgenic calli expressing 
constructs containing apoplast-directing signals showed higher levels of recombinant ADA 
expression of up to 115 ng mg
-1
 TSP. The most significant ADA activities were measured in 
transgenic BY-2 cell suspensions, however. Where, incorporation of a signal for 
arabinogalactan addition at the C-terminus of the recombinant ADA gene, targeted for 
secretion, produced a maximum yield of approximately 13 mg L
-1
. Representing a 336-fold 
increase over ADA activities recorded in a BY-2 suspension transformed with a cytosolic 
counterpart. 
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1.1 Adenosine deaminase and ADA deficiency 
Human adenosine Deaminase (ADA; EC 3.5.4.4) is an enzyme, which consists of 363 amino 
acids and is 41kDa in size. Also referred to as adenosine aminohydrolase, ADA is a 
ubiquitous enzyme, belonging to the purine metabolism pathway (figure 1.2), it catalyses the 
conversion of adenosine into inosine (figure 1.1) and deoxyadenosine (dAdo) into 
deoxyinosine, through hydrolysis of a purine amino group (Benveniste and Cohen, 1995).  In 
addition to catalytic function in the cell cytoplasm, ADA was found to interact with cell 
surface receptor CD26 and other specific adenosine receptors. ADA appears to co-localise 
with these adenosine receptors found on dendritic cells and interact with CD26  on T-
lymphocytes leading to an increased production of pro-inflammatory cytokines (interferons 
and interleukins) and T-helper cells (Pacheco et al., 2005).  
 
          Adenosine               Inosine 
Figure 1.1:  Catalytic reaction of adenosine into inosine.  ADA also hydrolyses deoxyadenosine.  The amino groups 
are cleaved during hydrolysis, which results in an amide, and an ammonia molecule. 
 
The disease adenosine-deaminase-deficiency is a severe combined immunodeficiency, a fatal 
inherited disorder caused by mutations in the ADA gene on chromosome 20, which affects 
the development and function of immune cells (figure 1.4). Although ADA is present in all 
tissues, there is higher activity in lymphocytes during their development (Tsuboi et al., 1995). 
The number of individuals diagnosed with deficiency of ADA ranges from 1:200,000 to 
1:1,000,000 births, affecting all ethnic groups. However the prevalence is higher in certain 
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communities where the consanguinity is greater (Hershfield, 2011). The disease is 
characterized by a purine defect that leads to impaired immune function, recurrent infections 
and systemic metabolic abnormalities. It is an autosomal-recessive disorder representing 20% 
of the severe immune deficiency disorders (SCID) (Aiuti, 2004). As shown in figure 1.3, 
deficiency of ADA causes an increase in adenosine and 2’-deoxyadenosine (dAdo) in the 
plasma and an increase of nucleotides in lymphoid tissues, red blood cells and organs such as 
the kidney and the liver. These accumulations lead to an inactivation of S-
adenosylhomocysteine hydrolase which in due course inhibit certain lipids, proteins and 
nucleic acid methylations. When dAdo levels increase there is also a significant inhibition of 
another enzyme, ribonucleotide reductase, which in turn causes a deoxynucleotide (dNTP) 
imbalance.  The imbalance of dNTP leads to impairment of the T lymphocytes’ ability to 
repair and synthesise DNA. This causes an increase of denatured DNA in the cell nucleus, 
which in turn activates apoptosis (Benveniste and Cohen, 1995). Improper ADA function, 
imbalances of dATP, dAdo, and dNTP, as well as S-adenosylhomocysteine hydrolase 
impairment leads to an active apoptosis of thymocytes, resulting in T-cell death and severe 
combined immunodeficiency syndrome (Gangi-Peterson et al., 1999). As B-cell activity is 
controlled by T-cells, a decrease in T-cell function also results in dysfunctional B-cells. 
Furthermore, during maturation and recombination of the T-cell receptor, thymocytes are 
increasingly affected by ADA deficiency (Benveniste and Cohen, 1995). At this stage an 
imbalance of the nucleotide pool, caused by a deficiency of ADA, leads to N-region insertion 
alterations during T-cell receptor V(D)J recombination. A change in N-region substitutions 
with A-T nucleosides rather than G-C nucleosides leads to reduced frequency of 
recombination in T-cell immunoglobulins. In addition to the above, Van de Wiele et al., 
(2002) have shown that dATP-induced release of cytochrome c in mitochondria, also initiates 
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apoptosis and this is now thought to be the main mechanism of dATP toxicity in ADA 
deficient patients.  
 
Since the disorder is genetic, symptoms of ADA deficiency SCID are seen in affected infants 
at birth. However in some instances, ADA deficiency cannot be detected until later childhood 
or even adulthood due to mutations which partially impair the activity of ADA. Complete 
deficiency of ADA causes severe onset syndrome in SCID infants which exhibit 
lymphopenia, growth failure, opportunistic infections, and impaired function of cellular and 
humoral immunity, due to severe depression of T-cell function and antibody responses. There 
are about 40 identified alleles known to cause ADA SCID and some locations on the gene are 
highly susceptible to mutations (Hirschhorn et al., 1990). 
 
 
Figure 1.2:  Purine metabolism pathway, modified from Kather, (1990). 
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Figure 1.3: Summary of the effects of ADA deficiency. 
 
 
Figure 1.4:  Lymphocyte development and effects of ADA deficiency and other SCID disorders, adapted from Kumar 
et al., (2009). 
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1.2 Management options for ADA-SCID 
Management of ADA deficiency is based on restoration of a functional immune system and 
can be attained by three main management options which include bone marrow transplant 
(BMT), somatic gene therapy (GT) and enzyme replacement therapy (ERT) (Booth et al., 
2007).  In the first of these, the bone marrow transplant from a haploidentical donor is a fairly 
up-front process as the patients are already immunocompromised. It is difficult however to 
find donors with haploidentical characteristics and who themselves are not ADA deficient 
(Haddad et al., 1999). Once the bone marrow transplant has been performed, the success rate 
of recovery is above 90% with fully recovered B-cell and T-cell functions (Hershfield et al., 
2001; Rubocki et al., 2001). Buckley et al. (1999) reported that 11 ADA deficient patients 
out of 13 survived after bone marrow transplantation with an improvement of T-cell numbers 
and function after 3 to 4 months of transplantation.  
 
The second option, somatic gene therapy, represents a promising therapeutic option in 
general for inherited disorders of the immune system. Treatment of inherited diseases using 
gene transfer approach was first performed on adenosine deaminase deficiency (Anderson et 
al., 1990). The early trials of gene therapy showed the possibility and safety of engineering 
peripheral blood lymphocytes and haematopoietic stem cells using retroviral vectors (Aiuti, 
2004). Results of these studies showed that gene therapy with peripheral blood lymphocytes 
allowed correction of the T-cell defect, but provided insufficient systemic detoxiﬁcation 
shown by increased purine metabolites leading to decreased numbers of B-cells. However the 
gene transfer of bone marrow stem cells demonstrated a full correction of metabolic and 
immunological defects of adenosine deaminase deficiency with normalisation of peripheral 
blood lymphocyte counts, thymic activity restoration and improved immunoglobulin levels 
(Aiuti, 2004).  
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The third option, enzyme replacement therapy (ERT) with PEG-ADA has been used for more 
than 20 years to treat ADA deficient SCID patients (Booth et al., 2007). To begin with, ERT 
was based on the use of frozen irradiated red blood cells (erythrocytes) which can indirectly 
add the missing supply of ADA. However, Polmar et al., (1976) showed that some patients 
treated with this therapy showed a similar depressed immune response as that found in 
untreated ADA deficient patients. As a result it was thought that introduction of ADA, by 
directly injecting the enzyme, is a far better approach than using irradiated red blood cells. 
However, non-conjugated ADA enzyme was found to undergo rapid degradation in the serum 
and in some cases deleterious immune responses resulted. Hence, polyethylene glycol (PEG) 
conjugated bovine ADA (PEG-ADA) is used by intramuscular injection to treat ADA 
deficiency.  PEG conjugation blocks protease access to ADA in the serum and consequently 
lengthens the plasma half-life of ADA by more than 100-fold (Bordignon et al., 1995). 
Weekly administration of PEG-ADA (15-60 U kg
-1
 per week) improves the deleterious 
effects of ADA deficiency by correcting metabolic abnormalities, as PEG-ADA permits 
variable improvements in lymphocyte counts and immune function. As expected dAdo and 
dATP levels are also decreased and improvements in growth, reduced incidents of life-
threatening infections resulted from this treatment (Gaspar et al., 2009; Hershfield, 2011). If 
treatment is continued for longer than a year most individuals develop antibodies against 
bovine PEG-ADA which leads to inhibition of catalytic activity and enhanced clearance in 
some patients (Chaffee et al., 1992). Continuing PEG-ADA therapy is also extremely costly 
and can cost from $ 200,000 to $ 300,000 per patient annually (Chan et al., 2005). Hence, 
ERT with a recombinant human ADA is thought to be a viable and cheaper alternative in the 
treatment of patients over a life-long period. As plants possess well established foreign 
protein production mechanisms and human-like post-translational modification systems, 
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along with many other advantages over mammalian and prokaryotic production systems, 
plant production systems represent a reasonable choice for the development of a recombinant 
human ADA production system. 
 
1.3 ADA and cancer treatment 
High levels of adenosine are known to indirectly stimulate the proliferation of some forms of 
cancer, inhibiting the activation of cytokine production in killer T-cells which in turn 
stimulates metastasis (Sitkovsky et al., 2005; Loshkin et al., 2006). Since ADA catalyzes the 
conversion of adenosine to inosine, it has a potential as a drug in the treatment of adenosine-
sensitive tumours. For example, Sitkovsky et al., (2005) have shown that ADA along with 
adenosine receptor antagonists can enhance the immune reaction against some tumours. In 
addition, adenosine deaminase in conjugation with intravenous doses of polyalkylene oxide 
has been shown to substantially reduce the growth and spread of some tumours in mice 
(Filpula et al., 2009). Hence, there would seem to be another potential use for recombinant 
human adenosine deaminase in the treatment of some types of cancer. 
 
1.4 Production of biopharmaceuticals in transgenic plants and cell cultures 
Plants and plant products have been used for centuries for the treatment of human disease. 
Botanical gardens presented a wealth of materia medica for therapeutic use by the latter part 
of 16
th 
century. In the 17
th
 century, a scientific approach and the discovery of new 
pharmacological remedies led to the identification of active principles and purification for 
therapeutic use (Winslow and Kroll, 1998). At present, about a quarter of prescription drugs 
also contain medicaments which are of botanical origin. The current advances in 
biotechnology have led to renewed hopes in producing new medicaments from botanical 
sources, including fully functional pharmacologically imperative recombinant human 
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proteins (Fischer and Emans, 2000). Recombinant human insulin produced in bacteria was 
the first commercially produced biopharmaceutical to be made in 1982 by Lilly, USA; and 
coincides with the development of a first genetically modified plant (Fraley et al., 1983). The 
development of genetically modified plant was followed by successful production of 
biopharmaceuticals in plants, such as expression of human growth hormone fusion protein 
(Barta et al., 1986), interferon (DeZoeten et al., 1989), monoclonal antibodies (Hiatt et al., 
1989), and human serum albumin (Sijmons et al., 1990). Since then, scores of 
biopharmaceuticals were produced in plant expression systems (table 1.1). 
 
Although bacteria are classed as convenient and cost-effective production systems for 
producing smaller human proteins (e.g. human insulin), incapacity of assembly steps and 
post-translational modifications, which are essential for biological activity of most human 
proteins, hinders their use for production of more complex proteins. In addition, effective 
removal of contaminating lipopolysaccharides from recombinant protein is extremely 
expensive in bacterial expression systems. Plants on the other hand possess an efficient 
protein synthesis mechanism, and with established gene expression systems, plants can be 
used to produce large amounts of proteins (Fischer and Emans, 2000). Due to the absence of 
mammalian pathogens, unlike mammalian cell systems, plant expression systems possess 
some important advantages over mammalian and bacterial expression systems (table 1.2) 
(Fischer and Emans, 2000). Other advantages of plant-derived biopharmaceuticals also 
include: higher product safety, higher production scale, lower production costs, easy storage 
and distribution. 
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Table 1.1: Plant-produced therapeutic proteins, antibodies and vaccines in clinical development or 
on the market. 
Product Plant host Indication Route of 
administration 
Product 
development stage 
Reference 
Vaccines 
E.coli LT-B Potato  
Maize 
Diarrhoea Oral Phase 1 
Phase 1 
Mason et al., (1998); 
Tacket et al., (2004) 
Norwalk virus CP Potato Diarrhoea Oral Phase 1 Mason et al., (1996) 
Rabies virus GP/NP Spinach  Rabies Oral Phase 1 Modelska et al., (1998) 
Newcastle disease 
virus HN 
Tobacco cell 
suspension 
Newcastle disease 
(poultry) 
Subcutaneous USDA approved 
(Marketed) 
http://www.dowagro.co
m 
Personalized  
anti-idiotyped 
scFVs: 
Nicotiana 
benthamiana 
Non-Hodgkin’s 
lymphoma 
Subcutaneous Phase 1 (ongoing) Bendandi et al., (2010) 
H5N1 influenza HA 
VLP 
Nicotiana 
benthamiana 
H5N1 “avian” 
influenza 
Intramuscular Phase 1 (ongoing)  
Phase 2 (Health 
Canada approved 
and enrolling 
volunteers) 
Yusibov et al., (2012) 
H5N1 influenza 
HAI1 
Nicotiana 
benthamiana 
H5N1 “avian” 
influenza 
Intramuscular Phase 1 (ongoing) Yusibov et al., (2012) 
H1N1 influenza 
HAC1 
Nicotiana 
benthamiana 
H1N1 “swine” 
influenza 
Intramuscular Phase 1 (ongoing) Shoji  et al., (2012) 
Antibodies 
Anti-CD20 Duckweed Non-Hodgkin’s 
lymphoma, 
rheumatoid arthritis 
Intravenous Pre-clinical Cox et al., (2006) 
Anti-Streptococcus 
surface antigen l/ll 
Tobacco Dental caries Topical Phase 2; EU 
approved 
http://www.planetbiote
chnology.com 
Anti-αCCR5 Nicotiana 
benthamiana 
HIV Topical Pre-clinical Pogue et al., (2010) 
Anti-HIV gp120 Maize 
Nicotiana 
benthamiana 
HIV Topical Pre-clinical Yusibov et al., (1997) 
Heptitis B surface 
antigen 
Potato  
Lettuce 
Hepatitis B vaccine 
purification 
Not applicable Phase 1 Kapusta et al., (1999); 
Streatfield, (2006) 
Therapeutic and dietary proteins 
Glucocerbrosidase Carrot cell 
suspension 
Gauchers disease Intravenous USFDA approved in 
2012 (Marketed) 
Shaaltiel et al., (2007) 
Insulin Safflower Diabetes Subcutaneous Phase 1/2 
(marketing 
expected) 
Markley et al., (2006) 
Gastric lipase Maize Cystic fibrosis, 
pancreatitis 
Oral Phase 2 (marketed 
as analytical 
reagent) 
Zhong et al., (2006) 
Lactoferrin Maize Gastro-intestinal 
infections 
Oral Phase 1 (marketed 
as analytical 
reagent) 
Samyn-Petit et al., 
(2001) 
Intrinsic factor Arabidopsis 
thaliana 
Vitamin B12 
deficiency 
Oral Phase 2 Fedosov et al., (2003) 
Table modified from Yusibov et al., (2011); Paul and Ma, (2011). 
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Table 1.2: Comparison of recombinant protein production in a range of model systems. 
 Transgenic 
plants 
Plant viruses Yeast Bacteria Mammalian 
cell cultures 
Transgenic 
animals 
Cost/storage Cheap/RT Cheap/- 20 
o
C Cheap/-20 
o
C Cheap/-20 
o
C Expensive Expensive 
Distribution Easy Easy Feasible Feasible Difficult Difficult 
Gene size Not limited Limited Unknown Unknown Limited Limited 
Glycosylation 'Correct'? 'Correct'? Incorrect Absent 'Correct' 'Correct' 
Multimeric protein 
assembly (SigA) 
Yes No No No No Yes 
Production cost Low Low Medium Medium High High 
Production scale Worldwide Worldwide Limited Limited Limited Limited 
Production vehicle Yes  Yes Yes Yes Yes Yes 
Propagation Easy Feasible Easy Easy Hard Feasible 
Protein folding 
accuracy 
High? High? Medium Low High High 
Protein homogeneity High? Medium Medium Low Medium High 
Protein yield High Very high High Medium Medium-High High 
Public perception of 
risk 
High High Medium Low Medium High 
Safety High High Unknown Low Medium High 
Scale-up costs Low Low High** High** High** High 
Therapeutic  risk* Unknown Unknown Unknown Yes Yes Yes 
Time required Medium Low Medium Low High High 
*-Residual viral sequences, oncogenes, endotoxins; **-Large, expensive fermenters. Table adapted from Fischer & Emans, 
(2000). 
 
 
In the year 2006, Dow AgroSciences acquired the licence for first plant-produced 
biopharmaceutical product, a poultry vaccine developed against Newcastle disease virus. This 
achievement of Dow AgroSciences is a significant breakthrough for plant-produced 
biopharmaceuticals. The Concert
TM
 Plant-cell-produced, bio-contained system utilizes tobacco 
plant cells as an alternative to an expression of foreign proteins in whole plants (Kaiser, 2008). 
A recombinant glucocerebrosidase (Taliglucerase alfa), an enzyme produced by Protalix 
Biotherapeutics which is used to treat Gaucher’s disease, was the first plant cell-produced 
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human enzyme to be approved by the United States Food and Drug Administration which was 
approved in 2012 (Pfizer Press Releases, 2012). 
 
Table 1.1, shows an array of plant species used in recent years to produce biopharmaceuticals. 
The choice of plant species varies and may depend on the type of pharmaceutical product, 
storage of the product and ease of downstream processing. Most of the early attempts to 
generate transgenic plants were performed in tobacco which remains a model expression 
system to date. Due to ease of gene transfer, well established expression systems and being a 
non-food crop, tobacco has an advantage over other plant systems. Furthermore, well-
established tobacco suspension culture expression systems provide a better containment 
opportunity and also evade the undesirable effects of alkaloids which are present in tobacco 
whole plants. They also allow foreign protein secretion into the medium, which greatly cuts the 
cost of downstream processing. 
 
1.5 Expression of recombinant genes in plant cells and tissues  
Expression of foreign proteins in plant cells and tissues requires a promoter to drive the 
expression of linked foreign cDNAs. The Cauliflower Mosaic Virus (CaMV) 35S promoter 
(Odell et al., 1985) is the most commonly used constitutive promoter when foreign genes in 
plants are expressed. Mason et al., (1992) demonstrated the production of first plant-derived 
vaccine (hepatitis B surface antigen (HBsAg) in tobacco plants and established the use of the 
CaMV 35S promoter in expressing biopharmaceuticals. Mason et al., (1992) prepared a 
construct containing CaMV 35S promoter upstream of the hepatitis B surface antigen 
(HBsAg) coding region trailed by the downstream nopaline synthatase (NOS) terminator. The 
CaMV 35S promoter sequence has been modified in recent years to enhance efficiency of 
expression by approximately 10-fold (He et al., 2008). The Ubiquitin promoter used in 
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expression of scFv antibodies and insulin-like growth factor-1 (IGF-1) in rice cells (Panahi et 
al., 2004; Torres et al., 1999) and the hybrid (ocs)3mas promoter used in over expression of 
HBsAg in soybean cell cultures (Smith et al., 2002) are two other constitutive promoters 
commonly used in foreign gene expression in plant cells, especially monocotyledons.  
 
Another kind of promoter which has been reported extensively in recent years is the inducible 
promoter, where expression regulation is controlled by external stimuli such as sucrose, salts, 
steroids, alcohol or environmental stress factors (Huang and McDonald, 2009). As cell 
growth and protein production are not related to each other, use of inducible expression may 
be advantageous in some cases, allowing individual optimisation of both processes, to yield 
maximum protein levels (Sharma and Sharma, 2009).  Rice α-amylase 3D (RAmy3D) 
promoter is a commonly used inducible promoter where sucrose starvation promotes the 
high-level expression of the foreign genes in rice and has been used to produce a range of 
human therapeutic proteins in rice cell suspension cultures including α1-antitrypsin, serum 
albumin, lysozyme (Huang and McDonald, 2009), granulocyte-macrophage colony-
stimulating factor (Shin et al., 2003), growth hormone (Kim et al., 2008a) and interlukin-12 
(Shin et al., 2010b).  
 
Once transformed, transcription of the gene of interest can be affected by different factors 
such as, the position of gene insertion in the plant genome (Springer et al., 1995) and the 
organization of the gene integration (Hepburn et al., 1983). Agrobacterium-mediated 
transformation is associated with random integration of T-DNA into the plant genome 
(DeBeuckeleer et al., 1981). The earliest reports show that transgene silencing by DNA 
methylation also plays a pivotal role in transcription (Hepburn et al., 1983). Stam et al., (1997) 
described that transfer of tandem copies of T-DNA at a single locus is frequently associated 
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with Agrobacterium-mediated transformation and it was also found that tandem inverted T-
DNA repeats situated closer to the right border are also frequently associated with transgene 
silencing due to promoter methylation.  
 
Choice of strong translational enhancer/regulation sequences is equally as important as the 
choice of promoter in increasing the yield of recombinant products. Gallie and Walbot, 
(1990) reported that the addition of 204-bases of the tobacco mosaic virus (TMV) 3’-
untranslated region to foreign mRNA increased the gene expression a further 100-fold, 
increasing the stability of mRNA and enhancing the translation in a similar manner to 
polyadenylated mRNA. Furthermore, Gallie, (2002) demonstrated that the RNA 5’-leader 
sequence (omega-Ω) of TMV functions as a translational enhancer through recruiting the 
ribosomal initiation factor, eIF4F, and significantly enhances translation in both eukaryotes 
and prokaryotes.  Another reported translational regulator used in plant expression constructs 
is the 5’ UTR of ribulose-1, 5-bisphosphate carboxylase/oxygenase (RUBISCO), an enzyme 
which catalyzes the primary stage in carbon fixation in plants (Mazur and Chui, 1985). Patel 
et al., (2004) and (2006) demonstrated that the untranslated region from C4 Amaranthus and 
Flaveria bidentis RUBISCO small subunit1 mRNAs causes translational enhancement which 
led to increased expression of downstream foreign genes.  
 
Although expression of foreign genes in plants can be enhanced using various promoter 
sequences such as 35S CaMV, 5’ and 3’-untranslated regions, in order to achieve commercial 
success of plant based production systems, improved strategies employed to accumulate 
foreign proteins are essential (Doran, 2006). Foreign proteins produced in plant systems 
undergo continuous degradation due to processes such as proteolysis and irreversible surface 
adsorption (Doran, 2006). Hence, it is of prime importance to employ measures in order to 
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reduce foreign protein degradation and loss.  One such technique to preserve foreign proteins 
from proteolytic degradation is to target and anchor the recombinant proteins in the 
endoplasmic reticulum (ER) (Conrad and fiedler, 1998). The plant cell ER contains less 
endogenous protease-activity, providing a protective environment for foreign proteins (Nuttal 
et al., 2002). The incorporation of C-terminal motifs, such as KDEL and HDEL into 
recombinant proteins directed to the ER causes the retention of proteins within the ER and in 
turn prevents the protein from proteolytic degradation in the cytoplasm. Hellwig et al., (2004) 
described that foreign protein retention in the ER resulted in 10-100 times greater yields than 
those obtained by secretion. Petruccelli et al., (2006) also demonstrated the accumulation of 
monoclonal antibodies increased by 4-11-fold when retained in the ER as a fusion with the 
KDEL peptide.  
 
Direction of recombinant proteins to the apoplast through sub-cellular targeting is another 
approach used to protect proteins from proteolytic degradation in the cytosol and also eject 
such proteins into the medium of cell suspensions. The apoplast is the non-living part of plant 
tissue, located out-side the cell membrane and composed of the cell walls, the intercellular 
spaces, and the lumen of dead structures such as xylem cells. Cell wall proteins which 
contain appropriate N-terminal signal peptide sequences undergo secretion into the apoplastic 
space. Signal sequences from proteins such as tobacco pathogenesis related protein (PR1a), 
when used in combination with recombinant proteins can target foreign proteins into the 
apoplast (Pen et al., 1993a). For instance the incorporation of the PR1a signal peptide at the 
N-terminus of the thermostable eubacterium endo-1, 4-β-D-glucanase was found to increase 
the yield by up to 26% of TSP in Arabidopsis leaves (Ziegler et al., 2000). Another N-terminal 
apoplast directing signal is found in plant extensins which are a well-characterized 
hydroxyproline-rich glycoprotein family, forming a major component of the cell wall 
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(Showalter, 1993). Like the PR1a signal peptide, incorporation of an extensin signal peptide at 
the N-terminus of recombinant proteins directs secretion into the apoplast. Francisco et al., 
(1997) expressed bryodin 1, a potent ribosome-inactivating protein, as a soluble recombinant 
protein using the extensin signal peptide to secrete the protein into the culture medium. The 
purified bryodin 1 yield was 30 mg L
-1
 of culture and showed an identical inhibitory activity 
to the native protein isolated from the roots of Bryonia dioica. Apoplast direction of 
recombinant therapeutic proteins has also been reported by Xu et al., (2007), where, an 
extensin signal peptide was used in conjunction with a C-terminal hydroxyproline (Hyp)-rich 
peptide to produce a hydroxyproline (Hyp)-rich glycoprotein. Chimeric expression of such 
glycoproteins (HRGPs) where a short C-terminal Hyp-Ser sequence directs extensive O-
glycosylation, leads to addition of arabinooligosaccharides. Recombinant interferon-α2-
arabinogalactan peptides (IFNα2-AGPs) targeted for secretion in this way increased yields by 
350–1400-fold, compared to the non-glycosylated IFNα2 control.  Finally, the signal peptide, 
AP24, from osmotin was used to direct recombinant proteins into the apoplast causing a 10
4
-
fold increase in the yield of recombinant epidermal growth factor in tobacco plants (Wirth et 
al., 2004).  
 
Glycosylation of the recombinant proteins 
During protein trafficking in plant cells, proteins undergo several post-translational 
modifications such as glycosylation, phosphorylation, methylation, ADP-ribosylation, 
oxidation and glycation (Gomrod and Faye, 2004). Covalently attaching an oligosaccharide 
side chain to a protein is known as glycosylation. Carbohydrates moieties attached to proteins 
are of two types. Carbohydrates linked to the amide moiety of asparagine (Asn) are known as 
N-glycans. Whereas carbohydrates linked to the hydroxyl group of threonine (Thr), serine 
(Ser) or hydroxyproline (Hyp) are known as O-glycans. Apart from nucleocytoplasmic O-
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GlcAcylation, both N- and O-glycosylation occur in the secretory pathway (Gomrod et al., 
2010). Biological activity of many therapeutic glycoproteins depends on the glycosylation 
structure of the protein. Hence, it is of extreme importance to have production systems which 
exert complex glycosylation patterns. The use of plant production system over production 
systems such as bacterial or yeast is beneficial due to the plant’s capability to exert complex 
glycosylation patterns similar to that found in human cells. Although plant expression 
systems exert complex glycosylation, inability to produce exact human-like glycosylation 
patterns on recombinant proteins plays a major limitation in using plant-made 
pharmaceuticals in human therapy especially for parenteral administration (Faye et al., 2005). 
This is because the existence of immunogenic glycoepitopes in complex plant N-glycans has 
been found to be immunogenic to mammals (Gomrod et al., 2005). However, strategies such 
as retaining recombinant proteins in the ER, inhibition of host plant glycosyltransferases and 
expression of heterologous glycosyltransferases for the addition of mammalian-like glycans, 
have been developed in recent years to re-design the protein N-glycan structures in plant 
expression systems (Saint-Jore-Dupas et al., 2007). 
 
As well as N-glycans, plant protein O-glycans are also structurally different from human 
glycol-proteins.  The most abundant O-glycans in human cells are mucin-type, O-GlcNAc 
and a xylose residue linked to Ser and Thr residues. Some of these may be extremely 
important in the physicochemical properties of some proteins. The most abundant O-
glycosylated proteins present in plants are the extensins and various other arabinogalactan 
proteins. The extensins are O-glycosylated with galactose residues linked to most of the 
Serine (Ser) residues and arabinosyl residues linked to hydroxyproline (Hyp) residues 
(Showalter, 2001). The AGPs are the largest and the most extensively glycosylated proteins 
where, Hyp residues are linked with very large arabinogalactan glycomodules or smaller 
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arabinooligosaccharides (Qi et al., 1991). The use of extensive plant O-glycosylation to 
increase the stability of administered recombinant proteins in vivo has been investigated 
recently by Xu et al., (2007).   Human INFα2 fused to an AGP O-glycomodule had an 
increased serum half-life in mice of 9 hours.  Furthermore, these INFα2 fusions are non-
immunogenic when administered intravenously in mice (Xu et al., 2007). Immuno-tolerance 
of AGPs fused to recombinant proteins was also recently confirmed with recombinant human 
growth hormone (hGH), which showed no adverse immune reaction when injected into mice 
(Xu et al., 2010).  
 
1.6 Suspension cultures 
Production of recombinant proteins of industrial and pharmaceutical importance in plant cell 
cultures is common because the cell cultures can be scaled up in controlled environments 
such as fermenters which provide containment. Developed in the 1950’s, plant cell 
suspension culture technology has been used for producing secondary metabolites such as 
digoxin, paclitaxel, and artemisinin (Georgiev et al., 2009; Huang and McDonald, 2009). 
With the latest advances in modern plant molecular biology, cell culture systems are used as a 
feasible alternative production system for therapeutic proteins. Human serum albumin 
(Sijmons et al., 1990) and chloramphenicol acetyltransferase (Hogue et al., 1990) were the 
first therapeutic proteins to be produced in plant cell suspension cultures. The first plant cell 
suspension culture produced therapeutic protein to be approved by the USDA was the poultry 
vaccine manufactured in transgenic tobacco cell cultures by Dow AgroSciences, against 
Newcastle disease virus (NDV) (Kaiser, 2008). Although, many recombinant proteins have 
been produced in plant cell suspension culture systems to date, tobacco BY-2 cell 
suspensions are the most common in use. Owing to a rapid doubling time, well established 
genetic transformation, low proteolytic activity, low production of secondary metabolites, the 
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capability to carryout post-translational modifications and reduced post-translational 
silencing effects, expression of therapeutic proteins in tobacco BY-2 plant cell cultures 
possess prominent advantages over whole plants (Lee et al., 2000; Su and Lee, 2007). 
Furthermore, purification of recombinant proteins from suspension cultures is relatively 
straightforward when targeted for secretion (Doran, 2000): where secreted proteins can be 
isolated from the suspension medium by filtration, precipitation and chromatographic 
techniques (Fischer et al., 1999a) 
 
Efficient downstream processing of recombinant proteins from suspension cultures is 
extremely vital in order to increase the yield of recombinant proteins from plants. Hence, it is 
pivotal to adopt techniques to extract entire recombinant protein products preserved from any 
degradation. Once cells lyse to release intracellular products, the proteases in plant cells 
begin to degrade the proteins. Hence, choice of a suitable buffer and growth medium 
containing either protein stabilizing agents or protease inhibitors is imperative to enhance 
yields. Incorporation of 0.75 g L
-1
 polyvinylpyrrolidone (PVP)(MW 360,000), a protein 
stabilizing agent, into the culture medium was found to enhance the yield of extra-cellular 
heavy chain monoclonal antibodies by 35-fold due to the protein stabilizing effect of PVP 
(LaCount et al., 1997). Further to this, Lee et al., (2002) tested two other stabilizing polymers 
(polyethylene glycol and gelatine), as well as PVP in order to stabilize the secreted protein, 
hGM-CSF, in the culture medium. Gelatine was found to be the most effective stabilizing 
agent among three polymers. Addition of 5 % gelatine into the culture medium increased the 
yield by 4.6-fold over a corresponding control (Lee et al., 2002). However, it was further 
revealed that the addition of gelatine into the culture medium seemed to be negatively 
affecting cell growth in suspension after day 5 and in turn reduced overall production of 
hGM-CSF (Lee et al., 2002).  
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1.7 Plant produced human enzymes for enzyme replacement therapy 
Like ADA deficiency, Gaucher’s disease (GD) is another autosomal recessive inherited 
disorder which can be treated by ERT. Gaucher’s disease is a condition caused by 
glucocerebrosidase (GCD) enzyme deficiency which leads to lysosomal dysfunction. 
Gaucher’s disease is of three types. Type I (non-neuropathic type), Type II (acute infantile 
neuropathic form) and Type III (the chronic neuropathic form). The most common of the 
three, GD type 1 can be treated by ERT owing to the lack of a central nervous affect 
(Pastores et al., 2011). The concept of treating GD with ERT was first proposed in the 1960s 
and with the advent of Alglucerase extracted from human placental tissue (Genzyme) in 
1991, ERT for GD became a reality. A recombinant version of glucocerebrosidase,  
Imiglucerase (Cerezyme), produced in Chinese hamster ovary (CHO) cells was soon after 
approved by the FDA for patient use in 1994 and it was found that ERT with Cerezyme 
significantly improved the condition of the patients (Aerts et al., 2010). In 2010 another 
recombinant version of GCD, Velaglucerase Alfa (Vpriv), produced in cell lines of human 
fibroblasts through gene-activation technology, was approved by the FDA. A recombinant 
GCD produced in plant cells is also in production as Shaaltiel et al., (2007) have successfully 
produced a recombinant human GCD (prGCD) with terminal mannose glycans, in carrot cell 
suspensions, directed to vacuoles with the use of C-terminal plant-specific sorting signals.  
Biological uptake of the GCD in humans’ suffering from Gaucher’s disease, via macrophage 
mannose receptors is assisted by mannose residues. Hence, the in vitro exposure of mannose 
residues, as in the case for Cerezyme, is not required. Following the scrutiny of clinical, 
preclinical and phase I trials (Aviezer et al., 2009) prGCD (Taliglucerase alfa) has been 
approved by the United States Food and Drug Administration (FDA) in 2012 and is the first 
plant-derived human enzyme product to be approved by FDA (Pfizer Press Releases, 2012). 
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In another attempt to produce a recombinant enzyme for ERT, De Marchis et al., (2011) have 
demonstrated the production of recombinant α-mannosidase (LAMAN) in transgenic tobacco 
plants for the treatment of a rare lysosomal storage disorder, alpha-mannosidosis: a 
congenital autosomal recessive disorder that leads to mental and physical deterioration due to 
accumulation of oligosaccharides in lysosomes. The cause of the disease is a deficiency of 
the enzyme α-mannosidase which cleaves α-linked mannose residues from glycoproteins 
preventing the accumulation of oligosaccharides in normal individuals. 
 
Fabry’s disease is another rare autosomal recessive lysosomal storage disease caused by a 
deficiency in the lysosomal enzyme α-galactosidase A (GAL-A). A defect in this enzyme 
results in accumulation of glycosphingolipids substrates, which fatally affect heart, brain and 
kidneys and in due course bring about organ failure and death (Breunig and Wanner, 2003). 
ERT with a once in two weeks administration of recombinant human α-galactosidase A (rh-
GAL A) produced in cultured human fibroblast (Agalsidase α) and Chinese hamster ovary 
(CHO) cell lines (Agalsidase β) has shown significant improvement in the symptoms of this 
disease (Breunig and Wanner, 2003). As the production of recombinant α-galactosidase A in 
cultured human fibroblast and CHO cell lines are extremely costly, efforts are underway to 
produce human α-galactosidase A in plant expression systems (Garger et al., 2005).  
 
The production system for most of these enzymes is based on well-established protocols 
using Chinese hamster ovary (CHO) cell lines. Alternative production options based on plant 
cell systems, however, came to forefront after a viral infection disrupted the CHO-based 
production of glucocerebrosidase at Genzyme (Rybicki, 2010). Moreover the cost of 
recombinant enzyme production based on CHO cell lines is extremely high which questions 
the widespread affordability of such a production system. Hence, like GCD, research into the, 
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production of many other human enzymes used in ERT are currently underway using plant 
cell based systems (table 1.3). 
 
Table 1.3: Plant produced human enzymes. 
Disease Enzyme Current system Plants reference 
Gaucher’s disease Human 
Glucocerebrosidase 
Carrot cell 
suspension 
Carrot cell 
suspension 
Shaalitiel et al., (2007) 
α-mannosidosis Human α-mannosidase Chinese Hamster 
Ovary 
Tobacco De Marchis et al., 
(2011); Fogh et al., 
(2003) 
Fabry’s disease  Human α-galactosidase A Chinese Hamster 
Overy and human 
fibroblast   
Carrot cell 
suspension 
www.protalix.com 
Maroteaux-Lamy 
syndrome 
Human lysosomal enzyme 
N-acetylgalactosamine-4-
sulfatase 
Chinese Hamster 
Overy 
Tobacco Garger et al., (2005) 
Mucopolysaccharidosis-I Human α-iduronidase Chinese Hamster 
Overy 
Tobacco BY-2 
cell suspension 
Fu et al., (2009) 
Pompe disease α-glucosidase Chinese Hamster 
Overy 
Tobacco Garger et al., (2005) 
Organophosphate 
poisoning (Nerve agents) 
Human 
Acetylecholinestarase-R  
Carrot cell 
suspension 
Nicotiana 
benthamiana  
 
Carrot cell 
suspension 
Woods et al., (2008)  
 
 
www.protalix.com 
Diabetes Human insulin Bacteria and 
yeast 
Arabidopsis 
thaliana  
 
Safflower 
Nykiforuk et al., (2006)  
 
 
Markley et al., (2006) 
 
 
1.8 Production systems for ADA 
In an attempt to develop a non-antibiotic selection system for transgenic plants and calli, 
Petolino et al., (1999) demonstrated the expression of a murine ADA cDNA in transgenic 
maize under the control of the maize ubi-1 promoter. Transformation was executed using a 
micro-particle bombardment method in embryonic maize calli along with plasmids comprising, 
gusA and bar gene. Transformants expressed β- glucuronidase (GUS) and accumulated a 41 
kDa protein which was immunoprecipitated with ADA-specific polyclonal antibodies and 
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ADA enzyme activities were measured in transgenic calli and regenerated plants (Petolino et 
al., 1999). Use of ADA as a selection marker for selecting plant transformants has also been 
investigated in hot pepper plants (Lim et al., 1999). Recombinant ADA has also been produced 
in insects, where Medin et al., (1990) successfully expressed a human ADA cDNA in 
baculovirus-infected Spodoptera frugiperda and Trichoplusia ni insect larvae and obtained 
ADA enzyme levels up to 70 U mg
-1
 TSP.  There are also several other reports of the 
production of human ADA in E.coli for the purpose of investigating folding mutations of the 
enzyme (Santisteban et al.,  2003).  
 
1.9 Aims of study 
The overall aim of the work presented in this thesis was to effectively express a human ADA 
cDNA in whole tobacco plants and cell suspensions under the control of various cytosolic 
and sub-cellular targeting signals. Constructs for cytosolic expression, containing different 
translational regulation sequences, would be investigated for their ability to increase levels of 
ADA enzyme activity in transformants. These ADA activities would be compared with 
activities measured in transformants containing corresponding sub-cellular targeting 
constructs. 
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2.1 Materials 
2.1.1 Bacterial strains and plasmids 
Bacterial strains 
Escherichia coli: DH5α: F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG 
Φ80dlacZΔM15 Δ(lacZYA-argF)U169, hsdR17(rK
-
 mK
+), λ– (Hanahan, 1985) 
 
Agrobacterium tumefaciens: AGL1: AGL0 (C58 pTiBo542) recA::bla, T-region deleted Mop 
(+) Cb(R) [AGL0 is an EHA101 with the T-region deleted, which also deletes the aph gene] 
(Lazo et al., 1991). 
 
Plasmids 
a. pCMV6-ADA   
The pCMV6-ADA plasmid was used as a source of the human ADA cDNA (1.5 kbp) 
and was purchased from Origene
TM
 (Andersson et al., 1989). The full-length ADA 
cDNA fragment is unidirectionally inserted downstream from a eukaryotic 
transcriptional promoter in the pCMV6 vector between EcoRI and SalI. 
 
b. pUBS 
The pUBS plasmid is a small, high-copy number E. coli cloning vector containing a 
pUC18 plasmid backbone and Bluscript plasmid KS+ multiple cloning site (Bringloe et 
al., 1995).  
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c. pJIT 
 
The pJIT vector carries the 35S cauliflower mosaic virus (CaMV) promoter and terminator 
along with a small MCS (figure 2.1) (Hellens et al., 2000). 
 
Figure 2.1: A restriction map of pJIT (www.pgreen.com). 
 
d. pGreenI0029 and pSoup 
The pGreenI0029 and pSoup binary vectors are used for Agrobacterium-mediated 
transformation of plants. The NptI gene of pGreenI0029 conveys resistance to kanamycin, 
and can be used as a selection marker for plasmid transformation. The pGreenI0029 
plasmid contains a MCS incorporated in lacZ’ gene which allows blue/white selection. 
Constructs can be subcloned from pJIT using the EcoRV site.  
 
The pSoup vector contains a virulence origin gene (oriV) which acts in trans for T-DNA 
incorporation into the plant genome (Hellens et al., 2000). 
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(a) 
 
 
 
 
 
 
(b) 
 
Figure 2.2: Restriction enzyme maps of Plant binary vectors (a): pGreenI0029 plasmid, (b): pSoup plasmid (Hellens et 
al., 2000). 
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2.1.2 Plant material 
BY-2 callus 
Nicotiana tabacum BY-2 calli obtained from Syngenta, UK were maintained on MS agar 
medium at 25 °C and subcultured monthly by excising a small part of calli and transferring 
onto fresh sterile MS Agar medium for callus (section 2.1.4). 
 
Plant material 
Tobacco plants (Nicotiana tabacum: Samsun Var:) grown in vitro were initially obtained 
from Syngenta, UK. They were propagated in an incubator at 25 °C with supplementary 
artificial lighting providing photosynthetically-active irradiance of 150 µmol photons m
-2
 S
-1
 
on a 24 hour photoperiod and sub-cultured monthly by excision of inter-nodal stems with an 
auxiliary bud and replanting in sterile MS agar medium (section 2.1.4). 
 
BY-2 cell suspension 
A small part (2 g) of Nicotiana tabacum BY-2 calli initially obtained from Syngenta, UK was 
cut into small 2 mm
2
 pieces in a sterile Petri dish and transferred into 20 ml of fresh sterile 
culture medium in a 100 ml conical flask, containing MS medium for cell suspension (section 
2.1.4). The cultures were shaken at 120 rpm in the dark at 25 °C for 7 days after which the 
tobacco BY-2 starter suspension was transferred into 100 ml of fresh sterile MS-culture 
medium in a 250 ml conical flask (section 2.1.4). Tobacco BY-2 cell suspensions were 
propagated weekly by inoculating 100 ml of modified MS medium with 20 ml of a week-old 
suspension culture.  
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2.1.3 Sources of reagents and enzymes 
Restriction endonucleases were purchased from Sigma Aldrich (UK), Roche (UK) or New 
England Biolabs (UK). Bradford reagent, Isopropylthio-(3-D-galactoside (IPTG) and 5-
bromo-4-chloro-3-indolyl-(3-D-galactoside (X-gal), Polyvinylpyrrolidone, MS basal 
medium, total mRNA isolation kit, ampicillin, kanamycin, carbenicillin, tetracycline, 
cefotaxime, Rifampicin, acetosyringone, RNase A, proteinase K, O-phenanthroline and rabbit 
antiserum to ADA were purchased from Sigma Aldrich (UK). Calf intestinal alkaline 
phosphatase, T4 DNA ligase, restriction endonucleases, DNA molecular weight markers and 
DIG nucleic acid hybridization kit were obtained from Roche Diagnostics. Primers used in 
PCR and DNA sequence analysis were obtained from Eurofin MWG operon, Germany. 
Plasmid miniprep, gel-extraction and total plant DNA isolation kit were obtained from 
Qiagen, UK. Horseradish peroxidase (HRP) conjugated anti-rabbit IgG was obtained from 
Novus biological, UK. Adenosine deaminase assay kit was obtained from Bioquant, USA. 
Sodium hypochlorite solution was obtained from Unilever, UK. Stock reagents, solutions and 
media were sterilised by autoclaving under one atmospheric pressure at 121 °C for 15 min.  
Materials unsuitable for autoclaving were sterilised where necessary by passage through 
Millipore disposable filters (0.4 µm). Most reagents were AnalaR grade and obtained from 
BDH unless otherwise indicated. 
 
2.1.4 Solutions and media not described in the text. 
TE buffer 
10 mM Tris-HCl pH 8.0, 1 mM EDTA.Na2 
 
Solution I 
50 mM glucose, 25 mM Tris-HCl pH 8.0, 10 mM EDTA.Na2, 100 µg ml
-1
 RNase A 
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Solution II 
0.2 M NaOH, 1 % (w/v) SDS 
 
Solution III 
1.32 M potassium acetate pH 5.0 
 
1X TAE buffer    
0.04 M Tris (BDH AnalaR), 1.43 % (v/v) Glacial Acetic Acid (BDH AnalaR), 0.0125 M 
EDTA (BDH AnalaR) 
 
20x SSC 
3.0 M NaCl (Oxoid), 0.3 M Sodium Citrate (Sigma) 
 
10x SSC 
1.5 M NaCl (Oxoid), 0.15 M Sodium Citrate (Sigma) 
 
LB broth 
1 % (w/v) Bacto Tryptone (Oxoid), 1 % (w/v) NaCl (Oxoid), 0.5 % (w/v) yeast extract 
(Oxoid) to pH 7.5 with NaOH 
 
LB plates     
LB broth, 1.5 % agar (Oxoid) 
 
MS broth 
0.44 % (w/v) Murashige and Skoog basal medium (Sigma), 30 % (w/v) Sucrose (Oxoid) 
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MS for BY-2 cell suspension 
MS broth, 0.02 % (w/v) 2,4-Dichlorophenoxy acetic acid (Sigma)      
 
MS Agar for Callus    
MS broth, 0.02 % (w/v) 2, 4-Dichlorophenoxy acetic acid (Sigma), 0.8 % (w/v) Plant agar 
(Sigma) 
 
MS Agar for plants     
MS broth, 0.8 % (w/v) Plant agar (Sigma) 
  
 
NBM Agar 
MS broth, 0.00001 % (w/v) α-Napthaleneacetic acid (Sigma), 0.0001 % 6- Bezylaminopurine 
(Sigma) 0.8 % (w/v) Plant agar (Sigma) 
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2.2 General DNA techniques 
2.2.1 Small-scale isolation of plasmid DNA (minipreps) 
The method was based on that of Birnboim and Doly (1979). A culture of E. coli containing 
the required plasmid was grown overnight at 37 °C in 10 ml of LB broth containing 
appropriate antibiotic for the plasmid (100 µg ml
-1
 ampicillin or 100 µg ml
-1
 kanamycin or 25 
µg ml
-1
 tetracycline). Aliquots of bacteria (1.5 ml) were pelleted in microfuge tubes by 
centrifugation for 5 min and re-suspended in 200 µl of solution I by vortexing. Solution II 
(200 µl) was added and the tube gently inverted several times at room temperature. After 5 
min, 200 µl of solution III was added and the tubes were left on ice for 5 min to allow 
precipitation of E. coli chromosomal DNA and denatured protein. The insoluble material was 
pelleted by centrifugation for 10 min in a microfuge. Protein contaminants dissolved in the 
supernatant were removed by successive extractions with phenol and chloroform as follows. 
The supernatant containing plasmids from each tube was transferred into a clean microfuge 
tube and 0.5 ml phenol/chloroform (1:1 v/v) solution was added. The two layers were mixed 
vigorously using a vortex for 1 min. The layers were separated by centrifugation in a 
microfuge for 5 min at top speed. The upper aqueous phase was transferred into clean 
microfuge tube without disturbing the white precipitate at the interface and the extraction was 
repeated with fresh phenol/chloroform (1:1 v/v). The aqueous layer was again transferred into 
a new microfuge tube and an equal volume of chloroform was added to remove any residual 
phenol. The tube was vortexed and layers were separated by centrifugation in a microfuge for 
1 min at top speed. The aqueous phase (about 0.4 ml) was transferred into a clean microfuge 
tube and DNA was precipitated by addition of one tenth volume of 3 M sodium acetate pH 
5.5 and 2.5 volumes of ice-cold absolute ethanol. The contents were mixed thoroughly and 
incubated on ice for 15 min. The ethanol-precipitated DNA was pelleted in a microfuge at top 
speed for 10 min and the supernatant discarded and the pellet washed carefully with 0.5 ml 
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70 % (v/v) ethanol to remove excess sodium acetate. The supernatant was discarded carefully 
and the DNA pellet air-dried for 10 min to remove the last residue of ethanol. The pellet was 
finally re-suspended in 50 µl of TE buffer pH 8.0. 
 
2.2.2 Small-scale isolation of plasmid DNA (minipreps) using Qiagen QIAprep Kit 
This alkaline lysis miniprep method is partially based on that of Birnboim and Doly (1979) as 
described in section 2.2.1. A culture of E. coli containing the required plasmid was grown 
overnight at 37 °C in 10 ml of LB broth containing appropriate antibiotic for the plasmid 
(100 µg ml
-1
 ampicillin or 100 µg ml
-1
 kanamycin or 20 µg ml
-1
 tetracycline). The plasmid 
extractions were carried using the Qiagen QIAprep Kit by following the manufacturers’ 
protocol. 
 
2.2.3 Large-scale isolation of plasmid DNA using QIAGEN Maxi Kit 
A culture of E.coli containing the required plasmid was grown overnight in 100 ml of LB 
broth, containing the appropriate antibiotic for the plasmid (100 µg ml
-1
 ampicillin or 100 µg 
ml
-1
 kanamycin or 20 µg ml
-1
 tetracycline), in a 250 ml conical flask. The culture was 
transferred to a 250 ml polypropylene bottle followed by centrifugation in a Sorvall 
Centrifuge (Thermo Scientific, rotor F14S) for 15 min at 6000g at 4 °C. The plasmid 
extractions were carried using the Qiagen QIAprep Kit by following the manufacturers’ 
protocol. 
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2.2.4 Isolation of total DNA from plant material 
Tobacco leaf or callus tissue (2 g) was ground to a fine powder in a mortar and pestle with 
liquid nitrogen. The ground, frozen plant tissue was added into 4 ml of extraction buffer (100 
mM Tris-HCl pH 8.5, 100 mM NaCl, 50 mM EDTA.Na2 pH 8.0) containing 10 µl of 20 mg 
ml
-1
 proteinase K and 40 µl of 1 M O-phenanthroline. The mixture was shaken gently after 
adding 200 µl of 10 % (w/v) SDS prior to 10 min incubation at 60 °C with occasional 
mixing. In order to precipitate protein and RNA, 1.35 ml of 5 M Potassium acetate was added 
and tubes incubated on ice for 30 min. The precipitate was pelleted by centrifugation at 
3000g in a Sorvall centrifuge (Thermo Scientific, rotor SA-300) for 15 min. The supernatant 
was gently extracted twice by addition of equal volume of phenol/chloroform followed by 
centrifugation at 6000g. The DNA was precipitated by adding 0.54 volumes of isopropanol 
followed by centrifugation. The DNA pellet was re-suspended in 1.6 ml of 0.5M NaCl.  To 
purify the DNA further, 400 µl of 50 % (w/v) PEG-6000 was added and the DNA left to 
precipitate on ice for 2 hours. Finally, DNA was pelleted by centrifugation at 6000g and re-
suspended in 200-400 µl of TE buffer. 
 
2.2.5 Isolation of total DNA from plant material using Qiagen DNeasy Plant Mini Kit 
Tobacco leaf or callus tissue (100 mg) was ground to a fine powder in a microfuge tube using 
a plastic microfuge grinder pestle and liquid nitrogen. The total DNA extractions were carried 
out using the Qiagen DNeasy Plant Mini Kit by following the manufacturers’ protocol. 
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2.2.6 Digestion of plasmid and PCR amplified DNA with restriction endonucleases 
For analytical purposes, digestions were carried out with 0.1 µg of DNA and 1 to 10 units of 
restriction endonuclease in 20 µl reaction volumes for an appropriate duration (usually 1-2 
hours) in a reaction buffer and at a temperature recommended by the manufacturer. For 
preparative scale, digestions were carried out with 2-20 µg of DNA in larger volumes using 
greater amounts of restriction endonuclease as necessary but taking care not to exceed a 
glycerol concentration of 5%.  
 
2.2.7 Agarose gel electrophoresis of DNA 
Agarose gel electrophoresis was performed to separate double-stranded DNA fragments 
using 0.7-2 % (w/v) agarose gels depending on the size of the fragment to be analysed. 
Agarose gels were prepared in perspex trays from agarose in 1 x TAE buffer containing 0.04 
M Tris-acetate and 0.00125 M EDTA with 0.005% SafeView DNA stain and were placed 
horizontally in SCIE-PLAS gel electrophoresis tanks, containing enough TAE buffer with 
0.005 % SafeView DNA stain to submerge the gel. Prior to loading, DNA samples (0.1-10 µg 
of DNA) were mixed with one tenth volume of agarose loading buffer containing 50 % (v/v) 
glycerol, 0.1 % (w/v) bromophenol blue in TE buffer. Electrophoresis was carried out under a 
constant voltage (100 V) for 1-3 hours. Using a suitable standard (Roche DNA molecular 
weight marker III or IV) fragment sizes were determined after visualising with a UV-
transilluminator and taking a digital photograph with a Kodak Gel-Logic Imaging System. 
 
2.2.8 Recovery of DNA from agarose gels using Qiagen QIAquick Gel Extraction Kit 
The fragment to be isolated was visualized under 366 nm UV light and excised with a sterile, 
clean sharp scalpel blade from a 1-2 % Safeview-stained agarose gel. The DNA was purified 
using Qiagen QIAquick Gel Extraction Kit by following the manufacturers’ protocol. 
CHAPTER 2                                                                                                                                                                                 MATERIALS AND METHODS 
 
36 
 
2.2.9 Ligation of DNA restriction fragments with vector DNA 
Vector DNA (1 to 5 µg) was digested with suitable restriction endonuclease(s) in a total 
volume of 50 µl to generate a linearised vector which contains compatible ends with the 
restriction fragments to be ligated. After an appropriate digestion time (2-3 hours), the 
digestion was incubated at 75 °C for 10 min in order to inactivate restriction enzymes. If the 
plasmid cleavage was with a single enzyme, this was followed by addition of 20 units of calf 
intestinal alkaline phosphatase followed by incubation at 37 °C for 1 hour. Cut, 
dephosphorylated fragments of vector DNA were isolated from agarose gels by the QIAquick 
gel extraction method (section 2.2.8). DNA fragment inserts and cut, phosphatase-treated 
vectors (100-200 ng) were mixed 3:1 molar ratio for sticky ends and 7:1 molar ratio for blunt 
ends followed by addition of 3 µl of 10x Ligase buffer (50 mM Tris-HCl, 10 mM MgCl2, 1 
mM ATP, 10 mM Dithiothreitol, pH 7.5) and 10-100 units of T4 DNA ligase in 30 µl total 
reaction volume. The ligation mixture was incubated at 16 °C overnight. Control ligations 
were also carried out with cut, dephosphorylated vector without the insert DNA. After 
ligation, 5 µl of ligation mixture was used to transform competent bacterial cells with the 
ligated product. 
 
2.2.10 Transformation of E. coli with plasmids 
E. coli (DH5α) bacteria were transformed with plasmids using a modification of the method 
of Cohen et al., (1972). LB broth (100 ml) in a 250 ml conical flask was inoculated using 0.5 
ml of an E. coli overnight culture and incubated at 37 °C for 2-3 hours with continuous 
shaking at 200 rpm in an orbital shaker to obtain a culture of E. coli with an A600 of 
approximately 0.5. The cells were then cooled on ice followed by centrifugation for 5 min in 
a Hitachi Himac-CP at 2000g. The supernatant was discarded and the pellet re-suspended in 
10ml of ice-cold 100 mM MgCl2. After 15 min on ice the cell suspension was subjected to 
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centrifugation again and the cells re-suspended in 5 ml of ice-cold 100 mM CaCl2. Cell 
suspensions were divided into 50 µl aliquots in sterile microfuge tubes and plasmid DNA 
(10-20 ng) or ligation mixture (5 µl, section 2.2.9) were incorporated and tubes incubated on 
ice for 30 min.  A heat shock was performed by placing the cells/plasmid mixture in a 42 °C 
water bath for exactly 2 min. The tubes were placed on ice immediately for 2 min and 1 ml of 
LB broth added followed by incubation at 37 °C for 1 hour to allow expression of the 
plasmid-encoded antibiotic-resistance gene. The cells were pelleted by centrifugation in a 
microfuge for 1 min, re-suspended in 100 µl LB broth and spread on an LB plate containing a 
suitable antibiotic (100 µg ml
-1
 ampicillin or 100 µg ml
-1
 kanamycin), X-gal (100 µg ml
-1
) 
and IPTG (50 µg ml
-1
) as appropriate. Plates were incubated overnight at 37 °C.  
 
2.2.11 Amplification of DNA 
DNA was amplified by the polymerase chain reaction (PCR) where each 50 µl reaction mix 
contained 10 pmol forward primers, 10 pmol reverse primers, 10-500 ng of template DNA, 
PCR grade water and 25 µl of High fidelity PCR master mix (Roche). Solutions added were 
mixed thoroughly prior to incubation in the PCR thermal cycler (Primus MWG Biotech) at a 
denaturation temperature of 94 °C for 60 s, annealing temperature of 56 °C for 30 s and 
extension temperature of 72 °C for 90 s for a total number of 30 cycles with a final extension 
time of 10 min. 
 
2.2.12 DNA hybridization techniques 
2.2.12.1 Preparation of Southern blots 
Total DNA (10 µg) was digested using appropriate restriction endonucleases and incubated 
overnight at 37 °C in a volume of 400 µl (section 2.2.6). DNA was precipitated with 2.5 
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volumes of ice-cold ethanol and 0.4 volumes of 5 M sodium acetate pH 5.5 followed by 
centrifugation for 10 min at top speed in a microfuge. Precipitated DNA was re-suspended in 
20 µl TE buffer and subjected to electrophoresis in a 0.7 % agarose gel containing 0.005 % 
SafeView DNA stain, for 16 hours at a constant 80 V. After electrophoresis a digital 
photographic record of the gel was taken on a UV transilluminator. Before DNA transfer the 
gel was soaked in 500 ml of 0.25 M HCl for 15 min, 500 ml of 1.5 M NaCl, 0.5 M NaOH for 
30 min and 500 ml of 1.5 M NaCl, 0.5 M Tris-HCl pH 7.2 for 30 min.  
 
2.2.12.2 Blotting 
Two sheets of 3MM Whatman paper at about 15 mm larger than the gel to be blotted were 
folded over a rectangular glass plate and the glass plate placed on two dishes containing 20x 
SSC so that the end of 3MM paper was immersed in the liquid from either side. The agarose 
gel to be blotted was placed on top of the 3MM paper and a sheet of Saran wrap with a hole 
cut to the size of the gel placed around the gel to allow the flow of liquid through the gel 
only. A sheet of Hybond-N+ (Amersham) 1 mm larger than the gel was placed on top of the 
gel taking care to remove any trapped air bubbles. Three sheets of 3MM paper at slightly 
larger than the nylon membrane was wetted in 20x SSC and placed on top of the nylon 
membrane. A stack of paper towels was placed on top of this along with a glass plate and a 
1.5 kg weight. The blotting apparatus was left overnight to allow for capillary transfer of 
DNA fragments to the nylon membrane. After transfer the nylon membrane was removed 
carefully and soaked in 10x SSC and exposed to 235 nm UV light for 3 min to cross-link 
DNA fragments to the membrane. The nylon membrane was rinsed in sterile double distilled 
water and allowed to air dry. 
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2.2.12.3 Random primer labelling of DNA with DIG 
A Roche kit was used as described in the manufacturers’ protocol. PCR-amplified ADA 
DNA (1 µg) was mixed with 4 µl of DIG-High Prime solution (Digoxigenin-11-dUTP, 
Klenow DNA polymerase enzyme) in a 20 µl of reaction mixture prior to overnight 
incubation at 37 °C. The reaction was stopped by addition of 2 µl of 0.2 M EDTA pH 8.0. 
Determination of the yield of DIG-labelled DNA was carried out with a series of dilutions as 
shown in table 2.1. Spots of 1 µl of dilutions were applied to a nylon membrane followed by 
exposure to 235 nm UV light for 3 min to cross-link DIG-labelled DNA fragments to the 
membrane.  The membrane was blocked by incubation for 30 min with gentle agitation in 10 
ml Blocking Solution (1x Salmon sperm solution, 0.1 M Maleic acid, 0.15 M NaCl; pH 7.5) 
followed by incubation for 30 min in 10 ml of Antibody Solution containing 1:5000 (150 mU 
ml
-1
) dilution of Anti-digoxigenin-AP in Blocking Solution. The membrane was washed 
twice for 15 min in 10 ml of Washing Buffer (0.1 M Maleic acid, 0.15 M NaCl, 0.3 % (v/v) 
Tween 20; pH 7.5) followed by equilibration for 5 min in 10 ml of Detection Buffer (0.1 M 
Tris-HCl, 0.1 M Nacl; pH 9.5). Finally, the membrane was incubated in 2 ml of freshly 
prepared colour substrate solution containing 40 µl of 50x NBT/BCIP stock solution in 2 ml 
of Detection Buffer in the dark for 30 min. The colourimetric reaction was stopped by 
washing the membrane with TE buffer when the required intensity of the dots was appeared 
(Approximately 30 min). Then the optimal concentration of the DNA probe to be used was 
determined by analysing the dot blot. 
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Table 2.1: Dilution series of DIG labelled DNA.  
Tube Dilution Final concentration (pg µl-1) 
1  1000 
2 1:100 10  
3 1:3.3 3  
4 1:10 1  
5 1:10 0.3  
6 1:10 0.1  
7 1:10 0.03  
8 1:10 0.01  
9 - 0 
 
 
2.2.12.4 Hybridization of membrane-bound nucleic acid with DNA probes and 
immunological detection using Roche DIG High Prime Detection Kit 
An appropriate volume of DIG Easy Hyb pre-hybridization solution (0.1 ml cm
-2
 membrane) 
was pre-heated to 47 °C, added to a nucleic acid blot on nylon membrane and pre-hybridized 
for 30 min with gentle agitation. A DIG-labelled DNA probe in determined optimal dilution 
(about 25 ng ml
-1
, section 2.2.12.3) was denatured by boiling for 5 min and rapidly cooled on 
ice. The denatured DIG-labelled DNA probe was added to pre-heated DIG Easy Hyb solution 
(0.035 ml cm
-2 
membrane) and mixed well. The nylon membrane was transferred to the 
hybridization solution containing probe and incubated at 47 °C overnight with gentle 
agitation. After hybridization the membrane was washed twice for 5 min with 2x SSC, 0.1 % 
SDS at room temperature under constant agitation and twice for 15 min with 0.5x SSC, 0.1 % 
SDS at 65-68 °C under constant agitation. The membrane was rinsed briefly for 1-5 min in 
Washing Buffer containing 0.1 M Maleic acid, 0.15 M NaCl and 0.3 % (v/v) Tween 20; pH 
7.5. The membrane was then blocked by incubation for 30 min with gentle agitation in 100ml 
Blocking Solution (1x Salmon sperm solution, 0.1 M Maleic acid, 0.15 M NaCl; pH 7.5) 
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followed by incubation for 30 min in 20 ml of Antibody solution containing 1:5000 (150 mU 
ml
-1
) dilution of Anti-digoxigenin-AP in Blocking solution. The membrane was washed twice 
for 15 min in 100 ml of Washing Buffer followed by equilibration for 5 min in 20 ml of 
Detection Buffer (0.1 M Tris-HCl, 0.1 M NaCl; pH 9.5). Finally, the membrane was 
incubated in 10ml of freshly prepared colour substrate solution containing 200 µl of 50x 
NBT/BCIP stock solution in 10ml of Detection Buffer in the dark for 30 min. The 
colourimetric reaction was stopped by washing the membrane with TE buffer when the 
required intensity of the bands was achieved. The membrane was placed sandwiched in 
between two transparency films and photographic record was taken using an Epson image 
scanner. 
 
2.3 RNA methods 
2.3.1 Isolation of total RNA using a Sigma Plant total RNA Kit  
Beforehand the glassware was baked overnight at 250 °C and plasticware was thoroughly 
washed with 0.1 N NaOH/1 mM EDTA then rinsed with diethyl pyrocarbonate (DEPC)-
treated water to ensure the elimination of RNases. Prepared solutions were treated with 0.05 
% DEPC overnight prior to autoclaving.  Plant tissue or calli (2-10 g) were frozen in liquid 
nitrogen and ground to a fine powder using a mortar and pestle. The ground powder (90-110 
mg) was weighed after evaporation of liquid nitrogen in 2 ml microcentrifuge tube pre-
chilled in liquid nitrogen. The total RNA extraction was carried out using a Sigma Plant total 
RNA Kit by following the manufacturers’ protocol. Eluted RNA was stored at -20 °C.  
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2.3.2 Gel electrophoresis of RNA 
Total RNA was quantified beforehand using a NanoDrop 1000 spectrophotometer, following 
the manufacture's protocol. RNA loading equivalents were then verified by visualising equal 
loadings of SafeView-stained ribosomal RNA bands on a separate 1% agarose gel under a 
UV-transilluminator and taking a photographic record using a Kodak Gel-Logic Imaging 
System. Equal amounts of total RNA (3000 ng) were denatured by mixing with 15 μl of 
sample buffer (48 % (v/v) deionised formamide, 40 mM MOPS pH 7.0, 50 mM Na acetate, 5 
mM EDTA, 6 % (v/v) formaldehyde, 5 % (v/v) glycerol, 0.002 % (w/v) bromophenol blue). 
The sample mixture was incubated at 65 °C for 10 min before loading onto a 1.2 % (w/v) 
agarose gel in 1x running buffer containing 40 mM MOPS pH 7.0, 50 mM Na acetate, 5 mM 
EDTA, 2% (v/v) formaldehyde and 5 % (v/v) SafeView nucleic acid stain. Electrophoresis, at 
constant 40 V was carried out for approximately 5 hours in 1 x running buffer.  
 
2.3.3 Preparation and hybridization of northern blots 
After gel electrophoresis, the gel was equilibrated by incubating twice in 200 ml of 50 mM 
sodium phosphate buffer pH 6.4 over a period of 40 min. A capillary blot was set up as 
described in section 2.2.12.2. After blotting, the nylon membrane was removed carefully and 
soaked in 10x SSC and exposed to 235 nm UV light for 3 min to cross-link the RNA 
fragments to the membrane. The nylon membrane was rinsed in sterile double distilled water 
and allowed to air dry (section 2.2.12.2). Hybridization was carried out as described in 
section 2.2.12.4. 
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2.3.4 Blot analysis 
TotalLab Quant software was used to analyse northern blots. The area of ADA mRNA 
hybridizing bands present on blots were compared to the areas of quantified marker bands in 
order to calculate approximate relative amounts of ADA mRNA in ng. The intensity of RNA 
bands on a northern blot was presumed to be directly proportional to the amount of RNA 
(Wright et al., 1997).  
 
2.4 Tobacco plant and tobacco BY-2 cell transformation 
DNA constructs were transferred into tobacco BY-2 cell suspension culture and whole plants 
by Agrobacterium-mediated transformation. Binary vector pGreenI0029 constructs were used 
in transformations, along with the helper plasmid pSoup (Hellens et al., 2000). 
 
 
2.4.1 Transfer of a pGreenI0029 plasmid constructs to Agrobacterium by 
electroporation 
Agrobacterium tumefaciens AGL1 was grown in 10 ml LB Broth containing 100 µg ml
-1
 
rifampicin for 24 hours at 28 °C with continuous shaking at 300 rpm in an orbital shaker to 
obtain a culture of Agrobacterium with an A600 of approximately 1. The cells were then 
cooled on ice, followed by centrifugation for 5 min in a Hitachi Himac-CP at 2000g. The 
supernatant was discarded and the pellet was washed in 10 ml, 5 ml, 0.2 ml and 0.2 ml 
successive volumes of ice-cold 10 % (w/v) glycerol. Finally, the cells were re-suspended in 
0.1 ml of ice-cold 10 % (w/v) glycerol, separated into 40 µl aliquots and frozen in liquid 
nitrogen and stored for several months at -80 °C. Transformation was set up by addition of 
10-100 ng of construct in pGreenI0029 vector along with 10-100 ng of pSoup vector in 40 µl 
of electro-competent Agrobacterium cells in a 0.2 cm cuvette. Electroporation was carried out 
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in a Bio-Rad electroporation apparatus set at 25 µF, 2.5 kV, 400 Ω followed by dilution of 
the cells by addition of 950 µl of LB broth prior to incubation for 3 hours at 28 °C with 
continuous shaking at 300 rpm in an orbital shaker. The cells were pelleted by centrifugation 
in a microfuge for 1 min, re-suspended in 100 µl of LB broth and spread onto LB plates 
containing 100 µg ml
-1
 kanamycin / 20 µg ml
-1
 tetracycline followed by incubation for 3 days 
at 28°C.  A transformed Agrobacterium colony from the plate was inoculated into 10 ml of 
LB broth containing 100 µg ml
-1
 kanamycin / 20 µg ml
-1
 tetracycline and the culture 
incubated for 3 days at 28 °C with vigorous shaking until the absorption A600 had reached 1. 
The characteristics of the plasmids in the culture were confirmed through plasmid extraction, 
followed by restriction enzyme digestion and gel electrophoresis (section 2.2.6 and 2.2.7). 
 
2.4.2 Transformation of tobacco BY-2 cell suspensions 
The protocol was developed from the method of Rempel and Nelson, (1995). Using 400 µl of 
a 3-day-old binary vector transformed Agrobacterium culture (section 2.4.1), a new LB broth 
containing appropriate antibiotics (100 µg ml
-1
 kanamycin / 20 µg ml
-1
 tetracycline) was 
inoculated and incubated overnight at 28 °C with vigorous shaking at 200 rpm. The 
absorbance of an overnight-grown culture was measured at A600 and diluted to an A600 of 1 in 
LB broth. For tobacco BY-2 transformation, 5 ml of 4-day-old propagated BY-2 cell 
suspension culture containing 5µl of 20mM acetosyringone was co-cultured with 25 µl, 50 µl 
and 100 µl of transformed Agrobacterium LB broth culture (A600=1.0) successively in 100 mm 
Petri dishes. The dishes were sealed with parafilm and incubated at 25 °C for two days. Co-
cultivated tobacco BY-2 cells were transferred from the plate into a 30 ml plastic sterilin tube 
and kept undisturbed for about 10 min until the cells had settled to the bottom of the tube. 
The supernatant was discarded and the cells were washed twice with MS media and twice 
with MS media containing 500 µg ml
-1
 carbenicillin / 500 µg ml
-1
 cefotaxime. Finally, the 
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cells were re-suspended in 5 ml of MS media containing 500 µg ml
-1
 carbenicillin /500 µg 
ml
-1
 cefotaxime. Washed cells (2 ml) were spread onto 100 mm Petri dishes containing MS 
agar, 500 µg ml
-1 
carbenicillin, 500 µg ml
-1 
cefotaxime and 100 µg ml
-1 
kanamycin. Cells 
were spread by gently rocking and swirling the plates and plates were left uncovered in the 
laminar flow hood for 5-10 min until the liquid was absorbed. Finally, the plates were sealed 
with Parafilm and incubated at 25 °C in the dark. Calli were visible after 20-30 days and 
visible calli were transferred onto new MS agar plates containing 
carbenicillin/cefotaxime/kanamycin and grown for 7-14 days in the dark at 25 °C prior to 
expression analysis.  
 
2.4.3 Transformation of tobacco and regeneration of whole plants 
The following protocol was developed from the method of Horsch et al., (1985). LB broth 
containing appropriate antibiotics (100 µg ml
-1
 kanamycin / 20 µg ml
-1
 tetracycline) was 
inoculated with a transformed Agrobacterium culture (section 2.4.1) and incubated overnight 
at 28 °C with vigorous shaking at 200 rpm to obtain a culture of Agrobacterium with an A600 
of approximately 1. Agrobacterium cells were pelleted by centrifugation at 3000 rpm for 15 
min and re-suspended in MS medium, pH 5.9 and absorption was measured at A600 and 
diluted to an A600 of 0.6 by diluting in MS medium.   The Agrobacterium suspensions (25 ml) 
were dispensed into 100 mm Petri dishes.  
 
Healthy and fully-extended leaves were dissected from micro-propagated tobacco plant 
cultures and sterilised by submerging in 30 % sodium hypochlorite solution for 1-2 min. The 
mid-rib and the outer leaf margin were removed and cut into about 1 cm x 1 cm squares with 
a sterile scalpel.  These were transferred directly to the Agrobacterium suspension in a Petri 
dish abaxial surface lowermost and shaken gently to ensure the full submersion of the cut 
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edges of the leaves. These explants were maintained in the Agrobacterium suspension at 
room temperature for 20 min, then removed and dabbed on sterile filter paper to remove 
excess suspension. Explants were transferred to NBM agar, with the abaxial surface of each 
explant in contact with the medium. Plates were sealed with Parafilm and incubated in a lit 
(80 µmol photons m
-2
 s
-1
) incubator at 25 °C, 16 hour photoperiod for 3 days. After which the 
explants were carefully transferred onto NBM agar medium containing 100 µg ml
-1
 
kanamycin, 500 µg ml
-1
 cefotaxime and 500 µg ml
-1
 carbenicillin. Shoots started to 
regenerate from the callus forming on leaf explants after 4-6 weeks. The shoots were cut with 
flame-sterilised scissors and transferred onto Elongation Medium (MS medium, 30 g L
-1
 
sucrose, 8 g L
-1
 plant agar, 100 µg ml
-1
 kanamycin, 500 µg ml
-1
 cefotaxime, 500 µg ml
-1
 
carbenicillin, pH 5.9).  Readily rooted stable transgenic plants were formed after 3- 4 weeks, 
whilst untransformed shoots bleached and died. 
 
2.5 Protein methods  
2.5.1 Isolation of total soluble proteins from plant material  
Tobacco leaf or calli tissues (0.1-1 g) were ground to a fine powder in a microfuge tube using 
a microfuge tube grinder in liquid nitrogen and homogenised in 400 µl of chilled extraction 
buffer containing 50 mM potassium phosphate pH 7.5, supplemented with 37.50 g L
-1
 
polyvinylpyrrolidone 40,000MW. The homogenate was then subjected to centrifugation at 
10,000g for 10 min at 4 °C to remove plant cell debris.  
 
2.5.2 Enzymatic assay for adenosine deaminase  
An Adenosine deaminase assay kit (Bioquant, USA) was used to determine levels of ADA in 
transformed plant and cell extracts (section 2.5.1). The assay is based on the enzymatic 
conversion of adenosine to inosine by ADA followed by the conversion of inosine to 
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hypoxanthine by purine nucleoside phosphorylase (PNP). Furthermore, xanthine oxidase 
(XOD) catalizes the conversion of hypoxanthine to uric acid and hydrogen peroxide. In the 
presence of peroxidase (POD), hydrogen peroxide reacts with N-Ethyl-N-(2-hydroxy-3-
sulfopropyl)-3-methylaniline (EHSPT) and 4-aminoantipyrine (4-AA) to generate a quinine 
dye which can be detected in a kinetic manner by measuring the change in absorbance at 550 
nm on a Thermo Multiskan plate reader (Thermo, USA). 
 
Principle: 
 
 
 
 
 
 
 
 
Total soluble proteins (TSP) were isolated from plant tissues or calli using 400 µl of chilled 
extraction buffer (section 2.5.1). From the soluble protein solution, 5 µl was removed and 
mixed with 180 µl of R1 solution (50 mM Tris.HCl pH 8.0, 2 mM 4-AA, 0.1 U ml
-1
 PNP, 0.2 
U ml
-1 
XOD, 0.6 U ml
-1 
Peroxidase) and incubated for 3 min at 37 °C. R2 solution (90 µl) 
containing 50 mM Tris.HCl pH 4.0, 10 mM adenosine and 2 mM EHSPT was added and 
incubated for 5 min at 37 °C. The absorbance was monitored at 550 nm in a Thermo 
Multiskan plate reader (Thermo, USA) for 3 min with 1 min intervals to obtain absorbance 
min
-1
 values. Assays were performed in triplicate. The average rate of the absorbance change 
(ΔA min-1) was calculated from 3 separate assays per transformants and ADA activity in 
units per litre protein extract was calculated using the formula below. Similarly, 5 µl of calf 
550nm)max  ( dye Quinone +O4HEHSPT +AA -4 + O2H      
O2H + acid Uric2O + O2H + neHypoxanthi      
 phosphate-1 Ribose + neHypoxanthiPi + Inosine      
 NH + Inosine OH + Adenosine      
 22
POD
22
22
XOD
 22
PNP
3
ADA
2




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intestinal ADA (Sigma) was analysed as a control. For plants ADA activities from young, 
medium and old leaf samples were combined and assayed. 
 
 
 
 
 
Tv  =  Total reaction volume (ml) = 0.275 ml 
Sv =  Sample volume (ml) = 0.005 ml 
ε  =  μmolar extinction coefficient of quinone dye (ε = 32.2 x 10
-3 
μM-1cm
-1
) 
L  =  Cuvette light path length (1.0 cm) 
 
2.5.3 Protein Assay  
Determination of the amount of total soluble protein from protein extracts (section 2.5.1) 
were performed using a method based on that of Bradford, (1979). Bovine serum albumin 
(BSA) 1 mg ml
-1
 was prepared in distilled water and diluted to 0.1 mg ml
-1
 in protein 
extraction buffer (section 2.5.1). Diluted BSA (100 µg ml
-1
), distilled water and 25 µl of 
Bradford reagent (Sigma) was mixed as shown in the table 2.2 in 96 well microtitre plates 
and the absorbance measured at 590 nm using a Thermo Multiskan plate reader (Thermo, 
USA). Assays were performed in triplicate and a standard curve was plotted. The protein 
extract from transformed plants or calli was diluted 10 fold and 2 µl of diluted sample was 
added to 98 µl of distilled water prior to addition of 25 µl Bradford reagent. Absorbance at 
590 nm was measured and the amount of total soluble protein determined from the standard 
curve. 
1708x minA 
 L x Sv x 
 Tv x minA 
 )L (UnitsADA 1-
-1
1- 



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Table 2.2: Protein assay. 
BSA 100µg ml-1 (µl) H2O (µl) Bradford (µl) total µg BSA 
0 100 25 0.0 
3 97 25 0.3 
6 94 25 0.6 
9 91 25 0.9 
12 88 25 1.2 
 
 
2.5.4 SDS-polyacrylamide gel electrophoresis of proteins 
The method used was that of Laemmli, (1970) using the Bio-Rad Miniprotein II apparatus. A 
12 % (w/v) polyacrylamide gel was prepared in a total volume of 10 ml by adding 20 µl of 
TEMED and 100 µl of 10 % (w/v) ammonium persulphate to a solution containing 12 % 
(w/v) acrylamide, 0.4 % (w/v) NN'-methylenebisacrylamide, 0.375 M Tris-HCl pH 8.8 and 
0.1 %  (w/v) SDS. Also a stacking gel was prepared in a total volume of 5 ml by adding 10 µl 
of TEMED and 50 µl of 10 % (w/v) ammonium persulphate to a solution containing 5 % 
(w/v) acrylamide, 0.133 % (w/v) NN'-methylenebisacrylamide, 0.125 M Tris-HCl pH 6.8 and 
0.1 % (w/v) SDS. The gel was prepared in a Bio-Rad gel casting unit using 5 ml of 12 % 
polyacrylamide gel mixture and 2 ml of 5 % polyacrylamide stacking gel mixture. Sample 
proteins were diluted at 1:4 ratios with sample buffer containing 0.625 mM HCl, 9.5 % (w/v) 
glycerol, 2 % (w/v) SDS, 5 % (v/v) 2-β-mercaptoethanol and 0.00125 % (w/v) Bromophenol 
blue. Proteins containing samples and pre-stained protein standards were separated by 
electrophoresis through the polyacrylamide gel using a running buffer containing 0.2 M 
glycine, 0.1 % (w/v) SDS and 0.025 M Tris pH 8.3 at constant voltage (200 V) for one hour. 
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2.5.5 Western blotting 
Transfer of proteins from polyacrylamide gels to nitrocellulose was performed by a method 
based on that of Polvino et al., (1983). The gel was placed on a sheet of Hybond-C 
(Amersham) nitrocellulose membrane and sandwiched between two sheets of Whatmann 
3MM paper soaked in transfer buffer (25 mM Tris base, 192 mM glycine, 20 % (v/v) 
methanol, 0.1 % (w/v) SDS). The sandwich was then placed on the Mylar mask in a 
SemiPhore semi-dry transfer unit and two additional pieces of buffer-soaked Whatmann 
3MM paper placed on the stack. The transfer of proteins was performed under a constant 
current of 100 mA for 30 min. After transfer the membrane was immersed in 5% Skimmed 
milk-TBS (20 mM Tris-HCl pH 7.5, 0.5 M NaCl) on a plastic tray and incubated overnight at 
25 °C, followed by two washes in TBST (20 mM Tris-HCl pH 7.5, 0.5 M NaCl, 0.05 % (v/v) 
Tween-20). The membrane was incubated for 1 hour with continuous rocking with TBST 
containing rabbit anti-ADA antibodies at an optimal dilution of 1:3000 (optimal dilution was 
determined by the dot blot of a series of antibody dilutions). The membrane was then washed 
twice in TBST and incubated for 1 hour with continuous rocking in TBST containing anti-
rabbit IgG conjugated to horseradish peroxidase. Incubation was followed by two washes in 
TBST prior to incubation for 5 min in 10ml Developing Buffer containing 4 mg ml
-1
 luminol 
in TBS pH 7.5, 0.2 mg ml
-1
 4-iodophenol and 25 µl of 30 % hydrogen peroxide (H2O2). The 
membrane was sandwiched between transparency film and hybridizing bands were visualised 
in Typhoon scanner (Amersham). TotalLab Quant software was used to analyse western blots. 
The area of hybridizing bands present on blots were compared to the areas of quantified control 
ADA bands in order to calculate approximate relative amounts of recombinant ADA in micro 
grams. 
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2.5.6 Thrombin cleavage of ADA-hydroxyproline fusion.  
Tobacco BY-2 calli, cell suspension extract or cell suspension media (400 µl) of ADA-
hyroxyproline fusion protein was mixed with 20 Units of thrombin prior to incubation at 22 
°C for 16 hours. A control ADA lacking hydroxyproline fusion was also incubated. 
 
2.6 Statistical analysis 
Expression levels of the same transgene in independent transformants do not assume a normal 
distribution. Therefore, Mann-Whitney U test, a distribution-free statistical test based on 
median values was used to evaluate significant difference between any two gene-constructs. 
Any two gene constructs being compared were combined and ranked by ascending expression 
levels. U-values were calculated using the following formulae: 
 
 
 
 
Where R1 is the sum of the ranks assigned to ADA specific-activities from construct-1, whose 
sample size is n1 and R2 is the sum of ranks assigned to ADA specific-activities from construct-
2, whose sample size is n2. The U values were compared with a critical region table indicating 
the level of significance at 5%.  
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3.1 Overview 
Plants possess an efficient eukaryote protein production mechanism, and with presently 
accessible gene expression systems, plants can readily produce enormous amounts of 
recombinant protein (Obembe et al., 2011). Tobacco cells and whole plants are frequently 
used in foreign gene expression owing to the characteristics of simple, well established 
transformation and propagation protocols. The recombinant protein gene construct design is 
an important factor determining the foreign protein yield. For example, choice of promoter 
affects the yield of recombinant products by influencing the transcription rate. Hence, the 
choice of promoter should be evaluated on an empirical basis. Since the isolation in the early 
1980’s by Chua and collaborators at the Rockefeller University, the CaMV 35S promoter is 
the most extensively used promoter in plant expression systems expressing recombinant 
proteins at high-levels (Odell et al., 1985; Sanders et al., 1987; Gutierrez-Ortega et al., 2005). 
The CaMV 35S promoter sequence has been modified by tandem duplication of a 250 bp 
upstream sequence which in turn enhances the efficiency of expression by approximately 10-
fold (Kay et al., 1987). However, subsequently the use of strong promoters has often been 
associated with posttranscriptional gene silencing and their use is now limited (Que et al., 
1997; Schubert et al., 2004). Since first use in the 1980’s, the CaMV 35S promoter has been 
used to produce many proteins of therapeutic and industrial importance, such as Cholera 
toxin B, SARS virus glycoprotein S, avidin and adiponectin  (Jani et al., 2002; Kang et al., 
2004c; Li et al., 2006b; Murray et al., 2002). The CaMV 35S promoter has the ability to 
carry out continuous expression of recombinant proteins and is not greatly influenced by 
environmental conditions or tissue types, hence it is the promoter of choice in many plant 
expression systems (Ho et al., 1999; Huang and McDonald, 2009).  
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Translational regulation is also an important factor in eukaryotic gene expression. Choice of 
strong translational enhancer/regulation sequences is equally as important as the choice of an 
efficient promoter when seeking to increase the yield of recombinant products. Most of the 
regulation in translation occurs at the initiation steps in the 5’-untranslated region (mRNA 5’ 
leader sequence). There are two very important mechanisms by which translational initiation 
occurs in eukaryotic cells. They are (i) cap-dependent initiation and (ii) internal ribosome 
entry (Pickering and Willis, 2005). RNA plant viruses, on the other hand, exhibit several 
different mechanisms by which they regulate gene expression at the translational level. 
Tobacco mosaic virus (TMV) UTRs represent the most widely used translational regulation 
sequences for generate high yield constructs in plants (Schmitz et al., 1996).  
 
There are several other plant translational regulator sequences used to make foreign gene 
constructs, one of which is the RUBISCO small subunit 5’ UTR. Ribulose-1, 5-bisphosphate 
carboxylase/oxygenase (RUBISCO) is an enzyme which catalyzes the primary step in carbon 
fixation in plants (Mazur and Chui, 1985). It is a multimeric enzyme composed of eight large 
and eight small subunits and is the most abundant protein present in plants. Patel et al., (2004) 
demonstrated that the untranslated region from C4 Amaranth RUBISCO small subunit1 
mRNAs confer translational enhancement which leads to increased expression of foreign 
proteins. Patel et al., (2006) further demonstrated that incorporation of untranslated regions of 
Flaveria bidentis RUBISCO small subunit1 also enhanced translation of associated sequences. 
 
Although, the foreign protein expression in plants can be enhanced by the use of various 
promoter and UTR sequences, in order to achieve commercial success of plant-based 
production systems, improvments of foreign protein accumulation is also pivotal (Doran, 
2004). Once produced most foreign proteins expressed in heterologous systems undergo 
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constant degradation due to processes such as proteolysis and irreversible surface adsorption 
(Doran, 2006). Hence, it is of much importance to take steps in order to reduce foreign 
protein loss by these processes, in turn leads to accumulation.  Conrad and Fielder, (1998) 
showed that directing produced proteins to the endoplasmic reticulum (ER) effectively 
reduces the foreign protein degradation and loss. Wirth et al., (2004) showed that 
recombinant human epidermal growth factor directed to ER increased the yield by a 10
4
-fold 
as compared to cytosolic counterpart. The plant cell ER contains less protease activity and 
also contains important chaperones (Protein binding motifs BiP) which give a protective 
environment to foreign proteins (Nuttal et al., 2002). Hence, the use of signal peptides 
(KDEL or HDEL) in order to retain recombinant proteins in the ER can also be used to 
reduce protein degradation and direct correct folding of the polypeptide chain. 
 
Certain proteins which contain an N-terminal signal peptide sequence undergo secretion into 
the apoplastic space. Signal sequences such as tobacco pathogenesis related protein (PR1a) 
when used in conjunction with recombinant proteins can direct foreign proteins into the 
apoplast (Pen et al., 1993a). Ziegler et al., (2000) effectively produced the catalytic domain of 
a bacterial thermostable endo-1, 4-β-D-glucanase in the apoplast of Arabidopsis leaves and 
BY2 cell suspensions. Incorporation of a PR1a signal peptide at the N-terminus increased the 
accumulation level by up to 26% of TSP (Ziegler et al., 2000). Another apoplast directing 
signal is found at the N-terminus of plant extensins which are well-characterized 
hydroxyproline-rich glycoproteins forming a major component of the cell wall (Showalter, 
1993). Incorporation of an extensin signal peptide sequence at the N-terminal of the 
recombinant protein directs secretion into the apoplast. For example, Francisco et al., (1997) 
expressed Bryodin 1, a potent ribosome-inactivating protein, as a soluble recombinant protein 
in BY-2 cell cultures, using the extensin signal peptide sequence to secrete the protein into 
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the culture medium. Purified Broyodin 1 yield was 30 mg L
-1
 of culture and showed identical 
inhibitory activity to native Bryodin 1 isolated from the roots of Bryonia dioica. 
 
Hydroxyproline(Hyp)-rich glycoproteins (HRGPs) are structural glycoproteins distinctively 
associated with the plant cell wall (Lamport, 1977). HRGP motifs are evolutionary conserved 
and extremely O-glycosylated through the Hydroxyproline (Hyp) residues.  Shpak, (2001) 
reported that two types of glycomodules are resulted by unique post-translational 
modifications, involving Hyp motifs. One of which is formed by the addition of short 
unbranched arabinooligosaccharides to a contiguous Hyp residues, whereas the other is formed 
by the addition of branched arabinogalactan polysaccharides to clustered non-contiguous Hyp 
residues (Shpak, 2001). This includes repeats of X-Hyp-X-Hyp motifs where X is frequently 
Ser or Ala and leads to an increase in molecular weight of the protein (Kieliszewski and 
Lamport, 1994). Chimeric constructs of foreign genes linked to these HRGP motifs at the C-
terminal have shown high-level expression of linked therapeutic proteins. For example 
HRGPs linked to interferon alpha2 (IFNα2) direct extensive Hyp O-glycosylation leading to 
addition of arabinooligosaccharides resulting in an arabinogalactan protein (AGP) which 
when, targeted for secretion into the apoplast, increased the yield of secreted recombinant 
protein by 350–1400-fold as compared to a non-glycosylated IFNa2 control (Xu, 2008). 
Targeting recombinant proteins into the apoplast through sub-cellular targeting protects 
recombinant proteins from proteolytic degradation and accumulation.  
 
The above strategies for stabilizing foreign gene mRNAs and targeting recombinant products 
have been employed in designing and generating various ADA constructs in order to increase 
the yield of recombinant human ADA in tobacco whole plants and cell suspensions.  
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3.2 Constructs designed to increase cytosolic levels of human ADA  
  Table 3.1: Cytosolic constructs. 
Constructs  Code 
Human ADA cDNA pCDNA_ADA 
Minimal 5’ UTR   p∆5’UTR_ADA 
TMV Omega 5’UTR  p5’Omega_ADA 
TMV Omega 5’_3’ UTR p5’_3’ Omega_ADA 
RUBISCO SS 5’ UTR pSS 5’UTR_ADA 
 
 
3.2.1 Human ADA cDNA (pCDNA_ADA) construct design 
In order to generate an ADA cDNA insert with restriction enzyme sites for insertion into the 
35S CaMV cassette of pJIT a three step cloning procedure was necessary. Firstly, the ADA 
cDNA clone (figure 3.1) provided in pCMV6 was isolated from the vector by NotI digestion. 
The NotI digested and gel-purified ADA cDNA was inserted into NotI digested pUBS and the 
resulting construct was transformed into E.coli and transformants selected. The recombinant 
plasmid pUBSADA was extracted from one transformant and digested with XbaI to produce 
an insert with XbaI ends. The gel- extracted ADA cDNA was ligated into XbaI digested pJIT 
in between the 35S CaMV promoter and terminator cassette. The insertion of ADA cDNA into 
pJIT was confirmed by restriction enzyme mapping using XbaI to release ADA cDNA from 
pJIT (figure 3.2b). Restriction enzyme digestion of plasmid minipreps of pJITADA digests, 
(lanes 2 to 9 of figure 3.2b) generated two fragments at 1.4 kbp and 2.9 kbp which confirmed 
the insertion of ADA (1.4 kbp) into pJIT (2.9 kbp). 
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Finally, the construct in pJIT 35S cassette was inserted into the pGreenI0029 T-region by 
digestion of pJITADA and pGreenI0029 with EcoRV. E.coli DH5α was transformed with 
ligated pGreenI0029-35SADA and transformants selected. Putative transformants containing 
pGreenI0029-35SADA plasmid were isolated and the insertion of 35SADAcDNA into 
pGreenI0029 was confirmed by restriction enzyme mapping using EcoRV to release 35SADA 
cDNA from pGreen (figure 3.3b). Restriction enzyme digestion of isolated pGreenI0029-
35SADA with EcoRV generated two fragments in all digests (figure 3.3b) at 2.1 kbp and 4.6 
kbp. Hence, confirming the insertion of 35SADA (2.1 kbp) into pGreenI0029 (4.6 kbp). 
 
Electrocompetent Agrobacterium tumefaciens AGL1 were transformed with pGreenI0029-
35SADA along with the helper plasmid pSoup (section 2.4.1). Transformants were selected 
and transformation was confirmed by remapping of plasmid isolates from Agrobacterium 
transformants using SalI. (figure 3.4) SalI restriction enzyme digestion of plasmids isolated 
from transformed Agrobacterium clones generated two linearized vector fragments in all 
digests shown in figure 3.4. DNA fragments running at approximately 6.1 kbp confirmed the 
presence of pGreenI0029-35SADA plasmid whereas fragments running at approximately 9.7 
kbp confirmed the presence of pSoup. Tobacco BY-2 cell suspensions and whole plants were 
transformed with the pGreenI0029-35SADA construct using Agrobacterium mediated 
transformation (section 2.4.2 and section 2.4.3) and transformants were selected after 5-6 
weeks of transformation and ADA activity measured (section 2.5.2). 
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Figure 3.1: Human ADA cDNA, DNA sequence in blue, depicts the open reading frame of ADA. Sequence in green 
before ATG start codon depicts 129 bp 5’ UTR region whereas sequence in red depicts 345 bp 3’ UTR (Wiginton et al., 
1983). 
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(a) 
 
 
 
(b) 
 
Figure 3.2: (a) A human cDNA clone for ADA inserted into pJIT XbaI sites. Downstream of the 35S CaMV promoter 
(b) SafeViewTM stained 1% agarose gel, lanes 1 to 10 XbaI digested pJITADA; lane 11: Roche molecular weight marker 
IV. 
 
CHAPTER 3                                   DESIGN AND GENERATION OF ADA GENE EXPRESSION CONSTRUCTS IN PGREEN FOR TOBACCO 
TRANSFORMATION 
 
61 
 
 
(a) 
 
 
 
(b) 
Figure 3.3: (a) Human ADA cDNA including 35S CaMV promoter and terminator inserted into the EcoRV site of 
pGreenI0029 (b) SafeViewTM stained 1% agarose gel, lanes 1 to 10: EcoRV digested pGreenI002935SADA; lane 11: 
Roche DNA molecular weight marker IV. 
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Figure 3.4: SafeViewTM stained 1% agarose gel, lanes 1 to 5: SalI digested pGreenI002935SADA (6193 bp) and pSoup 
(9274 bp); lane 6: Roche DNA molecular weight marker IV. 
 
 
3.2.2  Minimal 5’ UTR (p∆ 5’ UTR_ADA) construct design 
The minimal 5’ UTR, containing 21 bp was engineered between the 35S CaMV promoter and 
the ADA ATG initiation codon (figure 3.5). To make this construct, ADA was PCR amplified 
from pCMV6-ADA cDNA using a forward primer 
(5’GAAATCTAGAAAAATGGCCCAGACG3’) and reverse primer 
(5’CTTTGAATTCTCAGAGGTTCTGCCCT3’). Primers were designed to contain an XbaI 
(TCTAGA) restriction site, an ATG initiation codon followed by the next 9 nucleotides of the 
ADA ORF cDNA sequence in the forward primer. The reverse primer included an EcoRI 
(GAATTC) restriction site, a TCA complimentary stop codon and 13 nucleotides from the 5’ 
end of the complementary ORF of ADA.   
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Figure 3.5: Schematic diagram depicting minimal 5’ UTR configuration. 
 
PCR-amplified ADA (PCRADA) was digested with XbaI/EcoRI, gel-extracted and inserted 
into XbaI/EcoRI digested pJIT in between 35S promoter and terminator cassette (figure 3.6). 
The resulting construct was transformed into E.coli and transformants were selected. Several 
ampicillin-resistant colonies were chosen and pJIT-∆ 5’ UTR-PCRADA was extracted. The 
insertion of PCR-ADA into pJIT was confirmed by restriction enzyme mapping using XbaI and 
EcoRI to release PCR-ADA from pJIT. 
Finally, the construct ∆ 5’ UTR-PCRADA in pJIT, along with the 35S cassette (figure 3.6) 
was inserted into pGreenI0029 T-region by digestion of pJIT-∆ 5’ UTR-PCRADA and 
pGreenI0029 with EcoRV, followed by gel- extraction and ligation of vector and insert DNA. 
E.coli DH5α was transformed with the ligated pGreenI0029-35S-∆ 5’ UTR-PCRADA and 
transformants were selected. The pGreenI0029-35S-∆ 5’ UTR-PCRADA plasmid was 
isolated and the insertion of 35S-∆ 5’ UTR-PCRADA into pGreenI0029 was confirmed by 
restriction enzyme mapping using EcoRV to release 35S-∆ 5’ UTR-PCRADA from pGreen.  
Electrocompetent Agrobacterium tumefaciens AGL1 were transformed with pGreenI0029-
35S-∆ 5’ UTR-PCRADA along with the helper plasmid pSoup as described in section 2.4.1. 
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Transformants were selected and transformation was confirmed by mapping of plasmid 
isolates from Agrobacterium transformants using SalI.  
 
Figure 3.6: Schematic diagram of the gene construct CaMV promoter- p∆ 5’ UTR_ADA. 
 
 
3.2.3 TMV Omega 5’ UTR (p5’ Omega_ADA) construct design 
A synthetically synthesized 5’ TMV Omega (Ω) sequence (Gallie, 2002) (MWG-Biotech AG) 
(Figure 3.7) containing 80 bp and HindIII/XbaI restriction sites was inserted upstream (into 
HindIII and XbaI sites) of the ADA ORF in p∆ 5’ UTR_ADA construct (figure 3.6). The 
resulting construct was transformed into E.coli and transformants were selected. Several 
ampicillin-resistant colonies were chosen and putative pJIT-5’ Ω-PCRADA transformants 
were extracted for plasmid DNA. The insertion of 5’ Ω into p∆ 5’ UTR_ADA was confirmed 
by restriction enzyme mapping using HindIII and EcoRI to release 5’ Ω-PCRADA from pJIT, 
and further confirmed using DNA sequence analysis. 
 
 
 
Figure 3.7: Tobacco Mosaic Virus (TMV) 5’Omega UTR DNA sequence with HindIII and XbaI restriction enzyme sites 
(Gallie et al., 1987). 
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Figure 3.8: A PCR-amplified ADA cDNA and 5’Ω TMV UTR DNA inserted into pJIT, downstream of the 35S CaMV 
promoter (p5’ Omega_ADA construct). 
 
Finally, the construct p5’ Omega_ADA in pJIT, along with the 35S cassette (figure 3.8) was 
inserted into pGreenI0029 T-region by digestion of p5’ Omega_ADA and pGreenI0029 with 
EcoRV, followed by gel- extraction and ligation of vector and insert DNA. E.coli DH5α was 
transformed with the ligated pGreenI0029-35S-5’Ω-PCRADA and transformants were 
selected. The pGreenI0029-35S-5’Ω-PCRADA plasmid was isolated and the insertion of 35S-
5’Ω-PCRADA into pGreenI0029 was confirmed by restriction enzyme mapping using EcoRV 
to release 35S-5’Ω-PCRADA from pGreen.  
 
Electrocompetent Agrobacterium tumefaciens AGL1 were transformed with pGreenI0029-
35S-5’Ω-PCRADA along with the helper plasmid pSoup. Transformants were selected and 
transformation was confirmed by remapping of plasmid isolates from Agrobacterium 
transformants using SalI restriction enzyme.  
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3.2.4 TMV Omega 5’ and 3’ UTR (p5’_3’ Omega_ADA) construct design 
A synthesized 3’ TMV Omega (Ω) sequence (Gallie, 2002) (from MWG-Biotech AG) (figure 
3.8) containing 204 bp and EcoRI restriction sites was inserted downstream (into EcoRI site) of 
p5’Omega_ADA (figure 3.10). The resulting construct was transformed into E.coli and 
transformants were selected. Several ampicillin-resistant colonies were chosen and putative 
p5’_3’ Omega_ADA plasmids were extracted. The insertion of 3’ UTR into p 5’Omega_ADA 
was confirmed by restriction enzyme mapping using EcoRI to release 5’ Ω-PCRADA-3’UTR 
from pJIT and further confirmed using DNA sequence analysis. 
 
 
Figure 3.9: Tobacco Mosaic Virus (TMV) 3’ un-translated region DNA sequence (Gallie and Walbot, 1990). 
 
 
 
Figure 3.10: TMV Ω 3’UTR inserted into EcoRI site of p5’ Omega_ADA construct. 
 
 
Finally, the construct p5’_3’Omega_ADA, along with the 35S cassette was inserted into 
pGreenI0029 T-region by digestion of p5’_3’Omega_ADA construct in pJIT and pGreenI0029 
with EcoRV, followed by gel-extraction and ligation of vector and insert DNA. E.coli DH5α 
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was transformed with the ligated pGreenI0029-p5’_3’Omega_ADA construct and the 
transformants were selected. The pGreenI0029 plasmid containing p5’_3’Omega_ADA 
construct was isolated and the insertion of p5’_3’Omega_ADA construct into pGreenI0029 
was confirmed by restriction enzyme mapping using EcoRV to release 35S-5’Ω-PCRADA 
from pGreen.  
 
Electrocompetent Agrobacterium tumefaciens AGL1 were transformed with pGreenI0029-
35S5’_3’Ω-PCRADA along with the helper plasmid pSoup. Transformants were selected and 
transformation was confirmed by remapping of plasmid isolates from Agrobacterium 
transformants using SalI restriction enzyme. 
 
3.2.5 RUBISCO small subunit 5’ UTR (pSS 5’UTR_ADA) construct design 
To engineer pSS 5’UTR_ADA a synthetically synthesized 5’ RUBISCO small subunit DNA 
sequence (Mazur and Chui, 1985) (figure 3.11) containing 128 bp and HindIII/XbaI restriction 
sites was inserted up-stream of the PCR amplified ADA in p∆5’UTR_ADA (figure 3.12). The 
resulting construct was transformed into E.coli and transformants were selected. Several 
ampicillin-resistant colonies were chosen and putative pSS 5’UTR_ADA transformants were 
extracted. The insertion of 5’ RUBISCO small subunit sequence into p∆5’UTR_ADA was 
confirmed by restriction enzyme mapping using HindIII and EcoRI to release 5’ SS UTR-
PCRADA from pJIT and further confirmed using DNA sequence analysis. 
 
 
Figure 3.11: 5’ Tobacco RUBISCO small subunit 5’ UTR DNA sequence (Mazur and Chui, 1985). 
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Figure 3.12: A RUBISCO small subunit 5’UTR inserted into p∆5’UTR_ADA construct (pSS 5’UTR_ADA construct). 
 
Finally, the construct pSS 5’UTR_ADA, along with the 35S cassette (figure 3.12) was inserted 
into pGreenI0029 T-region by digestion of pSS 5’UTR_ADA construct in pJIT and 
pGreenI0029 with EcoRV, followed by gel-extraction and ligation of vector and insert DNA. 
E.coli DH5α was transformed with the ligated pGreenI0029- pSS 5’UTR_ADA construct and 
the transformants were selected. The pGreenI0029 plasmid containing pSS 5’UTR_ADA 
construct was isolated and the insertion of pSS 5’UTR_ADA construct into pGreenI0029 was 
confirmed by restriction enzyme mapping using EcoRV to release 35S-5’SS UTR-PCRADA 
from pGreen.  
 
Electrocompetent Agrobacterium tumefaciens AGL1 were transformed with pGreenI0029-
35S-5’SS UTR-PCRADA along with the helper plasmid pSoup. Transformants were selected 
and transformation confirmed by re-mapping of plasmid isolates from Agrobacterium 
transformants using SalI.  
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3.3 Constructs designed to increase levels of human ADA in tobacco by 
directing recombinant protein to the apoplast 
   Table 3.2:  Subcellular targeting constructs. 
Constructs  Code 
TMV Omega 5’UTR PR1a  
TMV Omega 5’UTR Extensin  
p5’Omega-PR1a_ADA 
p5’Omega-Extensin_ADA  
3’Hydroxyproline  p5’Omega-Extensin_ADA-3’Hydroxyproline  
 
3.3.1 TMV Omega 5’UTR PR1a and TMV Omega 5’UTR Extensin (p5’Omega-
PR1a_ADA and p5’Omega-Extensin_ADA) construct design 
A PR1a-ADA transcriptional fusion sequence, including 87 bp coding for the N-terminal 
portion of PR1a (Ziegler et al., 2000) and the first 20 5’-terminal codons of the ADA ORF was 
synthesized (figure 3.13). PR1a-ADA was designed to contain from 5’ end an XbaI site, an 
ATG initiation codon, 87 bp of PR1a sequence and the first 60 bp of 5’ ADA ORF sequence 
up to an internal BamHI site in the ADA ORF (figure 3.13). To insert the PR1a sequence 5’ 
to the ADA ORF, the PR1a-ADA fusion sequence was digested with XbaI/BamHI, gel-
extracted and inserted into XbaI/BamHI-digested p5’Omega_ADA in pJIT (figure 3.15a). 
E.coli DH5α was transformed with p5’Omega-PR1a_ADA and transformants were selected. 
Several ampicillin-resistant colonies were chosen and putative p5’Omega-PR1a_ADA 
plasmids were extracted. The insertion of PR1a-ADA fusion into p5’Omega_ADA was 
confirmed by DNA sequence analysis and restriction enzyme mapping using HindIII and 
EcoRI to release 5’ Omega-PR1a-PCRADA from pJIT. 
Similarly an extensin-ADA fusion sequence, including a 5’ signal sequence from tobacco 
extensin (Loose et al., 1990) and the 5’ end of the ADA ORF sequence up to an internal 
BamHI site was synthesized (figure 3.14). The extensin-ADA was designed to contain a 5’ 
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XbaI site, an ATG initiation codon, 75 bp 5’ tobacco extensin sequence and the first 60 bp of 
5’ ADA ORF sequence up to an internal BamHI site (figure 3.14).  To insert the extensin 
sequence 5’ to the ADA ORF, the extensin-ADA fusion sequence was digested with 
XbaI/BamHI, gel-extracted and inserted into XbaI/BamHI digested, gel-extracted 
p5’Omega_ADA in pJIT (figure 3.15b). E.coli DH5α was transformed with p5’Omega-
Extensin_ADA and transformants were selected. Several ampicillin-resistant colonies were 
chosen and putative p5’Omega-Extensin_ADA plasmids were extracted. The insertion of 
Extensin-ADA fusion into p5’Omega_ADA was confirmed by DNA sequence analysis and 
restriction enzyme mapping using HindIII and EcoRI to release 5’ Omega-Extensin-PCRADA 
from pJIT. 
The pJIT constructs, p5’Omega-PR1a_ADA and p5’Omega-Extensin_ADA were separately 
isolated by EcoRV digestion of pJIT5’Omega-PR1a_ADA and pJIT5’Omega-Extensin_ADA 
prior to gel-extraction. Isolated 5’Omega-PR1a_ADA and 5’Omega-Extensin_ADA fragments 
were separately inserted into EcoRV digested and gel-extracted pGreenI0029 T-region. E.coli 
DH5α was separately transformed with pGreenI0029-5’Omega-PR1a_ADA and 
pGreenI0029-5’Omega-Extensin_ADA and transformants selected. Transformed colonies 
were grown separately and putative pGreenI0029-5’Omega-PR1a_ADA and pGreenI0029-
5’Omega-Extensin_ADA plasmids extracted. Insertion of constructs into plasmids was 
confirmed by restriction enzyme digestion of both the plasmids with EcoRV followed by 
agarose gel electrophoresis.  
Electrocompetent Agrobacterium tumefaciens AGL1 were transformed separately with 
pGreenI0029-5’Omega-PR1a_ADA and pGreenI0029-5’Omega-Extensin_ADA along with 
the helper plasmid pSoup. Transformants were selected and transformation was confirmed by 
mapping of plasmid isolates from Agrobacterium transformants using SalI.  
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Figure 3.13: Synthesized PR1a-ADA fusion containing 87 bp coding for the N-terminal portion of PR1a and the first 
60 bp of 5’ ADA ORF sequence up to an internal BamHI site. 
 
 
 
 
Figure 3.14: Synthesized extensin-ADA fusion containing 75 bp 5’ tobacco extensin sequence and the first 60 bp of 5’ 
ADA ORF sequence up to an internal BamHI site. 
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(a) 
 
 
 
 
(b) 
 
Figure 3.15: (a) Tobacco PR1a signal sequence inserted into p5’ Omega_ADA construct (p5’Omega-PR1a_ADA 
construct),  (b) Tobacco extensin signal sequence inserted into p5’ Omega_ADA construct (p5’Omega-Extensin_ADA 
construct). 
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3.3.2  3’Hydroxyproline (p5’Omega-Extensin_ADA-3’Hydroxyproline) construct design 
A partial ADA ORF- 3’serine-hydroxyproline fusion sequence (Xu et al., 2007) was designed 
and synthesized (figure 3.16) containing 346 bp from 3’ end of the ADA ORF sequence up to 
an internal PsiI site, a thrombin cleavage sequence, a 63 bp serine-hydroxyproline sequence 
and a TAG stop codon. A PsiI restriction enzyme site (TTATAA) was placed at the 5’ end, 
and a SacI restriction enzyme site (GAGCTC) was placed at the 3’ end. The ADA-
3’Hydroxyproline fusion sequence was digested with PsiI/SacI and gel-extracted. The ADA-
3’Hydroxyproline fragment was inserted into PsiI/SacI digested and gel-extracted 
pCDNA_ADA in pJIT (figure 3.2a). E.coli DH5α was transformed with pCDNA_ADA-
3’Hydroxyproline and transformants were selected. Several ampicillin-resistant colonies were 
chosen and the insertion of ADA-3’Hydroxyproline fusion into pCDNA_ADA was confirmed 
by DNA sequence analysis and restriction enzyme mapping using HindIII and SacI to release 
CDNA_ADA-3’Hydroxyproline from pJIT. 
 
To engineer an apoplast directing sequence at the 5’ end the construct p5’Omega-
Extensin_ADA (figure 3.15b) was digested with HindIII/BamHI and 5’Omega-Extensin-ADA 
fusion was gel-extracted and inserted into HindIII/BamHI digested and gel-extracted 
pCDNA_ADA-3’Hydroxyproline. E.coli DH5α was transformed with p5’Omega-
Extensin_ADA-3’Hydroxyproline (figure 3.17) and transformants were selected. Several 
ampicillin-resistant colonies were chosen and p5’Omega-Extensin_ADA-3’Hydroxyproline in 
pJIT was isolated. The insertion of 5’Omega-Extensin-ADA fusion into pCDNA_ADA-
3’Hydroxyproline was confirmed by restriction enzyme mapping using HindIII and SacI to 
release p5’Omega-Extensin_ADA-3’Hydroxyproline from pJIT. 
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Finally, the construct p5’Omega-Extensin_ADA-3’Hydroxyproline along with 35S cassette 
was inserted into pGreenI0029 T-region by digestion of p5’Omega-Extensin_ADA-
3’Hydroxyproline construct in pJIT and pGreenI0029 with EcoRV, followed by gel-extraction 
and ligation of vector and insert DNA. E.coli DH5α was transformed with the ligated 
pGreenI0029-p5’Omega-Extensin_ADA-3’Hydroxyproline construct and the transformants 
were selected. The pGreenI0029 plasmid containing p5’Omega-Extensin_ADA-
3’Hydroxyproline construct was isolated and the insertion of p5’Omega-Extensin_ADA-
3’Hydroxyproline construct into pGreenI0029 was confirmed by restriction enzyme mapping 
using EcoRV to release 35S-5’Omega-Extensin_ADA-3’Hydroxyproline from pGreen.  
 
Electrocompetent Agrobacterium tumefaciens AGL1 were transformed with pGreenI0029-
35S-5’omega-Extensin_ADA-3’Hydroxyproline along with the helper plasmid pSoup. 
Transformants were selected and transformation was confirmed by mapping of plasmid 
isolates from Agrobacterium transformants using SalI.  
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Figure 3.16: ADA-3’ Hydroxyproline fusion containing a PsiI restriction enzyme site, 346 bp from 3’ end of the ADA 
ORF sequence, a thrombin cleavage sequence, a 63 bp serine-hydroxyproline sequence , a TAG stop codon and a SacI 
restriction enzyme site. 
 
 
 
Figure 3.17: p5’Omega-Extensin_ADA-3’Hydroxyproline construct. 
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Tobacco plants were transformed with the cytosolic constructs and tobacco BY-2 suspensions 
were transformed with both cytosolic and sub-cellular targeting constructs, using 
Agrobacterium mediated transformation. The transformants were selected after 6-8 weeks of 
transformation and ADA enzyme-activity of stable transformants were measured (section 
2.5.2). 
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4.1 Overview 
Tobacco (Nicotiana tabacum) is the most widely used organism for biopharmaceutical 
production in plants owing to well established properties of gene transfer, expression 
analysis; rapid scale-up potential and high biomass yield (Fischer & Emans, 2000). Stable 
nuclear transformation is broadly used for production of heterologous proteins and 
recombinant proteins are generally extracted from leaves. In addition secretory pathway-
targeting has been used for excretion of recombinant proteins from roots, leaves and cell 
suspensions (Komarnytsky et al., 2000). Expression of foreign proteins in plant cell 
suspensions possess some advantages over whole plants owing to their rapid growth due to 
short cell doubling times, improved consistency of protein products due to less variation in 
environmental conditions with controlled bioreactor use and most importantly reduced post-
translational silencing effects due to dedifferentiated cells that lack fully functional 
plasmodesmata (Lee et al., 2000; Su and Lee, 2007). 
 
Adenosine deaminase is found in numerous organisms ranging from bacteria to mammals and 
catalyses the conversion of cytotoxic adenosine analogues into their non-toxic inosine 
analogues. However, ADA has been found to be absent in plants (Dancer et al., 1997). In 
plants, toxic adenosine analogues are converted into non-toxic analogues either by adenosine 
kinase or by phosphoribosyltransferase (Pelcher, 1995). Absence of ADA in plants provides 
an excellent platform to produce recombinant ADA in plants. 
 
In this chapter, the expression of recombinant ADA in nuclear transformed plants and calli 
has been investigated. Nicotiana tabacum plants and BY-2 cells were transformed with 
various ADA constructs designed to express the enzyme in the cytosol. The resulting 
transgenic plants and calli were assessed for ADA mRNA and enzyme expression levels. 
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4.2 Results 
4.2.1 Cytosolic expression in transformed plants 
Nicotiana tabacum plants transformed with ADA cytosolic constructs were assessed for both 
ADA mRNA and enzyme expression. A non-transformed tobacco plant was also assayed. 
Young, medium and mature 5-6-week-old leaves of transformed plants were flash frozen in 
liquid nitrogen, ground to a fine powder and total soluble proteins extracted as described in 
section 2.5.1. The expression of ADA in plant extracts was tested by adenosine deaminase 
assay (section 2.5.2) to determine ADA levels and a Bradford assay used to determine total 
soluble proteins (section 2.5.3).   Up to 7 transgenic plants transformed with three cytosolic 
constructs were analysed for ADA enzyme-activity (figure 4.1 and figure 4.2). ADA specific-
activities in Units per milligram (U mg
-1
) TSP were calculated using ADA-activity and 
Bradford protein assay data of corresponding transformants. ADA specific-activities of young, 
medium and mature leaves were measured initially to investigate age-specific activity. An 
average value was calculated from ADA specific-activities of young, medium and mature 
leaves, as no consistent correlation of ADA expression was observed with age (figure 4.1). 
Expression levels of plants transformed with construct p∆5’UTR_ADA, containing PCR-
amplified ADA and a short 21 bp 5’ UTR sequence was used as a basal construct to compare 
the expression levels of two other cytosolic constructs. The mean value for ADA-activity 
measured in these plants was 9.1 x 10
-6
 U mg
-1
 TSP, barely above a background activity of 1.73 
x 10
-7
 U mg
-1
 TSP measured in non-transformed plants. Expression levels of the same 
transgene in independent transformants do not assume a normal distribution. Therefore, a 
distribution-free statistical test, namely the Mann-Whitney U test, which is based on median 
values, was used to evaluate difference between two gene-constructs. The U values were 
compared with a critical region table indicating the differences at 5 % as shown in table 4.1. 
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Figure 4.1: ADA specific-activities measured in the leaves of 6 transgenic plant lines transformed with pCDNA_ADA 
cytosolic construct. 
 
 
 
 
Figure 4.2: ADA specific-activities measured in tobacco plants transformed with various cytosolic constructs. Each circle 
represents ADA-activity from an independent transformant, and the yellow diamond denotes the median value. The 
number of plants assayed is shown in brackets after each construct. 
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Table 4.1: Pair-wise comparisons of ADA specific-activities measured in transgenic tobacco leaves 
using Mann-Whitney U test (5 % level). 
Constructs Population identity  p-Value  
p∆5’UTR_ADA versus pCDNA_ADA Different P<0.05=0.0027 
p∆5’UTR_ADA versus p5’Ω_ADA Different P<0.05=0.0088 
pCDNA_ADA versus p5’Ω_ADA Different P<0.05=0.0321 
 
 
Table 4.2: Pair-wise comparisons of median ADA specific-activities measured in transgenic tobacco 
leaves. 
Constructs Ratio of median 
ADA specific-
activities 
Fold increase 
median 
expression 
Fold increase of 
highest expressing 
plants 
p∆5’UTR_ADA versus 
pCDNA_ADA 
9.13x10-6 : 1.66x10-3 
 
182 273 
p∆5’UTR_ADA versus p5’Ω_ADA 9.13x10-6 : 5.79x10-5 7 416 
 
A pair-wise comparison of ADA specific-activities measured in transformed tobacco leaves 
(table 4.1) shows that two of the sample populations are statistically different as compared to 
plants transformed with construct p∆5’UTR_ADA.  As shown in figure 4.2 and table 4.1, 
comparison of the median ADA-activity ratios demonstrates that the presence of the human and 
TMV omega 5’UTR sequences caused a 7- to 182-fold increase in ADA specific-activity. One 
outlying transgenic line of p5’Ω_ADA transformed plants showed the highest ADA specific-
activity of 3.72x10
-3
 U mg
-1
 TSP
 
(66 ng mg
-1
 TSP). The highest ADA specific-activity of a 
pCDNA_ADA transformed plant shows 2.41x10
-3
 U mg
-1
 TSP
 
(43 ng mg
-1
 TSP) (figure 4.2). 
This is respectively a 416-fold and a 273-fold increase in the ADA specific-activity as 
compared to the plants transformed with a short 5’UTR construct (table 4.2). 
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4.2.1.1 Detection of adenosine deaminase protein in transgenic tobacco plants using 
western blot analysis 
Western blot analysis was used to detect adenosine deaminase protein in crude leaf extracts 
from transgenic tobacco plants. Bovine ADA extracted from calf intestine (100 ng) obtained 
from Sigma, UK was used as a positive control and 2.1, 2.4 and 2.3 mg of total proteins 
extracted from respective T1, T2 and T3 transgenic plants, were separated by electrophoresis 
on a 12 % (w/v) polyacrylamide gel, containing 0.1 % (w/v) SDS as described in section 
2.5.4. Gel electrophoresed proteins were transferred to a nitrocellulose sheet (Hybond C) by 
semi-dry transfer under a constant current of 100 mA for 30 min. The membrane was probed 
with rabbit anti-ADA antibodies followed by incubation with a secondary antibody 
conjugated to horseradish peroxidase.  The blot (figure 4.3) was developed by Luminol 
colour substrate solution followed by detection on a Typhoon scanner (Amersham) as 
described in section 2.5.5. TotalLab Quant software was used to analyse western blots 
(section 2.5.5). Lanes 3, 4, and 5, of figure 4.3 show that recombinant human ADA has an 
approximate molecular mass of 42 kDa and bovine ADA in lane 2 of figure 4.3 has a 
molecular mass of 41 kDa. The reported size of both human and bovine ADA is 41 kDa 
(Wiginton et al., 1984; Kelly et al., 1996). The apparent 1 kDa size difference of the 
recombinant ADA could be due to an artefact of the gel system, since large amounts of total 
proteins are loaded in lane 3-5 compared with lane 2 (figure 4.3). Low molecular weight 
bands, particularly in lane 5 may be due to protein degradation. High molecular weight bands 
may be due to some read through of the stop codon to other putative stop codon further 
downstream (Angenon et al., 1990).  
 
Analysis of the western blot using TotalLab Quant software as described in section 2.5.5, 
estimated that 1 U of recombinant ADA is equal to approximately 17.7 µg of ADA protein. 
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This formula was used to calculate approximate estimations of ADA protein amounts in 
transformed tissues. 
 
 
Figure 4.3: Western blot of proteins extracted from the leaves of 3 transgenic tobacco plants transformed with 
cytosolic construct, pCDNA_ADA. Lane1: molecular weight marker; lane 2: bovine ADA; lane 3: protein extract 
from T1 leaves; lane 4:  protein extract from T2 leaves and lane 5: protein extract from T3 leaves.  
 
 
4.2.1.2 Southern blot analysis of genomic DNA from plants transformed with the 
pCDNA_ADA construct 
Total DNA was extracted from tobacco leaves of plants transformed with the pCDNA_ADA 
construct as described in section 2.2.4. Equal amounts of total DNA (10 µg) from three 
transformed plants and a non-transformed plant were digested with KpnI and SspI and 
fragments separated by electrophoresis on a 0.7 % (w/v) agarose gel. The DNA fragments were 
transferred to a Hybond-N+ nylon membrane and probed with a DIG-labelled ADA cDNA 
probe (section 2.2.12.3). High stringency washes (0.1x SSC, 0.1 % (w/v) SDS at 65 °C) were 
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carried out to remove non-specific nucleic acid binding (section 2.2.12.4). A photographic 
reproduction of the blot is shown in figure 4.4. 
 
If the inserted construct was a single copy, then the number of expected bands would be one 
per lane and above 2177 bp in size as there are no internal KpnI and SspI restriction enzyme 
sites present on the construct. Hybridization was obtained for 4 bands in lane 1(fragment sizes: 
6.3, 5.6, 4.5, and 4.1 kbp), 3 bands in lane 2 (fragment sizes: 3.2, 2.8 and 2.5 kbp), 8 bands in 
lane 3 (fragment sizes: 5.7, 5.3, 4.9, 3.9, 3.5, 3.1, 2.9 and 2.5 kbp). There was no specific 
hybridization in lane 4 (non-transformed plant) as expected and all hybridizing bands were 
above 2177 bp, the size of the T-DNA region.  
 
Multiple copies of ADA cDNA on the blot can be explained by the random integration of T-
DNA into the plant genome by Agrobacterium-mediated transformation (DeBeuckeleer et al., 
1981). Although the T1 plant genome exhibited the highest copy number (at least 8 copies), it 
does not correlate with higher ADA expression levels, where the T2 transformant had the 
highest ADA specific-activity (1.81 x10
-3 
U mg
-1
 TSP; table 4.3). The darker bands in figure 
4.4 could be due to insertion of tandem arrays of the insert. Hence, gene copy number may be 
greater than the number of hybridizing bands. The lack of correlation of copy number to ADA 
enzyme expression levels could be due to integration of the T-DNA inserts into either 
transcriptionally competent or silent regions of the plant genome (Springer et al., 1995) or 
alternatively, transgene silencing by DNA methylation (Hepburn et al., 1983). Transgene 
silencing can also occur post-transcriptionally due to instability of transcribed RNA (Meins F, 
2000). Furthermore, Agrobacterium-mediated transformation is often associated with transfer 
of tandem copies of T-DNA at a single locus and it was also found that head to head inverted 
CHAPTER 4                            CYTOSOLIC EXPRESSION OF HUMAN ADENOSINE DEAMINASE IN TRANSGENIC TOBACCO PLANTS AND 
BY-2 CALLI 
 
85 
 
T-DNA repeats around the right borer are also frequently associated with transgene silencing 
(Stam et al., 1997).  
 
 
 
Figure 4.4: Southern blot of genomic DNA (10 µg) of transformed (pCDNA_ADA) and non-transformed tobacco plant 
leaves. Lane 1: T3 DNA, Lane 2: T2 DNA, Lane 3: T1 DNA, Lane 4: Non-Transformed plant DNA, and Lane 5: Roche 
DNA molecular weight marker III. 
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Table 4.3: Genome T-DNA copy number and ADA specific-activities of transgenic tobacco plants 
transformed with the pCDNA_ADA construct. 
 
 
 
 
 
4.2.1.3 Northern blot analysis of ADA mRNA from plants transformed with the 
pCDNA_ADA construct  
To investigate any possible correlation of ADA mRNA and enzyme expression levels with 
ADA insert copy number, RNA extracted from leaves of transformed and non-transformed 
tobacco plants were analysed on northern blots (section 2.3.1). A photographic record of the 
blot and the stained ribosomal RNA present on an agarose gel is shown in figure 4.5.  
 
Transgenic cell lines were analysed for mRNA amounts using TotalLab Quant software in 
order to correlate these values with corresponding T-DNA copies and ADA-activities (table 
4.4) measured in the same plants (section 2.3.5). The T2 transformant in lane 5 of figure 4.5 
showed the highest ADA mRNA levels (27.2 ng; table 4.4) with an estimated 3 copies of the T-
DNA insert. Whereas, the T1 transformant in lane 6 showed the lowest ADA mRNA level (7.4 
ng) with an estimated 8 copies of the T-DNA insert. The lower ADA expression level of T1 
transformants could be due to the presence of silenced copies of ADA T-DNA inserts or 
posttranscriptional gene silencing (Que et al., 1997; Schubert et al., 2004). 
 
 
 
Construct ADA specific-activity (U mg-1 TSP) Minimum number of 
hybridizing bands 
pCDNA_ADA [T1] 1.31 x10-3 8 
pCDNA_ADA [T2] 1.81 x10-3 3 
pCDNA_ADA [T3] 1.73 x10-3 4 
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Figure 4.5: (a) Northern blot of total RNA extracted from pCDNA_ADA transformed and non-transformed tobacco 
plant leaves. Lane 1: Transformant T6, Lane 2: Transformant T5, Lane 3: Transformant T4, Lane 4: Transformant T3, 
Lane 5: Transformant T2, Lane 6: Transformant T1 and Lane 7: Non-Transformed plant, (b) SafeViewTM stained 2 % 
agarose gel of rRNA present in lane 1-7.  
 
 
 
 
Table 4.4: ADA specific-activities of tobacco plants transformed with pCDNA_ADA alongside ADA 
mRNA amounts measured in northern blots and T-DNA copy number. 
 
 
 
 
 
 
 
Transformant ADA specific-activity (U mg-1 TSP) ADA  
mRNA (ng) 
Estimated genome 
T-DNA copy 
numbers 
T1 1.31 x10-3 
 
7.4 8 
T2 1.81 x10-3 27.2 3 
T3 1.73 x10-3 15.7 4 
T4 2.41 x10-3 13.1 - 
T5 1.58 x10-3 20.1 - 
T6 1.47 x10-3 15.5 - 
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4.2.2 Expression of five ADA cytosolic constructs in tobacco BY-2 calli 
Tobacco BY-2 cells are yellow-coloured de-differentiated cells which exhibit rapid growth in 
culture medium at optimal culture conditions.  These cells generally multiply their numbers 
up to 100-fold within a week and owing to this property and the ability to transfer foreign 
genes with ease, BY-2 cells are used in many molecular farming experiments. Tobacco BY-2 
cells in suspension were transformed with different cytosolic constructs namely: 
p∆5’UTR_ADA, pCDNA_ADA, p5’Ω_ADA, p5’_3’ Ω_ADA and pSS 5’UTR_ADA as 
described in section 2.4.2. BY-2 calli lines transformed with these constructs were assessed for 
expression levels of both ADA mRNA and enzyme-activity as described in section 4.2.1. Up to 
29 transgenic cell lines of different cytosolic constructs were analysed for ADA enzyme-
activity as shown in figure 4.6. A Mann-Whitney statistical test was conducted as described by 
Pollard (1977). A p∆5’UTR_ADA construct containing PCR-amplified ADA ORF and a short 
21 bp 5’ UTR sequence was used as a basal construct to compare other cytosolic constructs. 
Any two constructs being compared were combined and ranked by ascending expression levels. 
U-values were calculated as describe in section 2.6. 
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Figure 4.6: ADA specific-activities measured in BY-2 calli transformed with various cytosolic constructs. Each circle 
represents ADA-activity from an independent transformant. The yellow diamond denotes the median value. The 
number of calli assayed is shown in brackets after each construct. * These transformed calli were analysed 9 months 
after the initial measurements were taken. **These transformed calli were analysed 30 days after the initial 
measurements were taken. 
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Table 4.5: Pair-wise comparisons of ADA specific-activities measured in transgenic tobacco BY-2 calli 
using the Mann-Whitney U test (5 % level). 
Constructs Population identity p-Value 
p∆5’UTR_ADA versus pCDNA_ADA Same  p>0.05=0.936515555 
p∆5’UTR_ADA versus p5’Ω_ADA Different P<0.05=0.000468447 
p∆5’UTR_ADA versus p5’_3’Ω_ADA Different P<0.05=9.63357 x10-7 
p∆5’UTR_ADA versus pSS 5’UTR_ADA Different P<0.05=2.17074 x10-6 
pCDNA_ADA versus p5’Ω_ADA Different P<0.05=0.000424491 
p5’Ω_ADA versus p5’_3’Ω_ADA Same p>0.05=0.051199836 
p5’_3’Ω_ADA versus pSS 5’UTR_ADA Different P<0.05=0.001362336 
 
Table 4.6: Pair-wise comparisons of median ADA specific-activities measured in transgenic tobacco 
BY-2 calli. 
Constructs Ratio of median ADA 
specific-activities 
Fold increase 
median 
expression 
Fold increase of highest 
expressing BY-2 cell line 
 
p∆5’UTR_ADA versus pCDNA_ADA 1.43x10-4 : 1.87 x10-4 1.3 15 
p∆5’UTR_ADA versus p5’Ω_ADA 1.43x10-4 : 2.02 x10-3 14 25 
p∆5’UTR_ADA versus p5’_3’Ω_ADA 1.43x10-4 : 2.94 x10-3 20.5 32 
p∆5’UTR_ADA versus pSS 
5’UTR_ADA 
1.43x10-4 : 1.65 x10-3 11.5 22 
 
A pair-wise comparison of ADA specific-activities in transgenic tobacco calli transformed with 
cytosolic constructs (table 4.5) shows that five out of seven sample populations are statistically 
non-identical.  Comparison of the median ratios of these constructs shows a 1.3 to 20.5-fold 
increase in ADA specific-activity as compared to calli transformed with p∆5’UTR_ADA 
construct (table 4.6). 
Four outlying ADA specific-activities measured in calli transformed with construct 
p5’_3’Ω_ADA showed the highest ADA specific-activities of up to 4.50 x 10-3 U mg-1 TSP 
(80 ng mg
-1
 TSP). The highest ADA specific-activity of a pCDNA_ADA, pSS 5’UTR_ADA 
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and p5’Ω_ADA transformed calli showed specific-activities ranging from 2.20 to 3.50 x 10-3 
U mg
-1 
TSP
 
(39 to 62 ng mg
-1
 TSP) (figure 4.6). This is respectively a 15-fold to 32-fold 
increase in the ADA specific-activity as compared to the calli transformed with a short 
5’UTR construct (table 4.6).  
 
4.2.2.1 Northern blot analysis of transcribed ADA mRNA from tobacco BY-2 calli 
transformed with five cytosolic constructs  
In order to assess whether ADA mRNA levels correlated with increased levels of ADA 
enzyme activity, northern blots of transformed tobacco BY-2 calli were performed. Total 
RNA was extracted as described in section 2.3.1 and equal amounts of RNA (3500 ng) were 
subjected to electrophoresis under denaturing conditions (section 2.3.2). The RNA was 
transferred to a Hybond-N+ nylon membrane as described in section 2.3.3 prior to probing 
with DIG-labelled ADA cDNA (section 2.2.12.3). A photographic reproduction of the blot 
was taken, as shown in figures 4.7 and 4.8. 
 
As the PCR-amplified ADA ORF is 1092 bp in size, transcribed mRNA which includes 5’ and 
3’ UTR sequences, would be larger than 1092 nucleotides (nt). Observed mRNA sizes were 
approximately 1100 nt and similar in size in the case of constructs p5’Ω_ADA and 
p∆5’UTR_ADA (figure 4.7 and 4.8). Transcribed mRNA in construct, pCDNA_ADA, 
exhibited a size of 1300 nt. It was assumed that the larger mRNA size in this construct is due to 
the lengthy 5’ and 3’ UTR sequences in the human ADA cDNA.  
 
Two transgenic cell lines from each construct were analysed for mRNA levels in order to 
investigate a possible correlation with their corresponding ADA activities (table 4.7). TotalLab 
Quant software was used to analyse northern blots (section 2.3.5). Table 4.7 shows ADA 
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enzyme and mRNA expression levels of constructs used for northern blot analysis. Lane 1 of 
figure 4.7a, the non-transformed cell line, showed no hybridizing bands. Calli cell lines T3 and 
T2 transformed with p5’Ω_ADA in lanes 2 and 3 of figure 4.7a exhibited 2.2 and 3.1 ng of 
ADA mRNA with respective 1.84 x 10
-3 
and 2.91 x 10
-3
 U mg
-1 
TSP ADA specific-activities 
(table 4.7). Whereas one calli cell line transformed with construct, p∆5’UTR_ADA [T15], 
showed a significantly higher ADA mRNA level (8.8 ng) but expressed a relatively lower 
amount of ADA specific-activity (4.15 x 10
-4
 U mg
-1
 TSP). Lower ADA activities in this 
construct could be due to the short 5’ UTR, which contains only a 21 bp 5’ UTR sequence. 
Pickering and Willis, (2005) demonstrated that most of the regulation in translation occurs at 
initiation steps in the 5’-untranslated region, which gives rise to the 5’ leader sequence in 
mRNA. Pickering and Willis, (2005) further elaborated the importance of 5’ leader sequences 
in cap-dependent initiation and ribosomal entry sites. Though the mRNA amounts were the 
highest in the p∆5’UTR_ADA [T15] construct, a lack of 5’UTR for the generation of  an 
efficient 5’ leader sequence appears to have contributed towards the lower amount of expressed 
ADA enzyme-activity. 
 
Calli cell lines (T2 and T3) transformed with pSS 5’UTR_ADA, in lanes 2 and 3 of figure 4.8, 
exhibited respectively 3.9 and 3.3 ng of ADA mRNA and showed relatively high ADA 
specific-activities (1.39 and 2.91 x 10
-3
  U mg
-1
 TSP respectively) (table 4.7). Although the 
calli cell lines transformed with pSS 5’UTR_ADA constructs, initially (5-6 weeks after 
transformation) showed a high ADA specific-activity, calli tested from subsequent sub 
culturing events showed drastically reduced (approximately 10-fold) ADA expression levels 
after 30 days as shown in figure 4.6. The decline in ADA enzyme-activity could be explained 
by degradation of mRNA as shown in figure 4.8. This adverse mRNA degradation in pSS 
5’UTR_ADA construct should be further investigated with new transformed cell lines and may 
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possibly be due to posttranscriptional gene silencing events. Conversely, calli transformed with 
construct p5’Ω_ADA showed no reduction in ADA specific activities after 9 months (figure 
4.6), exhibiting stable gene expression over a long period of time.  
 
Calli transformed with construct p5’_3’Ω_ADA [T9], also showed a relatively higher ADA 
specific-activity (3.40 x 10
-3
  U mg
-1
 TSP) among the transgenic BY-2 cell lines analysed for 
mRNA levels as shown in table 4.7. However, T9 calli exhibited only a moderate amount of 
mRNA levels (approx. 4.5 ng) (figure 4.8). As stated previously, the presence of TMV Ω 5’ 
UTR significantly enhances translation of the associated message and further addition of TMV 
3’ UTR increases the stability of mRNA further and also increases mRNA translation (Gallie 
and Kado, 1989; Gallie and Walbot, 1990). Hence, enhanced expression of  ADA in 
transgenic BY-2 cell lines of p5’_3’Ω_ADA with lower transcribed mRNA levels could be 
explained by the stabilization and enhancing effects of the incorporated 5’ and 3’ TMV UTR 
sequences. However, as shown in table 4.7, comparison of ADA specific-activities with 
mRNA levels seems to indicate that there is no general correlation between amounts of RNA 
and ADA enzyme-activities. 
 
 
Figure 4.7: (a) Northern blot of total RNA extracted from transformed and non-transformed tobacco BY-2 calli. Lane 1: 
non-transformed calli, Lane 2: p5’Ω_ADA [T3], Lane 3: p5’Ω_ADA [T2], Lane 4: p∆5’UTR_ADA [T15], Lane 5: 
p∆5’UTR_ADA [T11], Lane 6: pCDNA_ADA [T13] and Lane 7: pCDNA_ADA [T5], (b) SafeViewTM stained 2 % 
agarose gel of rRNA present in lane 1-7.  
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Figure 4.8: (a) Northern blot of total RNA extracted from transformed and non-transformed tobacco BY-2 calli. Lane 1: 
non-transformed calli, Lane 2: pSS 5’UTR_ADA [T3], Lane 3: pSS-5’UTR_ADA [T2], Lane 4: p5’_3’Ω_ADA [T11] and 
Lane 5: p5’_3’Ω_ADA [T9], (b) SafeViewTM stained 2 % agarose gel of rRNA present in lane 1-5.  
 
 
 
 
 
Table 4.7: ADA specific-activities of BY-2 calli transformed with cytosolic constructs alongside ADA 
mRNA amounts measured in northern blots. 
 
 
Constructs ADA specific-activity (U mg-1 TSP) ADA mRNA (ng) 
p5’Ω_ADA [T3] 1.84 x10-3 
 
2.2 
p5’Ω_ADA [T2] 2.91 x10-3 3.1 
p∆5’UTR_ADA  [T15] 4.15 x10-4 8.8 
p∆5’UTR_ADA  [T11] 4.34 x10-4 2.2 
pCDNA_ADA [T5] 1.66 x10-3 7.2 
pCDNA_ADA [T13] 2.87 x10-4 1.5 
pSS 5’UTR_ADA [T3] 1.39 x10-3 3.9 
pSS 5’UTR_ADA [T2] 2.91 x10-3 3.3 
p5’_3’Ω_ADA  [T11] 2.72 x10-3 10.0 
p5’_3’Ω_ADA   [T9] 3.40 x10-3 4.5 
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4.3 Discussion 
Transgenic tobacco plants and calli were successfully generated following Agrobacterium-
mediated transformation with different cytosolic constructs of the human adenosine 
deaminase gene. A number of primary transformants were tested for ADA enzyme-activity 
and protein using enzymatic assays and western blotting. Southern and northern blots were 
also performed for comparing insert copy number, levels of mRNA and enzyme activities 
between transformants.  
 
Initially a western blot was performed with pCDNA_ADA construct transformed plants. The 
size of recombinant ADA extracted from transformed tobacco plants was found to be 
approximately 1 kDa higher than the reported human ADA molecular weight (figure 4.3). 
Although this may be due to an artefact of the gel system, it is thought that the size of 
recombinant ADA produced in tobacco could be due to nucleocytoplasmic O-GlcNAcylation. 
Since, some plant proteins undergo extensive glycosylation after translation including 
nucleocytoplasmic O-GlcNAcylation (Gomord et al., 2010). This could be investigated 
further using western blot analysis of transformant extracts treated to remove any associated 
carbohydrate groups from proteins. 
 
There are many reports that show the expression levels of foreign genes in plants are not 
directly proportional to T-DNA insert copy number (Vergunst et al., 1998). This is partly due 
to integration of the insert T-DNA into transcriptionally silent regions of the plant genome 
(Springer et al., 1995). Transgene silencing by DNA methylation (Hepburn et al., 1983) or by 
promoter methylation (Meyer, 2000) together with post-transcriptional transgene silencing of 
transcribed RNA (Meins, 2000; Schubert et al., 2004) could also contribute to lack of 
correlation of insert copy number to expression levels. Moreover Agrobacterium-mediated 
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transformation is often associated with the transfer of tandem copies of T-DNA at a single 
locus and head to head inverted T-DNA repeats around the right border are also frequently 
associated with transgene silencing (Stam et al., 1997). Southern blot analysis confirmed that 
ADA expression levels in plants transformed with cytosolic constructs are not directly 
proportional to insert copy number. A transformed plant line with higher insert copy numbers 
actually showed comparatively lower ADA specific-activities than transformed plant lines 
with fewer insert copies. 
 
It was postulated that the 5’ leader and 3’ trailer sequences formed by human 5’ UTR and 
3’UTR DNA sequences, respectively, would be active to a certain extent in transgenic plants 
expressing recombinant ADA. And that the equivalent regions from TMV would stimulate 
gene expression further.  To test this hypothesis the median expression levels of ADA in 
transgenic plants of different constructs were compared. Whole plants transformed with the 
pCDNA_ADA construct showed a 182-fold increase in expression levels compared to 
transgenic plants transformed with the construct containing minimal  5’UTR 
(p∆5’UTR_ADA), whereas, plants transformed with the construct containing TMV omega 
5’UTR (p5’Ω_ADA) showed only a 7-fold increase in ADA-activity. However, one out-lying 
p5’Ω_ADA transformed plant showed the highest ADA specific-activity, 3.72 x10-3 U mg-1 
TSP
 
(66 ng mg
-1
 TSP). Whereas, the highest ADA specific-activity of a pCDNA_ADA 
transformed plant was 2.41 x 10
-3
 U mg
-1
 TSP (43 ng mg
-1
 TSP) (figure 4.2). This is 
respectively a 416-fold and a 273-fold increase in the ADA specific-activity compared to 
plants transformed with the short 5’UTR construct (table 4.2). Because, only small numbers 
of transgenic plants were assayed, higher ADA-activities of outlying plants do not allow 
unequivocal conclusions to be drawn. A greater number of transgenic plants should be 
investigated to clarify this data.  
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Tobacco BY-2 cells in suspension were also transformed with different cytosolic constructs 
containing minimal 5’UTR (p∆5’UTR_ADA), human 5’and 3’ UTR (pCDNA_ADA), TMV 
omega 5’UTR (p5’Ω_ADA), TMV omega 5’ and 3’ UTR (p5’_3’ Ω_ADA) and RUBISCO 
small sub unit 5’ UTR (pSS 5’UTR_ADA). Stable transformants were tested for ADA-
activity using enzymatic assays and northern blots were performed in order to compare the 
stability of mRNA to ADA enzyme-activities.  
 
Gallie and Kado, (1989) demonstrated that the presence of the TMV 5’ untranslated leader 
sequence (Ω) significantly enhances translation in both eukaryotes and prokaryotes. It was 
further revealed that the presence of a CAA-rich region within Ω is responsible for this 
translational enhancement (Gallie, 2002).  At the other end of TMV RNA genes, the 3’ UTR 
is involved in forming a complex tertiary structure containing a pseudoknot domain and a 
tRNA-like structure. The addition of 204-bases of this region to foreign mRNAs was shown 
to increase gene expression by 100-fold as compared to nonadenylated mRNA. The TMV 
3’UTR seeming to increase the stability of associated sequences and hence, increasing 
translation in a similar manner to polyadenylated mRNA (Gallie and Walbot, 1990). 
Confirming these findings, pair-wise comparisons of ADA specific-activities as shown in table 
4.6 revealed that the calli transformed with the pCDNA_ADA construct, containing human 5’ 
and 3’ UTR sequence caused only a 1.3-fold increase in median ADA specific-activity as 
compared to the calli transformed with construct containing minimal 5’UTR sequence 
(p∆5’UTR_ADA). On the other hand, calli transformed with the construct containing TMV 
omega 5’ UTR sequence (p5’Ω_ADA) caused a 14-fold increase in median ADA specific-
activity and incorporation of both TMV 5’ and 3’ UTR in the p5’_3’Ω_ADA construct, caused 
the highest increase in median ADA specific-activity of 20.5-fold. Moreover, one outlying 
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transgenic line of p5’_3’Ω_ADA transformed calli showed the highest ADA specific-activity 
of 4.50 x 10
-3
 U mg
-1
 TSP
 
(80 ng mg
-1
 TSP), a 32-fold increase in ADA specific-activity over 
short 5’UTR construct (table 4.6).  
 
Patel et al., (2004 and 2006) demonstrated that the 5’ UTR from both C4 Amaranthus and 
Flaveria bidentis RUBISCO small subunit1 mRNAs confer translational enhancement on 
associated ORFs which leads to an increase in expression of foreign proteins. Confirming these 
findings, the calli transformed with construct pSS5’UTR_ADA, containing RUBISCO small 
subunit 5’ UTR exhibited an 11.5-fold increase of ADA specific-activity as compared to 
construct p∆5’ UTR_ADA. One outlying transgenic line of pSS5’UTR_ADA transformed 
calli showed the highest ADA specific-activity of 3.20 x 10
-3
 U mg
-1
 TSP
 
(57 ng mg
-1
 TSP)
 
(figure 4.6) a 22-fold higher ADA specific-activity as compared to calli transformed with 
construct p∆5’ UTR_ADA. Moreover approximately 12 transgenic calli lines of 
pSS5’UTR_ADA construct exhibited higher ADA specific-activity as compared to the mean 
ADA specific-activity of calli lines of pSS5’UTR_ADA (figure 4.6). 
 
Though the initial ADA-enzyme expression levels were high in calli cell lines transformed 
with pSS 5’UTR_ADA construct immediately after selection of transformants, subsequent sub-
culturing event showed a much reduced ADA-activity after 30 days of initial measurement. 
Northern blot analysis revealed that degradation of transcribed mRNA levels in pSS 
5’UTR_ADA construct may have contributed towards the lower ADA expression levels. The 
reason for mRNA degradation in these calli lines may be due to posttranscriptional gene 
silencing events, since the nature of mRNA sequence may influence posttranscriptional gene 
silencing (Schubert et al., 2004). On the other hand the calli transformed with construct 
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p5’Ω_ADA showed a stable expression of ADA even after 9 months of sub-culturing events 
(figure 4.6). 
 
Increased in expression of ADA in different cytosolic constructs containing different 5’ UTR 
sequences and 3’ UTR sequences is thought to be due to translational enhancing and mRNA 
stabilizing properties of these sequences (Gallie and Kado, 1989). The link between 
untranslated regions and increased expression of ADA was further elaborated by northern 
blot analysis. Although the mRNA amounts were the highest in the construct containing 
minimal 5’UTR (p∆5’UTR_ADA; table 4.7), a lack of 5’UTR for the generation of 5’ leader 
sequence may have greatly contributed towards the lower amount of expressed ADA enzyme. 
It was also shown that the p5’_3’Ω_ADA, transgenic BY-2 cell lines had the lowest amounts 
of mRNA but the highest ADA expression, perhaps owing to mRNA stabilizing and 
translational enhancing effects of incorporated TMV 5’ and 3’ UTR sequences.  
 
Successful cytosolic expression of a functional human adenosine deaminase in transgenic 
tobacco plants and calli has been demonstrated in this chapter. Attempts to increase the ADA 
yield by enhancing expression proved to be successful as it was found that incorporation of 
translational enhancing sequences in calli, at least, improved ADA expression by a 
considerable amount. On consideration, only a few transgenic plants were analysed and 
further generation of plants transformed with cytosolic constructs may reveal results more 
closely aligned with those found in BY-2 calli. The effect of sub-cellular targeting sequences 
such as PR1a and extensin in enhancing yield of recombinant ADA further will be discussed 
in following chapters.  
 
  
 
 
 
 
 
 
 
Chapter 5 
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5.1 Overview 
Potential use of plant cell cultures as an alternative production system for pharmaceutical 
proteins is restricted due to low recombinant protein yield and plays a major limitation in 
commercialising the technique. Hence, wide arrays of strategies have been employed in an 
attempt to enhance protein yield at the molecular, cell culture and downstream processing 
steps. Molecular strategies such as enhancing gene transcription, improving translational 
efficiency, incorporation of novel protein fusion technology and incorporation of secretory 
pathway targeting technology have been widely used in recent years to enhance the yield of 
foreign proteins in plant cell cultures (Desai et al., 2010).   In this study, the incorporation of 
novel protein fusion technology and the incorporation of secretory pathway targeting 
technology have been employed to increase the expression of recombinant ADA in nuclear 
transformed BY-2 calli. Cells transformed with ADA constructs and the resulting transgenic 
calli have been assessed for ADA mRNA expression and ADA enzyme activities. 
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5.2 Results 
5.2.1 Apoplast-directed expression in transformed BY-2 calli 
Tobacco BY-2 cells in suspension were transformed with different constructs containing 
apoplast-directing signals described in chapter 3. These constructs are namely p∆5’UTR-
PR1a_ADA, p∆5’UTR-Ext_ADA, p5’Ω-PR1a_ADA, p5’Ω-Extensin_ADA, pSS 5’UTR-
PR1a_ADA, pSS 5’UTR-Extensin_ADA and p5’Ω-Extensin_ADA-3’Hydroxyproline (See 
section 3 for details). The BY-2 calli lines transformed with ADA apoplast-directed constructs 
were assessed for expression levels. Five to six-week-old transformed calli were flash-frozen in 
liquid nitrogen and ground to a fine powder. Total soluble proteins were extracted and the calli 
extracts were assayed for ADA enzyme-activity to determine ADA levels and a Bradford assay 
performed to determine total soluble proteins. Up to 30 transgenic cell lines of different 
apoplast-directed constructs were analysed as shown in figure 5.1. A Mann-Whitney statistical 
test was conducted as described by Pollard (1977). Calli transformed with various cytosolic 
constructs including  a minimally deleted 5’UTR construct, p∆5 ’UTR_ADA and a TMV UTR 
construct, p5’ Ω_ADA were used as  basal constructs with which to compare ADA levels in the 
corresponding calli transformed with apoplast-directed constructs. Any two constructs being 
compared were combined and ranked by ascending expression levels and the U values 
calculated as describe in section 2.6. 
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Figure 5.1: ADA specific-activities measured in BY-2 calli transformed with various cytosolic and apoplast directing 
constructs. Each circle represents ADA-activity from an independent transformant, and the yellow diamond denotes the 
median value. The number of calli assayed is shown in brackets after each construct. 
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Table 5.1a: Pair-wise comparisons of ADA specific-activities measured in transgenic tobacco calli 
using Mann-Whitney U test (5 % level). 
Constructs Population identity p-Value 
p∆5’UTR_ADA versus p∆5’UTR-PR1a_ADA Same P>0.05=0.17993 
p∆5’UTR_ADA versus p∆5’UTR-Ext_ADA Same P>0.05=0.39091 
p5’Ω_ADA versus p5’Ω-PR1a_ADA Same P>0.05=0.59516 
p5’Ω_ADA versus p5’Ω-Ext_ADA Same P>0.05=0.13643 
p5’Ω_ADA versus p5’Ω-Ext_ADA-3’HP Same P>0.05=0.74560 
p5’Ω_ADA versus p5’Ω-Ext_ADA-3’HP Thrombin treated Same P>0.05=0.41730 
 
 
Table 5.1b: Pair-wise comparisons of median ADA specific-activities measured in transgenic tobacco 
BY-2 calli. 
Constructs Ratio of median 
ADA specific-
activity 
Fold increase 
median 
expression 
Fold increase of 
highest expressing 
BY-2 cell line 
p∆5’UTR_ADA versus p∆5’UTR-PR1a_ADA 1.43x10
-4 
: 3.09 x10
-4
 2.1 1.8 
p∆5’UTR_ADA versus p∆5’UTR-Ext_ADA 1.43x10
-4
: 3.88 x10
-4
 2.7 2.2 
p5’Ω_ADA versus p5’Ω-PR1a_ADA 2.02 x10
-3
: 1.31 x10
-3
 0.65 1.9 
p5’Ω_ADA versus p5’Ω-Ext_ADA 2.02 x10
-3
: 7.45 x10
-4
 0.37 1.2 
p5’Ω_ADA versus p5’Ω-Ext_ADA-3’HP 2.02 x10
-3
: 2.03 x10
-3
 1.1 1.7 
p5’Ω_ADA versus p5’Ω-Ext_ADA-3’HP 
Thrombin treated 
2.02 x10
-3
: 2.56 x10
-3
 1.26 1.6 
 
 
A pair-wise comparison of apoplast-targeted constructs, containing TMV omega 5’UTR with 
cytosolic omega constructs, shows that ADA levels are not significantly different (table 5.1a). 
However, when the highest outlying ADA specific-activities of these constructs are compared 
an increase of ADA specific-activity of between 1.2 to 1.9-fold is observed (table 5.1b). 
Moreover, 2-5 transgenic lines from each apoplast-targeted construct exhibited a higher ADA 
specific-activity than the highest expressing p5’Ω_ADA construct (figure 5.1). 
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ADA expression data where PR1a and extensin signal sequences are incorporated with the 
short 21 bp minimally deleted 5’UTR (constructs p∆5’UTR-PR1a_ADA and p∆5’UTR-
Ext_ADA) also show no significant difference. However again, when the highest expressing 
lines are compared an increase of ADA specific-activity of between 1.8 to 2.2-fold is observed 
(table 5.1b). Moreover, 5-6 transgenic lines from each corresponding apoplast-targeted 
construct exhibited a higher ADA specific-activity than the highest expressing p∆5’UTR 
_ADA construct (figure 5.1). The highest outlying ADA specific-activity of p5’Ω-Ext_ADA-
3’HP  transformed calli  also showed an increase of 1.7-fold over the highest expressing calli 
line transformed with p5’Ω_ADA.  
 
5.2.2 Northern blot analysis of transcribed mRNA from calli transformed with different 
apoplast-directed constructs  
In order to assess whether mRNA levels correlated with increased levels of ADA enzyme 
activity, northern blots of transformed and non-transformed tobacco BY-2 calli were 
performed. Total RNA was extracted as described in section 2.3.1 and equal amount of RNA 
(3500 ng) were subjected to electrophoresis under denaturing conditions (section 2.3.2). The 
RNA was transferred to Hybond-N+ nylon membrane as described in section 2.3.3 prior to 
probing with DIG-labelled ADA cDNA (section 2.2.12.3). A photographic reproduction of 
the blot was taken, as shown in figures 5.2, 5.3 and 5.4. TotalLab Quant software was used to 
analyse northern blots (section 2.3.5). 
 
As PCR-amplified ADA is 1092 bp in size, transcribed mRNA would be larger than 1092 
nucleotides. Observed mRNA sizes were approximately 1100 nucleotides and similar in size 
in all constructs apart from construct p5’Ω-Ext_ADA-3’HP (figure 5.4, lanes 2 and 3). 
Transcribed mRNA in construct, p5’Ω-Ext_ADA-3’HP, exhibited a size of 1200 nucleotides 
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and the larger mRNA size in this construct caused by a lengthy DNA sequence (63 bp) 
coding for serine-hydroxyproline (Ser-Hyp) motifs incorporated at the 3’ end of the ADA 
ORF sequence. 
 
Two transgenic cell lines from each construct were analysed for mRNA levels in order to 
correlate them with their corresponding ADA activities (table 5.2). No correlation was 
observed between the levels of ADA mRNA and expressed ADA enzyme-activities, either 
between transformants from the same constructs or between transformants of different 
constructs. For example, calli lines transformed with the constructs p∆5’UTR_ADA [T11] and 
[T15] in figure 5.2, lanes 6 and 7 showed  very different mRNA levels of 13.7 and 2.7 ng of 
ADA mRNA but had very similar ADA specific-activities of about 4 x10-4 U mg-1 TSP (table 
5.2). Also the faint bands of constructs p∆5’UTR-PR1a_ADA [T3] and [T2] in figure 5.2, 
lanes 2 and 3 showed approximately 2.0 and 9.2 ng of ADA mRNA with respective 9.15 and 
6.05 x10
-4
 U mg
-1
 TSP ADA specific-activities (table 5.2). Comparing this data from different 
constructs, the cytosolic construct, p∆5’UTR_ADA [T11], showed a 6-fold higher ADA 
mRNA level but a 2-fold lower ADA specific-activity than the equivalent apoplast construct 
p∆5’UTR-PR1a_ADA [T3]. Furthermore, the construct p∆5’UTR-Ext_ADA [T11], if 
compared to the cytosolic construct, p∆5’UTR_ADA [T11], showed very similar amounts of 
ADA mRNA levels but a 2-fold higher ADA specific-activity. These increased activities of 
ADA but with lower amounts of mRNA than in corresponding cytosolic constructs may be due 
to the incorporation of PR1a and extensin signal peptides which direct the ADA enzyme into 
the apoplastic space which in turn prevents the ADA enzyme from proteolytic degradation in 
the cytosol.  Therefore, higher amounts of ADA mRNA do not necessarily yield higher ADA 
specific-activities. A similar conclusion can be drawn from PR1a and Hydroxyproline 
constructs when comparing with equivalent cytosolic constructs (table 5.2). 
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Figure 5.2: (a) Northern blot of total RNA extracted from transformed and non-transformed tobacco BY-2 calli. Lane 1: 
non-transformed calli, Lane 2: p∆5’UTR-PR1a_ADA [T3], Lane 3: p∆5’UTR-PR1a_ADA [T2], Lane 4: p∆5’UTR-
Ext_ADA [T11], Lane 5: p∆5’UTR-Ext_ADA [T5], Lane 6: p∆5’UTR _ADA [T11] and Lane 7: p∆5’UTR _ADA [T15], 
(b) SafeViewTM stained 2 % agarose gel of rRNA present in lane 1-7. 
 
 
 
 
 
 
Figure 5.3: (a) Northern blot of total RNA extracted from transformed and non-transformed tobacco BY-2 calli. Lane 1: 
non-transformed calli, Lane 2: p5’Ω-PR1a_ADA [T5], Lane 3: p5’Ω-PR1a_ADA [T2], Lane 4: p5’Ω-Ext_ADA [T14], 
Lane 5: p5’Ω-Ext_ADA [T10], Lane 6: p5’Ω_ADA [T3] and Lane 7: p5’Ω_ADA [T2], (b) SafeViewTM stained 2 % 
agarose gel of rRNA present in lane 1-7. 
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Figure 5.4: (a) Northern blot of total RNA extracted from transformed and non-transformed tobacco BY-2 calli. Lane 1: 
non-transformed calli, Lane 2: p5’Ω-Ext_ADA-3’HP [T6], Lane 3: p5’Ω-Ext_ADA-3’HP [T5], Lane 4: p5’Ω-Ext_ADA 
[T14], Lane 5: p5’Ω-Ext_ADA [T10], Lane 6: p5’Ω_ADA [T3] and Lane 7: p5’Ω_ADA [T2], (b) SafeViewTM stained 2 % 
agarose gel of rRNA present in lane 1-7. 
 
 
Table 5.2: ADA specific-activities of tobacco BY-2 calli transformed with cytosolic and apoplast-
directing constructs alongside ADA mRNA amounts measured in northern blots. 
Constructs ADA specific-activity (U mg-1 TSP) ADA  
mRNA (ng) 
p∆5’UTR _ADA [T15] 4.34 x10
-4
 
 
2.7 
p∆5’UTR _ADA [T11] 4.16 x10
-4
 13.7 
p∆5’UTR-PR1a_ADA [T2] 6.05 x10
-4
 9.2 
p∆5’UTR-PR1a_ADA [T3] 9.15 x10
-4
 2.0 
p∆5’UTR-Ext_ADA [T5] 1.13 x10
-3
 18.8 
p∆5’UTR-Ext_ADA [T11] 8.62 x10
-4
 13.0 
p5’Ω_ADA [T2] 2.91 x10
-3
 3.3 
p5’Ω_ADA [T3] 1.84 x10
-3
 4.7 
p5’Ω-PR1a_ADA [T2]  3.35 x10
-3
 8.7 
p5’Ω-PR1a_ADA [T5] 6.43 x10
-3
 8.3 
p5’Ω-Ext_ADA [T10] 4.00 x10
-3
 12.1 
p5’Ω-Ext_ADA [T14] 2.99 x10
-3
 10.6 
p5’Ω-Ext_ADA-3’HP [T5] 3.36 x10
-3
 4.7 
p5’Ω-Ext_ADA-3’HP [T6] 5.18 x10
-3
 12.5 
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5.3 Discussion  
Transgenic tobacco BY-2 calli were successfully generated following Agrobacterium-
mediated transformation with different constructs of the human adenosine gene. Stable 
transformants were assayed for ADA-activity and northern blots were performed to 
investigate a possible correlation between levels of ADA mRNA and enzyme activities. 
 
Incorporation of TMV 5’ omega sequence which gives rise to 5’ omega leader in mRNA aids 
in recruiting translational initiation factors and ribosomes which in turn enhances the translation 
of omega carrying sequences (Gallie and Walbot, 1992; Schmitz et al., 1996). Another strategy 
used to increase foreign gene expression is to incorporate signal peptides sequences such as 
tobacco pathogenesis related protein sequence (PR1a) in conjunction with recombinant ORF 
to direct foreign proteins into the apoplast (Pen et al., 1993a). Ziegler et al., (2000) 
successfully expressed the catalytic domain of a thermostable eubacterium endo-1, 4-β-D-
glucanase in the apoplast of tobacco BY-2 suspension cells and found that incorporation of 
PR1a signal peptide at the N-terminus increased the accumulation endo-1, 4-β-D-glucanase 
proteins. Xu et al., (2002) also demonstrated that the incorporation of PR1a signal peptide 
enhanced the yield by 2-fold as compared to cells transformed with a corresponding cytosolic 
construct.  
 
As with PR1a the extensin signal peptide directs the proteins into the cell secretory pathway 
enhancing the yield presumably by prevention of recombinant protein from proteolytic 
degradation in the secretory pathway and apoplast or alternatively enabling the protein to fold 
correctly into a biologically active molecule. Plant extensins are well-characterized 
hydroxyproline-rich glycoproteins which forms a scaffolding network by covalent extensin-
pectin interactions followed by polymerization to provide the required rigidity of the cell wall 
CHAPTER 5                     SUBCELLULAR DIRECTED EXPRESSION OF HUMAN ADENOSINE DEAMINASE IN TRANSGENIC BY-2 CALLI 
 
110 
 
(Lamport et al., 2011). Incorporation of the signal peptide sequence of extensin at the N-
terminus of recombinant proteins directs secretion into the apoplast (Showalter, 1993). 
Francisco et al., (1997) also demonstrated that incorporation of extensin N-terminal signal 
sequences enhanced the yield of bryodin 1(ribosome-inactivating protein) in BY-2 cell 
suspensions, as compared to the corresponding cytosolic construct.  
 
Evolutionary conserved Hydroxyproline(Hyp)-rich glycoproteins (HRGPs) results in two types 
of glycomodules  uniquely involving  Hyp contiguity (Lamport, 1977; Shapk, 2001). One of 
which is formed by the addition of short unbranched arabinooligosaccharides to a contiguous 
Hyp residues, whereas the other is formed by the addition of branched arabinogalactan 
polysaccharides to clustered non-contiguous Hyp residues (Shapk, 2001). Defined as the 
hyperglycosylated arabinogalactan-proteins (AGPs), these often result in an increased 
molecular mass of the polypeptide (Kieliszewski and Lamport 1994; Kieliszewski and Shapk, 
2000). Use of HRGPs for the purpose of enhancing the yield of secreted recombinant protein 
was demonstrated by Xu et al., (2008). The chimeric expression of HRGPs with recombinant 
interferon alpha2 (IFNα2) targeted for secretion using extensin signal peptide has not only 
increased the yield of recombinant protein by 350- to 1400-fold in the media as compared to a 
non-glycosylated IFNα2 control, but also increased the serum half-life and higher receptor 
binding capacity of IFNα2 when tested in mice (Xu et al., 2007; 2008) 
 
Confirming these findings the overall spread of data in figure 5.1 seems to suggest that 
incorporation of apoplast targeting signals gives rise to lines of calli which express ADA at 
higher levels than calli transformed with a cytosolic counterpart. For example, the range of 
activities measured in p5’Ω_ADA was between 0.02 - 3.4 x 10-3 U mg-1 TSP. Whereas, the 
p5’Ω-PR1a_ADA apoplast targeted calli varies from 0.14 - 6.5 x 10-3 U mg-1 TSP and for 
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p5’Ω-Ext_ADA and p5’Ω-Ext_ADA-3’Hydroxyproline constructs the range in expression is 
0.0061 - 4.0 and 0.034 - 6.0 x 10
-3
 U mg
-1
 TSP respectively.  
 
Due to either transgene silencing or post-transcriptional gene silencing of inserted constructs, 
it is possible that the mean and median data points are distorted. It has been shown that the 
inverted tandem repeats of T-DNA trigger transgene silencing, which results in poorly 
transcribed genes leading to a poor expression of recombinant proteins (Sijen et al., 2001). It 
was further found that the transgenes in multiple copies under the control of strong 
promoters, such as the double CaMV 35S promoter, triggers post-transcriptional gene 
silencing by surpassing a gene-specific threshold (Vaucheret et al., 2001; Schubert et al., 
2004). 
 
The most relevant results to this study were observed in construct p5’Ω-Extensin_ADA-
3’Hydroxyproline, which shows 6 transformed cell lines exhibit a higher ADA-activity than 
the highest p5’Ω_ADA cytosolic construct (figure 5.1). Successful expression of a functional 
human adenosine deaminase in transgenic tobacco BY-2 calli has been demonstrated in this 
chapter. Attempts to increase the ADA yield by enhancing expression proved to be successful 
as it was found that incorporation of TMV omega 5’ UTR sequences in calli improved ADA 
yield by a considerable amount and moreover, incorporation of apoplast-directing signals into 
the same construct produced calli cell lines with almost double the amounts of ADA-activity. 
Expression of proteins in fusion with AGP glycomodule Ser-Hyp (SO) repeats exhibited the 
highest mean ADA-activities. 
 
The increased yield of subcellular-directed expression of ADA should be highly pronounced 
in cell suspensions as subcellular-directed proteins have been found to be secreted into the 
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culture media (Xu et al., 2010). Hence, the effect of ADA constructs with subcellular-
directing sequences such as PR1a, extensin and Ser-Hyp (SO) fusions in transformed BY-2 
cell suspensions will be presented in the following chapter.  
  
 
 
 
 
 
 
 
Chapter 6 
Expression of human adenosine deaminase in 
transgenic tobacco BY-2 cell suspension 
cultures 
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6.1 Overview 
Using plant cell suspension cultures to express foreign proteins encompasses some 
advantages over whole-plants, microbial and animal cell culture systems (Hellwig et al., 
2004). These include a rapid cell doubling time, well established genetic transformation 
methodologies, low endogenous proteolytic activity, low production of secondary 
metabolites, capability to carryout post-translational modification and reduced post-
translational silencing (Lee et al., 2000; Su and Lee, 2007). Undifferentiated plant calli can 
be separated and propagated in culture media in a controlled condition to generate cell 
suspension cultures. Developed in the 1950’s, plant cell suspension culture technology has 
been used for the production of secondary metabolites such as digoxin, paclitaxel, and 
artemisinin (Georgiev et al., 2009; Huang and McDonald 2009). With increasing demand for 
therapeutic proteins, as well as modern advances in plant molecular biology, plant cell culture 
systems have developed as an alternative system for producing therapeutically imperative 
proteins.  The first two therapeutic proteins to be produced in transgenic plant cell suspension 
cultures were recombinant human serum albumin (Sijmons et al., 1990) and chloramphenicol 
acetyltransferase (Hogue et al., 1990). A recombinant poultry vaccine produced by Dow 
AgroSciences was the first plant cell suspension culture-produced therapeutic protein to be 
approved in February 2006 by the USDA (Kaiser, 2008). Another recombinant protein, 
human glucocerebrosidase (Taliglucerase alfa) used in ERT to treat Gaucher’s disease, has 
been produced by Protalix Biotherapeutics. This enzyme was the first plant cell-produced 
human enzyme to be approved by the United States Food and Drug Administration (FDA) in 
2012 (Pfizer Press Releases, 2012). Although, many recombinant proteins have been 
produced in plant cell suspension culture systems, using tomato, rice, soybean and tobacco 
plants (Huand and McDonald, 2009), tobacco BY-2 cell suspensions are the most commonly 
used cell system. In this study, BY-2 cell suspension cultures transformed with various ADA 
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cDNA constructs have been investigated for extra and intra-cellular ADA enzyme-activities 
over a period of 15 days. 
 
6.2 Results 
Tobacco BY-2 cells were transformed with cytosolic constructs or different constructs 
containing apoplast-directing signals. These constructs are namely: pCDNA_ADA, p5’Ω-
PR1a_ADA, p5’Ω-Extensin_ADA and p5’Ω-Extensin_ADA-3’Hydroxyproline (See section 3 
for details). The highest expressing transformed BY-2 calli cell lines were selected and 
suspension cultures were generated in MS media substituted with 0.75 g L
-1
 of PVP (M.W 
360,000) as described in section 2.1.2.  In initial experiments PVP was shown to dramatically 
improve ADA enzyme-activity when included in the media (figure 6.1). It was subsequently 
included in all experiments described in this chapter. Aliquots of BY-2 cell suspension cultures 
were collected on alternate days, starting from day 0 up to day 15. The collected samples were 
subjected to centrifugation to separate cells from culture media, which was then tested for ADA 
enzyme-activity using an adenosine deaminase assay to determine the extra-cellular enzyme-
activity secreted into the culture medium (section 2.5.2). Intra-cellular ADA-activities were 
assayed at the same time from pelleted cells, flash frozen in liquid nitrogen as described in 
section 2.5.1. Eight samples taken over 15 days from BY-2 cell suspensions transformed with 
various constructs were analysed and ADA-activities are shown in Units L
-1 
(figures 6.1 and 
6.2). A cytosolic construct, pCDNA_ADA, containing human 5’ and 3’ UTR was used as a 
basal construct with which to compare the corresponding ADA-apoplast-directed constructs.  
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6.2.1 Extra-cellular ADA-activities in BY-2 cell suspensions transformed with ADA 
expressing constructs  
 
There is between a 31 to 336-fold increase in secreted ADA-activity when apoplast targeting 
constructs are compared to the cytosolic control on day 7 (figure 6.1 and table 6.1). The highest 
extra-cellular ADA-activity was measured on the day 7 for p5’Ω-Ext_ADA-3’HP construct, 
transformed cell line which measured 739 U L
-1
, a 336-fold increase over the cytosolic 
construct. 
 
Extra-cellular ADA-activity of construct p5’Ω-Ext_ADA-3’HP transformed cell line peaked 
on day 7 followed by a drastic decline in ADA-activity in the next two days and increased 
ADA-activity thereafter. In a similar experiment investigating the monoclonal antibody levels 
in Nicotiana tabacum cell suspensions, Sharp and Doran, (2001) observed a slight increase in 
recombinant monoclonal IgG antibody levels in the medium on the day 16 of sampling after a 
drastic reduction of protein levels in suspension media following peak production on day 7. A 
similar pattern of ADA-activity was also observed in the construct p5’Ω-PR1a_ADA 
transformed cell line. Whereas the ADA-activity of construct p5’Ω-Ext_ADA transformed 
cell line showed a constant level of ADA from day 3 to day 11 followed by a steady decrease 
between days 13-15. The increase in ADA-activity on day 15 is thought to be due to cell 
death and the stabilizing effect of the PVP on released ADA in the media. As shown in the 
figure 6.1, the construct p5’Ω-Ext_ADA-3’HP transformed cell line showed a large sudden 
increase of ADA levels on day 13 of sampling. This could be due to stabilizing effect by both 
PVP and also the extensively glycosylated arabinogalactan motifs present on released ADA 
serving to protect associated ADA from proteolytic degradation. Xu et al., (2007) 
demonstrated that the incorporation of arabinogalactan motifs increased the resistance of the 
CHAPTER 6                             EXPRESSION OF HUMAN ADENOSINE DEAMINASE IN TRANSGENIC TOBACCO BY-2 CELL SUSPENSION 
CULTURES      
 
117 
 
recombinant IFNα2 to chymotryptic digestion by up to 13-fold. This could be further 
investigated with prolonged incubation times. 
 
 
 
Figure 6.1: Extra-cellular ADA-activities measured in various cytosolic and apoplast-directing constructs in transformed 
BY-2 cell suspensions. 
 
 
 
 
Table 6.1: Pair-wise comparisons of highest extra-cellular ADA-activities measured in transgenic 
tobacco BY-2 cell suspensions. 
Constructs compared Ratio of highest ADA-
activities (Day 7) 
Fold increase of highest 
ADA-activity on day 7 
p cDNA_ADA versus p5’Ω-PR1a_ADA 2.2: 186.0 85 
p cDNA_ADA versus p5’Ω-Ext_ADA 2.2: 68.4 31 
p cDNA_ADA versus p5’Ω-Ext_ADA-3’HP  2.2: 739.4 336 
p5’Ω-Ext_ADA versus p5’Ω-Ext_ADA-3’HP 68.4: 739.4 11 
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6.2.2 Intra-cellular ADA-activities in BY-2 cell suspensions transformed with ADA 
expressing constructs 
 
There is up to a 1.5-fold increase in the highest recorded intra-cellular ADA-activity when 
suspensions transformed with apoplast targeting constructs are compared to the cytosolic 
control construct (figure 6.1 and table 6.1). The highest intra-cellular ADA-activity was 
measured on day 7 for the p5’Ω-Ext_ADA-3’HP construct, transformed cell line which 
measured 19.1 U L
-1
, a 1.5-fold increase over the cytosolic construct. 
 
Unlike extra-cellular ADA-activity, intra-cellular ADA-activity of different constructs peaked 
on different days, ranging from day 7 to 11. The highest intra-cellular ADA-activity of the cell 
line containing apoplast targeting construct p5’Ω-PR1a_ADA, was measured on day 11 of 
sampling as 15.2 U L
-1
, a 1.2-fold increase over the cytosolic construct (table 6.2). Whereas, the 
highest intra-cellular ADA-activity of the cell line containing construct p5’Ω-Ext_ADA, was 
measured on day 7 of sampling (8.4 U L-1). Lower intra-cellular ADA-activity in cell 
suspensions can be explained by the targeting of ADA enzyme by N-terminal signal sequences 
into the secretory pathway, which in turn leads to secretion into the media, leaving little intra-
cellular ADA enzyme.  
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Figure 6.2: Intra-cellular ADA-activities measured in various cytosolic and apoplast-directing constructs in transformed 
BY-2 cell suspensions.  
 
 
 
 
 
Table 6.2: Pair-wise comparisons of highest intra-cellular ADA-activities measured in transgenic 
tobacco BY-2 cell suspensions. 
Constructs Ratio of highest ADA-
activities  
Fold increase/decrease of 
highest ADA-activity 
p cDNA_ADA versus p5’Ω-PR1a_ADA 12.7: 15.2 1.2 
p cDNA_ADA versus p5’Ω-Ext_ADA 12.7: 8.4 0.3 
p cDNA_ADA versus p5’Ω-Ext_ADA-3’HP
  
12.7: 19.1 1.5 
p5’Ω-Ext_ADA versus p5’Ω-Ext_ADA-3’HP 8.4: 19.1 2.3 
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Figure 6.3: Total soluble proteins (g L-1) measured in Tobacco BY-2 cell suspension.  
 
 
Table 6.3: Highest intra and extra-cellular ADA-activities in transgenic tobacco BY-2 suspensions.  
Constructs Intra-cellular 
(U L-1) 
Extra-cellular 
(U L-1) 
Total ADA in calli  
and medium (U L-1) 
Total ADA in calli  and 
medium (mg L-1) 
p cDNA_ADA  12.7 2.2  14.9 0.3 
p5’Ω-PR1a_ADA 15.2 186 201.2 3.6 
p5’Ω-Ext_ADA  8.4  68.4 76.8 1.4 
p5’Ω-Ext_ADA-3’HP 19.1 739.4 758.4 13.4 
 
As shown in table 6.3, the highest intra-cellular ADA-activity in suspensions was measured 
in the cell line transformed with construct p5’Ω-Ext_ADA-3’HP (19.1 U L-1/0.3 mg L-1). 
Whereas the highest extra-cellular ADA-activity in the same construct showed a 739.4 U L
-1 
(13 mg L
-1
), which is a 39-fold increase in the extra-cellular ADA levels as compared to 
intra-cellular levels in suspension (table 6.3). The highest intra-cellular ADA-activity of 
p5’Ω-Ext_ADA construct measured 8.4 U L-1 (0.15 mg L-1), whereas the extra-cellular ADA-
activity of the corresponding constructs measured 68.4 U L
-1
 (1.2 mg L
-1
), an 8-fold increase 
in the extra-cellular ADA levels as compared to intra-cellular levels in suspension. This 
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suggests that the majority of the produced ADA has been secreted into the medium and also 
the highly glycosylated ADA containing hydroxyproline motifs seems to be stabilizing the 
recombinant protein eventually enhancing the yield.  Table 6.3 confirms that most of the 
recombinant ADA targeted to the apoplast by N-terminal signal sequences, have been secreted 
into the medium, leaving little intra-cellular ADA enzyme.  
 
Measurement of TSP in cell suspensions over time is an indicator of cell growth (Lee et al., 
2001). As shown in figure 6.3, the amount of total soluble protein measured in tobacco BY-2 
cell suspensions shows a rapid increase by up to 2-fold from day 0 to day 5, followed by an 
almost constant level of TSP until day 11. A reduction in TSP occurred on day 13, followed 
by a slight increase on day 15. Nagata et al., (1992) and Horemans et al., (2003) also 
demonstrated that the exponential growth of BY-2 cells in suspension occurs from day 0 to 5, 
followed by a stationary phase. Sharp and Doran, (2001) reported that the growth of 
Nicotiana tabacum cells in suspension does not peak with foreign protein production, where 
maximum secreted levels of antibodies were observed on day 7 before maximum biomass 
was reached on day 14. Hence, higher amounts of biomass (or TSP) do not always peak with 
higher foreign protein production. Factors such as culture conditions and recombinant 
construct design determine when peak levels of targeted proteins are secreted into the 
medium.  Confirming this Magnuson et al., (1996) showed that secreted monoclonal antibody 
heavy chain γ in transgenic Nicotiana tabacum cell suspension peaked on day 7 followed by 
a rapid decrease. Similarly, Lee et al., (2001) showed that murine GM-CSF expressed in 
transgenic Nicotiana tabacum cell suspension reached maximum levels on day 6 followed by 
a decline. In line with these findings, the highest amounts of secreted ADA were observed on 
day 7, two days after amounts of TSP had reached maximum levels. 
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Table 6.4: High-yield expression of pharmaceutical proteins in plant cell suspension cultures. 
Therapeutic proteins Host cells Protein yields 
and signal used 
Promoter Localization Reference 
Human interferon α2b 
(hlFN α2) 
N. tabacum cv BY-2 28 mg L
-1
 (Ext) CaMV35S Secreted Xu et al.,  (2007) 
Human growth 
hormone (hCH) 
N. tabacum cv BY-2 35 mg L
-1 
(Ext) CaMV35S Secreted Xu et al.,  (2010) 
 0. sativa L. cv. 
Donjin 
57 mg L
-1 
(RAmy3D) 
RAmy3D Secreted Kim et al., (2008a) 
Hepatitis B surface 
antigen (HBsAg) 
glycine max cv 
Williams82 
(Soybean) 
22 mg L
-1  
(ER signal) 
(OCS)3mas Intracellular Smith et al., (2002) 
mAb against HBsAg N. tabacum cv BY-2 15 mg L
-1 
(Ext) CaMV35S ~50% 
secreted 
Yano et al., (2004) 
Bryodin 1 N. tabacum cv NT- 1 30 mg L
-1 
(Ext) CaMV35S  Secreted Francisco et al., (1997) 
Human α1-antitrypsin 
(rAAT) 
0. sativa (rice) 200 mg L
-1
 
(RAmy3D) 
RAmy3D Secreted Huang et al., (2001) 
 0. sativa cv Taipei 
309 
85 mg L
-1 
(RAmy3D) 
RAmy3D Secreted Terashima et al., (1999) 
 0. sativa (rice) 247 mg L
-1 
(RAmy3D) 
RAmy3D  Secreted McDonald et al., (2005) 
 0. sativa (rice) 110 mg L
-1 
(RAmy3D) 
RAmy3D Secreted Trexler et al., (2005) 
 0. sativa (rice) 50 mg L
-1 
(RAmy3D) 
RAmy3D Secreted Trexler et al., (2002) 
Human cytotoxic T-
lymphocyte antigen 4-
immunoglobulin 
(hCTLA4Ig) 
0. sativa (rice) 76.5 mg L
-1 
(RAmy3D) 
RAmy3D Secreted Park et al.,  (2010) 
Human granulocyte-
macrophage colony 
stimulating factor 
(hGM-CSF) 
0. sativa (rice) 129 mg L
-1 
(RAmy3D) 
RAmy3D Secreted Shin et al., (2003) 
Human lysozyme 0. sativa cv Taipei 
309 
3%-4% TSP* 
(RAmy3D) 
RAmy3D Intracellular Huang et al., (2002b) 
Human serum albumin 
(HSA) 
0. sativa (rice) 77 mg L
-1 
(RAmy3D) 
RAmy3D Secreted Huang et al., (2005) 
Human interlukin-12  
(IL-12) 
0. sativa (rice) 31 mg L
-1 
(RAmy3D) 
RAmy3D Secreted Shin et al., (2010b) 
Human alkaline 
phosphatase 
N. tabacum cv NT-1 27 mg L
-1
 CaMV35S Secreted Becerra-Arteaga et al., 
(2006) 
Mouse IgG anti 
Streptococcus surface 
antigen 
N. tabacum cv NT-1 10.8 mg L
-1
 CaMV35S Secreted Wongsamuth and 
Doran (1997) 
Human anti-HIV 
antibody 2G12 
N. tabacum cv BY-2 ~10 mg L
-1
 CaMV35S Secreted Holland et al., (2010) 
Human α-iduronidase N. tabacum cv BY-2 10 mg L
-1 
(proaleurain) 
CaMV35S Secreted Fu et al., (2009) 
Human lactoferrin Acanthopanax 
senticosus 
3.6% TSP* 
(ER signal) 
SWPA2 Intracellular Jo et al., (2006) 
 N. tabacum cv BY-2 4.3% TSP* 
(ER signal) 
SWPA2 Intracellular Choi et al., (2003) 
Human Adenosine 
deaminase 
N. tabacum cv BY-2 13 mg L
-1
(Ext, HP)
 
3.3 mg L
-1
 (PR1a) 
1.2 mg L
-1 
(Ext) 
CaMV35S Secreted Results mentioned in 
this thesis 
*TSP: total soluble proteins. Modified from Xu et al., (2011) 
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In line with previous attempts to express biopharmaceuticals in plant cell suspensions using 
apoplast targeting signals, BY-2 cell suspensions transformed with constructs containing 
apoplast targeting signals gave considerably higher levels of secreted ADA. Approximate 
extra-cellular ADA levels of 13 mg L
-1
, 3.3 mg L
-1
 and 1.2 mg L
-1
 were observed respectively 
in BY-2 cell suspensions transformed with p5’Ω-Ext_ADA-3’HP, p5’Ω-PR1a_ADA and 
p5’Ω-Ext_ADA constructs (table 6.4). These are comparable to the levels of 30 mg L-1 
measured for an extensin-bryodin constructs in tobacco cell suspensions. But lower than for 
example, hGM-CSF driven by a rice α-amylase leader measured in rice cell suspension. 
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6.3 Discussion  
Tobacco BY-2 cell suspensions were prepared from calli transformed with a cytosolic and 
three apoplast targeting constructs. The extra- and intra-cellular ADA-activities were 
measured on alternate days for 15 days in order to investigate the levels of ADA expression 
in cell suspension over time. The highest ADA enzyme-activities of suspensions transformed 
with various apoplast targeting constructs were compared to the highest ADA activity of a 
suspension transformed with a cytosolic construct in order to determine the overall increase 
in yield. 
 
Incorporation of signal peptide sequences such as tobacco pathogenesis related protein 
(PR1a) in conjunction with recombinant proteins directs associated proteins into the apoplast 
leading to higher yield in cell suspensions (Pen et al., 1993a; Ziegler et al., 2000). Confirming 
these findings a comparison of highest extra-cellular ADA-activity ratios (day 7) shows that 
the incorporation of a PR1a N-terminal signal sequence along with the TMV omega 5’UTR 
sequence in BY-2 cell suspensions increased the ADA-activity by 85-fold as compared to the 
pCDNA_ADA cytosolic construct (table 6.1). Whereas, the intra-cellular ADA levels only 
increased by 1.2-fold, showing that almost all the ADA enzyme is secreted into the external 
medium (table 6.2). 
 
As with PR1a, the extensin signal peptide directs linked proteins into the secretory pathway 
enhancing the yield presumably by directing recombinant proteins away from proteolytic 
degradation in the cytosol and also in some cases enabling proteins to fold into biologically 
active structures. Incorporation of plant extensin signal peptide sequence at the N-terminus of 
recombinant proteins has been shown to direct secretion of recombinant proteins into the 
apoplast, which in turn are secreted into the culture medium of cell suspensions, eventually 
CHAPTER 6                             EXPRESSION OF HUMAN ADENOSINE DEAMINASE IN TRANSGENIC TOBACCO BY-2 CELL SUSPENSION 
CULTURES      
 
125 
 
enhancing the recombinant protein yield (Showalter, 1993; Francisco et al., 1997). Confirming 
these findings the comparison of highest extra-cellular ADA activity ratios shows that the 
incorporation of an extensin N-terminal signal sequence along with TMV omega 5’UTR 
sequence in BY-2 cell suspensions increased the ADA activity by 31-fold as compared to the 
pCDNA_ADA cytosolic construct (table 6.1). A decreased ADA activity of 0.3-fold was 
observed in intra-cellular samples from the same culture (table 6.2). 
 
Another important strategy, by which recombinant proteins can be accumulated at high levels 
in cell suspension, is to express as a fusion with hydroxyproline (Hyp) residues at the C-
terminus (Xu et al., 2007). C-terminal hydroxyproline (Hyp) residues attract extensive O-
glycosylation, increasing the molecular size, stability and serum half-life of the associated 
proteins in a similar way to therapeutic protein PEGylation (Shapk, 2001; Xu et al., 2007). 
Confirming the findings of Xu et al., (2007; 2008 and 2010), the most relevant results to this 
study were observed in BY-2 cell suspension containing the construct, p5’Ω-Extensin_ADA-
3’Hydroxyproline, where a comparison of highest extra-cellular ADA-activity (day 7) shows a 
336-fold increase in ADA-activity as compared to the cell suspension transformed with the 
cytosolic construct pCDNA_ADA (figure 6.1 and table 6.1).  
 
Successful expression of a functional human adenosine deaminase in transgenic tobacco BY-
2 cell suspensions has been demonstrated in this chapter. Attempts to increase the ADA yield, 
by incorporation of apoplast-directing signals in constructs, increased the ADA yield in the 
culture medium. Expression of proteins in fusion with the AGP glycomodule, Ser-Hyp (SO) 
repeats, exhibited the highest ADA-activities (739.4 U L
-1
/13 mg L
-1
) secreted into culture 
medium in BY-2 cell suspensions. It’s also interesting to note that in cell suspensions of calli 
transformed with the hydroxyproline construct, ADA levels are more than 10-fold greater 
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than when the extensin signal is used alone (table 6.3). This magnitude of difference in 
expression is not the same when ADA amounts are compared between the two corresponding 
calli (see chapter 5 figure 5.1). Here there is only a 1.6-fold increase in ADA yields between 
the same two calli lines. Again, this may be due to the stabilizing affect of both the 
hydroxyproline glycomodule and PVP on secreted ADA, but cell age also seems to be of 
paramount importance here. Since, cells in suspension are all a few days old, whereas cells in 
calli range in age from a few days to a few weeks. Hence, in support of the findings of Xu et 
al., (2007, 2008 and 2010) a possible way forward to enhance the yield of foreign proteins in 
transgenic plant cell cultures is to express proteins as a fusion with AGP glycomodule Ser-
Hyp (SO) repeats targeted to secretion.  
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Enzyme replacement therapy with polyethylene glycol conjugated bovine ADA (PEG-ADA) 
has been in use since 1987 for the treatment of ADA deficiency associated severe combined 
immunodeficiency syndrome (Booth et al., 2007). Although ERT with PEG-ADA is 
generally well tolerated by patients, some patients develop neutralizing antibodies that 
hinders catalytic activity and enhances PEG-ADA clearance (Chaffee et al., 1992).  Hence, 
ERT with recombinant human ADA is thought to be an alternative to successfully overcome 
this problem. Adenosine deaminase catalyses the conversion of cytotoxic adenosine 
analogues into their non-toxic inosine analogues and is present in numerous organisms 
ranging from bacteria to mammals with the exception of plants (Dancer et al., 1997). 
Conversion of toxic adenosine analogues into non-toxic analogues in plants are catalysed 
either by adenosine kinase or by phosphoribosyltransferase (Pelcher, 1995). Absence of ADA 
in plants provides an excellent platform to produce recombinant ADA in plants.  
 
Although bacteria are classed as cost-effective and convenient production systems for many 
small human proteins such as human insulin and growth hormone, inability to carry out post-
translational modification and assembly steps which are required for biological activity of 
most complex proteins, hinders their use for producing such proteins (Sharma and Sharma, 
2009). As an alternative production system, plants exhibit an effective and efficient eukaryote 
protein synthesis mechanism, and with the advent of modern plant biotechnology, plants can 
be used to produce large quantities of protein with readily established gene expression 
systems (Shih and Doran, 2009). Plant expression systems are also free of mammalian 
pathogens and thus offer a prominent advantage over mammalian expression systems. As 
outlined in chapter 1, a wide array of techniques has been used in recent years to increase the 
expression levels of foreign genes in plants to ensure commercial feasibility. Moreover, a 
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readily available range of plant hosts and well established gene expression systems allows a 
variety of choices depending on the product under production and the site of production. 
 
The recent advances in the use of plant cell cultures producing valuable pharmaceutical 
proteins highlights their benefits over whole-plants. Cell cultures: exhibit rapid growth due to 
short cell doubling times; can be used in controlled bioreactors to improve protein 
consistency; can exert mammalian-like post-translational modifications; and most 
importantly have reduced post-transciptional silencing effects due to dedifferentiated cells 
(Lee et al., 2000; Su and Lee, 2007). Moreover, plant cell suspension cultures can be 
modified to secrete proteins into media in sterile conditions in vitro which in turn reduces the 
cost of downstream processing. Hence, there is great potential for the production of foreign 
proteins, cost-effectively in large quantities. Whole plants and other plant cell systems are 
therefore ideal candidates for the production of human ADA at high-levels.  
 
The work described in this thesis represents a study to assess the possibility of increasing 
expression levels of a functional human ADA in plants. The highest observed ADA specific-
activity of 3.70 x 10
-3
 U mg
-1
 TSP, which is ~65.5 ng mg
-1
 TSP of ADA (0.006 % of  TSP) 
was obtained from plants transformed with a p5’Ω_ADA cytosolic construct. Stable ADA 
expression in transgenic plants was achieved without any plant codon optimisation of the 
gene ORF and only between 6 and 7 transgenic plants were analysed from each construct, 
therefore there is a potential to further increase expression levels using codon optimisation 
and analysing greater numbers of transgenic plants.  
 
For a BY-2 cell line transformed with a cytosolic construct p5’_3’Ω_ADA, the highest 
observed ADA specific-activity measured was 4.50 x 10
-3
 U mg
-1
 TSP, which is ~80 ng mg
-1
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TSP of ADA (0.008 % TSP). This consolidates the findings of Schmitz et al., (1996) and 
Gallie and Walbot, (1990) where incorporation of omega TMV 5’ and 3’ UTR sequence was 
shown to increase expression levels of associated sequences. Northern blot analysis of 
transformed calli confirmed the mRNA stabilizing and translational enhancing effects of 
incorporated omega TMV 5’ and 3’ UTR sequences. In addition, southern blot analysis 
showed that ADA expression levels in plants transformed with cytosolic constructs are not 
directly proportional to insert copy number, confirming the findings of Jones et al., (1985) 
amongst many others. Transformed plants with higher insert copy number actually showed 
lower ADA specific-activities. Western blot analysis of these plants confirmed that the 
molecular weight of recombinant ADA was very similar to that measured for human ADA. 
 
In an attempt to increase the levels of ADA further, a strategy of targeting expressed proteins 
into the plant secretory pathway was employed, since cytosolic proteases have been 
implicated in destruction of over-expressed foreign proteins in the cytosol and some proteins 
fold up more efficiently into biologically active conformation in the ER (Doran, 2000). For 
this reason a tobacco pathogenesis related protein (PR1a) signal peptide sequence was placed 
at the N-terminus of the polypeptide sequence to direct associated ADA into the apoplast.  
This was predicted to increase the protein yield as shown by Pen et al., (1993a) and Ziegler et 
al., (2000). The plant apoplast is a non-living part of plant tissue, external to the cell 
membrane and composed of the cell walls, intercellular spaces, and the lumen of dead 
structures such as xylem cells. Since this region doesn’t contain proteases, proteins targeted 
here are predicted to accumulate. In this study an attempt was made to direct ADA to the 
apoplast by stable nuclear transformation of BY-2 calli with constructs containing a PR1a N-
terminal signal sequence. The highest observed ADA specific-activity of 6.50 x10
-3
 U mg
-1
 
TSP (~0.012 % of TSP) was obtained from BY-2 calli transformed with a p5’Ω-PR1a_ADA 
CHAPTER 7                                                             DISCUSSION      
 
131 
 
subcellular-targeting construct. This is almost 2-fold higher than obtained for the highest 
performing cytosolic construct. The same construct in cell suspension produced the highest 
overall ADA-activity of 201 U L
-1
 on day 7 of growth (table 7.1 and 7.2). In an attempt to 
consolidate this data, another apoplast directing signal taken from a tobacco extensin signal 
sequence was also investigated. Extensin (Ext) N-terminal signal sequences have been shown 
to increase the yield of a ribosome-inactivating protein (bryodin 1) in BY-2 cell suspensions 
(Francisco et al., 1997). Extensin N-terminal signal sequences incorporated into a p5’Ω-
Extensin_ADA subcellular-targeting construct, resulted in ADA specific-activities of up to 
4.30 x10
-3
 U mg
-1
 TSP, of ADA (~0.0076 % TSP) in one calli cell line. This is only slightly 
higher than (a 1.2-fold increase) than that found with the highest performing cell line 
transformed with a cytosolic construct. The highest observed overall ADA-activity of 76.8 U 
L
-1 
was obtained on day 7 for a BY-2 cell suspension transformed with the same construct 
(table 7.1 and 7.2). 
 
 
Although ADA levels were almost doubled in transformed BY-2 calli and cell suspensions by 
use of apoplast targeting signals, higher levels were sought by incorporation of Serine-
Hydroxyproline repeats at the C-terminus of ADA. Xu et al., (2007); (2008); (2010) 
demonstrated that the incorporation of the AGP glycomodule, Ser-Hyp (SO) repeats, at the 
C-terminus of recombinant proteins enhances secreted protein yield by between 350- to 1400-
fold in BY-2 cell suspension as compared to a non-glycosylated counterpart. Incorporating 
the AGP glycomodule Ser-Hyp (SO10) repeats at the C-terminus in the p5’Ω-Ext_ADA-3’HP 
subcellular-targeting construct resulted in ADA specific-activities of up to 6.00 x10
-3
 U mg
-1
 
TSP in BY-2 calli (~0.011 % TSP). This is significantly higher than (a 1.7-fold increase) that 
measured in the highest performing calli transformed with the cytosolic construct. Cell 
suspension data revealed that the highest observed combined intra and extra-cellular ADA-
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activity of 758.4 U L
-1
 was obtained on day 7 in BY-2 cell suspension transformed with 
p5’Ω-Ext_ADA-3’HP subcellular-targeting construct (table 7.1 and 7.2). Approximately a 4-
fold higher ADA level as compared to a cell suspension transformed with a PR1a construct. 
The increased yield is thought to be due to the protein stabilizing affect of the hydroxyproline 
glycomodule. Xu et al., (2007) found that AGP glycomudule Ser-Hyp (SO10) repeats not only 
increased the molecular weight of the protein but also the stability.  
 
Levels of expressed ADA do not always yield significantly more ADA product in calli, when 
different constructs are compared. However, when ADA production is compared between 
constructs in transformed cell suspensions much higher secreted levels (up to 7-fold, figure 
6.1) are evident. Hence, it is clear that the incorporation of the AGP glycomodule Ser-Hyp 
(SO10) repeats at the C-terminus of ADA ORF along with the protein stabilizing affect of 
PVP significantly increased the ADA yield in cell suspensions. Another factor taken into 
consideration here is the cell age difference between cell suspension and calli, where, age of 
cells in suspension can be measured in days but cells in calli range in age from a few days to 
a few weeks. Further to these findings, thrombin cleavage of glycosylated motifs didn’t 
increase the ADA-activity considerably. Hence, it would seem that the biological activity of 
ADA is not significantly hindered by the extensively glycosylated AGP glycomodule. Minute 
intracellular ADA levels (20 U L
-1
) also suggested that more than 95 % of the produced ADA 
has been secreted into the culture medium.  
 
 
 
 
 
 
CHAPTER 7                                                             DISCUSSION      
 
133 
 
Table 7.1: Summary of the highest ADA levels obtained in tobacco plants, BY-2 calli and BY-2 cell 
suspension transformed with various constructs. 
Construct ADA U mg-1 TSP Estimated  
ADA ng mg-1 TSP 
ADA as % TSP 
Plant cytosolic 3.70 x10-3 65.5 0.006 
Calli cytosolic 4.50 x10-3 80 0.008 
Calli PR1a  6.50 x10-3 115 0.012 
Calli extensin 4.30 x10-3 76 0.0076 
Calli AGP 6.00 x10-3 106 0.011 
BY-2 suspension cytosolic  1.50 x10-3 26.5 0.002 
BY-2 suspension PR1a 1.10 x10-2 195 0.019 
BY-2 suspension extensin 8.53 x10-3 151 0.013 
BY-2 suspension AGP 4.04 x10-2 715 0.072 
 
 
Table 7.2: Summary of the highest combined intra and extra-cellular ADA levels obtained in BY-2 
cell suspensions transformed with various constructs. 
Construct ADA U L-1 Estimated 
ADA mg L-1 
BY-2 suspension cytosolic  19.2 0.25 
BY-2 suspension PR1a 201 3.5 
BY-2 suspension Extensin 76.8 1.4 
BY-2 suspension AGP 758.4 13.4 
 
Problems regarding expensive and time-consuming downstream processing of plant produced 
proteins, especially when the host plant contains undesirable toxic compounds, are also 
addressed in this study where production of proteins in cell suspension provides for a more 
efficient method of extracting produced protein from the culture medium. Moreover, 
dedifferentiated BY-2 cells do not produce large amounts of phenolic and other toxic 
compounds found in whole tobacco plants. Further, the controversy surrounding GM plants 
grown in non-controlled environments would be irrelevant, as cell suspensions can be 
entirely contained in a controlled environment and offer a huge potential to produce 
biopharmaceuticals in a sterile environment (Kaiser, 2008; Shaaltiel et al., 2007). The 
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productions of the first two USFDA-approved biopharmaceuticals in plant cell culture 
endorse this approach for the production of future products.  
 
Although some plant glycosylation patterns are highly immunogenic to mammals (Doran, 
2000; Leonard et al., 2005), the presence of the AGP glycomodule Ser-Hyp (SO) repeats 
have been found to be non-immunogenic in mice (Xu et al., 2007; 2010). Further 
investigations should be conducted in order to categorically confirm this finding, because this 
novel technique provides a potential plant protocol to produce non-immunogenic proteins 
including ADA with a greatly enhanced plasma half-life in vivo when used therapeutically. It 
was found that hydroxyproline glycomodule fusion of therapeutic proteins is as effective as 
PEGylation in enhancing plasma half-life (Yang et al., 2004; Xu et al., 2010) 
 
This study was set up to investigate a range of strategies to increase the production of a 
functional human adenosine deaminase in plants and plant cell suspensions.  Amongst all the 
strategies employed, incorporation of the AGP glycomodule at the C-terminus of the ADA 
protein has clearly proven to be the most effective product-yield enhancing strategy. The 
work described in this thesis leaves scope for future investigation to enhance levels of 
recombinant human ADA (rhADA) further and to explore protocols for the isolation of a pure 
product from transgenic plant materials. Purification of ADA is pivotal in order to explore the 
clinical importance of rhADA. Although the secretion of rhADA into the media of BY-2 cell 
suspension cultures eliminates most of the difficulties involved in protein purification from 
plant materials, future research will focus on purification steps necessary of rhADA isolation. 
Proteins of therapeutic applications require the highest purity (>99 %). Purification of 
proteins involves a series of enrichment steps including use of column-based methods such as 
ion exchange chromatography, affinity chromatography, hydrophobic interaction 
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chromatography and size-exclusion chromatography; also selection-based methods such as 
microfiltration, ultrafiltration, pertraction and pervaporation. Such steps increase the 
production costs significantly, where more than 80 % of the total production costs in plant 
systems accounts for downstream processing (Hellwig et al., 2004). Once purified, 
investigations can be carried out to further characterise the rhADA using protein sequence 
analysis and enzyme kinetic studies. Once functionality and characterisation of rhADA are 
complete, investigation into biological activity of rhADA can be determined using ADA 
deficient mouse models (Blackburn et al., 1998). 
 
In order to explore the possibility of further increasing the yield of rhADA in plant cell 
suspensions an ER retention construct containing C-terminal KDEL sequence could be 
transformed into BY-2 cells and transformants would be analysed for ADA activity. The 
highest yields of some recombinant proteins were achieved by the retention in ER, rather than 
secretion into culture media (Doran, 2000). Conrad and Fielder, (1998) demonstrated that the 
ER retention of single-chain antibody fragments accounted for increased levels of between 10 
to100-fold compared to secreted antibody fragments. Hence, investigation into recombinant 
ADA retention in the ER could prove to be successful. Glycosylation studies of the ADA 
produced in different constructs should also be investigated in order to determine the 
glycosylation patterns generated when ADA is retained in the ER or secreted into the 
apoplastic space.  
 
Genomes of different organisms including plants employ codon bias as mechanisms for 
optimising and regulating protein expression (Gustafsson et al., 2004; Murray et al., 1989).  
Campbell and Gowri, (1990) reported the use of a preferred 44 codon set in plants, with a 
preference for codons ending in A or U by dicots such as tobacco. Various codon optimised 
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foreign genes have shown an enhanced expression in transformed plants including green 
fluorescent protein (Rouwendal et al., 1997).  Hence, it may be possible to enhance ADA 
expression levels further in tobacco by codon optimisation of the ADA ORF to reflect the 
codon bias of tobacco. 
 
The chloroplast expression system offers numerous benefits over nuclear expression systems, 
including high-level expression and stable transformation due to lack of epigenetic 
interference. Furthermore, because of cytoplasmic localisation, transgenic chloroplasts are 
not transmitted through pollen grains.  Many reports of transgene expression in tobacco 
chloroplasts show that foreign proteins can be produced in the range of 5-20 % TSP (Maliga, 
2004). Hence, expressing ADA in chloroplasts may provide an excellent opportunity to 
further increase expression levels by very large amounts.  
 
As well as AGP fusions employed in this study, other recently developed protein fusion 
strategies have been used to increase the accumulation and simplify the purification of 
recombinant proteins in plants. For example, foreign proteins have been fused to C-terminal 
elastin-like polypeptides (ELPs), containing pentapeptide repeats of ‘VPGXG’. These peptide 
fusions possess the thermally responsive properties of elastin, which enables easy and 
inexpensive purification known as inverse transition cycling (Meyer and Chilkoti, 1999). In 
addition, ELP fusion also enhances recombinant protein accumulation by reducing protein 
degradation through resisting hydrolysis and proteolytic degradation (Raucher and Chilkoti, 
2001; Zhang et al., 1996). ELP fusions have increased the yield of foreign proteins by 
between 2 to 100-fold (Conley et al., 2011). Interestingly, as with AGP fusions, ELP fusion 
does not greatly affect the biological activity of associated recombinant proteins (Floss et al., 
2009). Similarly, hydrophobin fusions have also been shown to increase associated 
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recombinant protein yield (Joensuu et al., 2010). Hydrophorbins are small surface-active 
proteins generally found in filamentous fungi (Conley et al., 2011). Due to their surface-
active properties, recombinant proteins fused to hydrophobins are easily purified by a 
surfactant-based aqueous two phase system, ensuring maximum purification (Linder et al., 
2004). In addition, hydrophobin fusions enhance the accumulation of associated proteins 
through protein stabilising affects and have also been found to be inert as fusions do not 
affect the biological activity of associated proteins. Finally, another strategy used to enhance 
recombinant protein yield in transgenic plants is to express foreign proteins as a fusion with 
zeolin. Zeolins are naturally occurring plant seed proteins containing proline-rich motifs 
(Herman and Larkins, 1999). These proteins have the ability to induce the formation of ER-
derived protein bodies in plant tissues which is thought to be the main factor responsible for 
ER retention (Kogan et al., 2001). Zeolin fusions have been found to increase the yield of 
foreign proteins by up to 100-fold (Torrent et al., 2009a). Hence, as well as expressing ADA 
as an AGP fusion protein, other types of fusions could potentially enhance yields further. 
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Appendix A- Presentations, posters and abstract publications 
Oral presentations 
 
Annual PGR conference at School of Health and Biosciences, University of East London, 
June 2010 
Oral presentation on “Expression of ADA in plant cell cultures”  
 
Annual PGR conference at School of Health and Biosciences, University of East London, 
June 2009 
Oral presentation on “Expression of ADA in plant cell culture”  
 
Annual PGR conference at School of Health and Biosciences, University of East London, 
July 2008 
Oral presentation on “Expression of ADA in plant cell culture”  
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Poster presentations 
Society of Experimental Biology annual conference, Glasgow (28
th
 June- 1
st
 July 2009)  
Poster presentation: “Expression of functional human adenosine deaminase in tobacco plant 
cell suspensions and whole plants” 
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Recombinant pharmaceutical manufacturing from plants - the future of molecular farming 
held at Euroscicon, Hertfordshire in 15
th
 October 2010  
Poster presentation: “Expression of a functional human adenosine deaminase in tobacco 
plant cell suspensions and whole plants” 
Winner of the best poster price   
 
